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tetrahydrocannabinol (thc) is the most well-known active compound 
from cannabis and is generally held responsible for the well-known effects 
such as ‘the munchies’, a term used for hunger pangs after cannabis use, 
and central effects on consciousness, such as feeling high and altered time 
perception (Zuurman et al., 2009; Zuurman et al., 2008; Mathew et al., 
1998; Plasse et al., 1991; Foltin et al., 1988). As a pharmaceutical substance, 
thc is mostly referred to as dronabinol, which is the generic name. Can-
nabis also contains many other cannabinoids such as cannabidiol, but for 
most of these compounds the pharmacologically activity is still unclear. 
functions of the endocannabinoid system
Currently, two cannabinoid receptors have been identified: cb™ and cb™ 
receptors, which have different functions and localisation patterns. cb¡ 
receptors are abundantly present in the nervous system, mostly located 
in cortical and limbic regions of the brain, as well as the cerebellum 
(Herkenham et al., 1991). In addition to the nervous system, cb™ receptor 
mrna has been found in the adrenal gland, bone marrow, heart, liver, 
kidney lung, prostate, ovary, and testicles of different species including 
humans (for review, see Pertwee (1997)). The cb™ receptor is less widely 
expressed than the cb™ receptor, and its mrna is mainly present in 
various parts of the immune system, such as tonsils, spleen, thymus, 
bone marrow, and in B lymphocytes, monocytes, macrophages, mast 
cells and microglia in several species, including humans (for review, see 
Pertwee (1997)). cb™ receptors are also expressed at lower densities in the 
brain, mainly on microglia (Gong et al., 2006; Nunez et al., 2004) (for an 
overview of the distribution of cb™ and cb™ receptors, see Figure 1).
The cannabinoid system mainly has a modulatory role in the regulation 
of complex physiological systems, such as metabolism (including diges-
tive and endocrine systems), and the nervous system and immune system 
(for a review, see Melamede (2005)). Under normal physiological condi-
tions, the endocannabinoid system is thought to generally have a low 
Mechanisms and functions of the
endocannabinoid system 
evolution of the endocannabinoid system
Although a very ancient biological system, the endocannabinoid system 
was only discovered and explored over the previous five decades. Named 
after the plant Cannabis sativa L, which produces over 60 cannabinoid 
compounds, the system is widely distributed phylogenetically: it appears 
in very ancient, primitive invertebrate species, such as hydras, and in 
the most evolved mammals, such as humans. Already a few billion years 
ago the endocannabinoid precursor phosphatidylethanolamine (pea) 
was expressed by the cytoplasmic membranes of bacteria. From there, 
the first molecules with cannabinoid receptor affinity were produced 
by cyanobacteria, which diverged from eukaryotes at least 2 billion 
years ago. After the cyanobacteria, endocannabinoids were produced 
by brown algae which diverged 1.5 billion years ago, again followed by 
sponges which diverged about 930 million years ago (for a review, see 
MacPartland (2004)). In absence of specific cannabinoid receptors the 
endocannabinoids initially had various other targets including 5-ht3A 
receptors and ion channels. About 790 million years ago, the primordial 
cannabinoid specific binding place evolved. The development of 
the endocannabinoid system has accompanied the evolution from 
monocellular organisms to higher animals, which is mirrored by its 
widespread involvement in intra- and intercellular signalling.
cannabis and thc
Cannabis sativa L (or cannabis) is the most commonly illicit drug of abuse 
world-wide. Its major uses are for recreational and medicinal pur-
poses, and the earliest evidence of cannabis use go back as far as 3000 
years b.c. (World Health Organisation, 2013; Mechoulam, 1986). ∆9-
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messenger signalling pathways (Bosier et al., 2008; Prather et al., 2000; 
Su and Vo, 2007; Mackie et al., 1995; Twitchell et al., 1997). The exact 
pathway depends on the receptor subtype that is activated (Figure 3). cb¡ 
receptors in the nervous system are located on the pre-synapse. In this 
way, endocannabinoids act as retrograde synaptic messengers (Figure 4). 
The receptors are able to regulate activation and inhibition of the post-
synaptic cell by stimulating the release of neurotransmitters like gaba 
and glutamate (Twitchell et al., 1997; Guo and Ikeda, 2004; Binzen et al., 
2006). 
pathology of the endocannabinoid system
Because of its essential basic physiological functions and its widespread 
presence throughout the body, the endocannabinoid system might 
be involved with many different pathological conditions. Although 
many findings are still controversial, studies in animal models and 
patients demonstrated changes in the endocannabinoid system activity 
in certain diseases or disease models, such as increased aea levels in the 
csf of schizophrenic patients (for example, see Richardson et al. (2008)). 
However, whether a deregulated system is a cause or a result of the 
disorder remains to be investigated and only little is known about the 
pathophysiology of the cannabinoid system.
psychiatry and neurology – Due to the clear psychotomimetic effects 
of cannabis consumption, the pathophysiology of the endocannabinoid 
system in psychiatric and neurologic disorders is relatively well studied. 
Many studies have led to the theory that chronic cannabis consumption 
can contribute to schizophrenia (for a review, see Ferretjans, Moreira, 
Teixeira, & Salgado (2012)). Several labs studied the endocannabinoid 
system in schizophrenia pathology, however, no consistency could 
be found regarding cb¡ expression in the brain, or blood and tissue 
concentrations of the major endocannabinoids as outlined in a review 
activity, whereas the system can become overactive in pathological con-
ditions or during stress. As earlier suggested by the late Ester Fride, this 
could be related to the numerous observations of biphasic cannabinoid 
effects (Fride, 2002). A clear example of biphasic characteristics follow-
ing pharmacological intervention, include effects on anxiety (Rey et al., 
2012): high doses of thc can induce panic attacks, whereas lower levels 
generally have a relaxing effect. This widespread involvement of endo-
cannabinoids provides numerous opportunities for the development of 
new medicines for metabolic, neural or immune disorders, including Al-
zheimer’s disease, multiple sclerosis, rheumatoid arthritis, diabetes mel-
litus, dyslipidemia and movement disorders.
pharmacology of the endocannabinoid 
system
In various mammal species, including humans, the endocannabinoid 
system includes two subtypes of G protein coupled cannabinoid 
receptors (cb¡ and cb™) and endogenous messengers. The two most 
important messengers are anandamide (aea) and 2-arachidonoyl 
glycerol (2-ag) (Figure 2) (Matsuda et al., 1990; Munro et al., 1993). aea 
acts as a partial agonist with stronger binding affinity (Ki) and efficacy 
at the cb¡ receptor (Ki = 61-543 nM) compared to cb™ (Ki = 279-1940 nM) 
(Pertwee, 2005). 2-ag has shown higher efficacy with similar affinities, 
and acts as a full agonist on both cb¡ and cb™ receptors (Ki = 58-472 
nM and 145-1400 nM respectively) (Pertwee, 2005). aea and 2-ag are 
synthesised by membrane components (arachidonic acid) and released 
‘on demand’ (Di Marzo et al., 1994). aea and 2-ag are broken down by 
the enzymes fatty acid amidohydrolase (faah) and monoglyceride lipase 
(magl) respectively (Cravatt et al., 1996; Dinh et al., 2002).
Endocannabinoids regulate a variety of cellular effects via inter- (para-
crine) and intracellular (autocrine) communication. The endogenous li-
gands bind to the v or cb™ receptor, which affects ion channels or second 
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cial effects of cannabinoids on symptoms of Alzheimer’s disease, includ-
ing mood, sleep and cognitive decline, and on neuroprotection, the exact 
role of the endocannabinoid system in Alzheimer’s disease is unknown 
(for review, see Orgado, Fernandez-Ruiz, & Romero (2009)). The endocan-
nabinoid system is involved in the majority of the processes that occur 
before, during and after ischemia, and result in vasodilatation, neuro-
protection, immunomodulation and antioxidation (Orgado et al., 2009; 
Martinez-Org et al., 2007). Also, the endocannabinoid system is involved 
in nociception, chronic inflammatory and neuropathic pain (Zogopoulos 
et al., 2013). Recently, it has come to light that some metabolites of aea 
and 2-ag can either exacerbate or inhibit nociceptive signalling (Rani et 
al., 2012). The exact role of the endocannabinoid system in ischemia and 
pain modulation is still under investigation at several labs.
The major function of the endocannabinoid system is believed to 
be the regulation of the feeding system (De Petrocellis et al., 1999). This 
applies to both the feeling of hunger and the direct involvement in en-
ergy regulation. An obvious example includes getting ‘the munchies’ or 
a craving for high caloric food after cannabis use. Also, endocannabinoid 
activity directs towards energy storage, for example by stimulating adi-
pogenesis and gluconeogenesis (for review, see Silvestri & Di Marzo (Sil-
vestri and Di Marzo, 2013) and Osei-Hyiaman et al. (2008)). This inspired 
academy and industry to investigate the possibilities of the endocannabi-
noid system in the light of eating disorders such as obesity and anorexia. 
However, studies on the potential therapeutic validity of cannabinoids 
in eating disorders are scarce and inconclusive. The same counts for sub-
stance abuse, in which no conclusions can be drawn on the exact mech-
anisms. However, it has been found that cb¡ contributes to the motiva-
tional and reinforcing properties of ethanol, and chronic consumption 
alters endocannabinoid transmitter levels and cb¡ expression in brain 
addiction pathways (Pava and Woodward, 2012). Also, several studies as-
sociated polymorphisms in the cnr1 and faah genes with drug-related 
behaviours (Lopez-Moreno et al., 2012). 
by Ferretjans, Moreira, Teixeira, & Salgado (2012). It has been suggested, 
however, that schizophrenia is associated with polymorphisms of the 
cnr1 gene, which is responsible for encoding the cb¡ receptor (Ujike 
et al., 2002), although many other genes have also been implicated. 
Variations of the cnr1 gene are also associated with major depression 
and with the mediation of antidepressant drug effects (Mitjans et al., 
2013). 
Other evidence regarding the pathophysiology of the endocannabi-
noid system in minor and major depression and suicide is contradictory 
(as outlined in a review by Micale, Di Marzo, Sulcova, Wotjak & Drago 
(2013)). It is more certain, however, that the endocannabinoid system 
plays a gate-keeper role with regard to activation of the hormonal hypo-
thalamic-pituitary-adrenal (hpa) axis, which has a major role in control-
ling reactions to stress. Stress has a large influence on cognition, anxiety 
and mood, and chronic stress can lead to depression-like symptoms. En-
docannabinoids regulate the neurotransmitter release leading to hor-
monal release by retrograde messaging, which is mostly related to down-
regulation of excitatory, glutamatergic transmission. 
Also for other brain regions, there are possible relationships between 
the endocannabinoid system and pathology. However, the exact role in 
pathological states remains still unclear. For example, in a rat model of 
autism the endocannabinoid system showed downregulation of 2-ag 
degrading enzymes in certain brain areas and higher tissue concentra-
tions of endocannabinoids following social exposure (Kerr et al., 2013), 
but no conclusions can be drawn regarding the pathophysiology of the 
endocannabinoid system in autism. Also, due to the expression of cb¡ re-
ceptors on inhibitory gabaergic as well as excitatory glutamatergic neu-
rons, cannabinoids can be both pro- and anti-convulsive, but their role in 
epilepsy is not well studied. A study by Sagredo et al. (2007) found that 
the cb¡ receptor is downregulated in early stages of Parkinson’s disease, 
and the cannabinoid system becomes overactive in advanced stages of the 
disease (Sagredo et al., 2007). Although previous studies reported benefi-
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nephropathy and in mice, suggested that cb™ signalling was impaired 
(Barutta et al., 2011). The exact role of the endocannabinoid system in the 
pathophysiology of diabetes, however, still needs to be investigated.
cardiovascular – The endocannabinoid system affects heart and 
arterial performance in pathological conditions, including regulation of 
vessel contractility and atherogenesis. This happens directly or indirectly 
via alteration of cardiometabolic risk factors and cb¡ and cb™ receptors 
often seem to act in opposing ways (for a review, see Montecucco & Di 
Marzo (2012)).
glaucoma – A study in patients showed lower cox-2 expression and 
lower pge2 concentration in aqueous humor compared to healthy 
individuals (Maihofner et al., 2001). As cox-2 and pge2 can be increased 
by cannabinoids and glaucoma can be treated by cannabinoids, it has 
been suggested that the endocannabinoid system might contribute to 
the control of processes leading to glaucoma (for review, see Nucci et al. 
(2008)).
oncology – Endocannabinoids might represent one of the many adap-
tive responses aimed at counteracting tumour cell growth. Several stud-
ies demonstrated that cannabinoids exert anti-proliferative and apop-
totic effects (for review, see Hermanson & Marnett (2011)). Also, increased 
endocannabinoid signalling is found in some human malignancies com-
pared with the corresponding healthy tissues, as well as in human cancer 
cells with a high degree of invasiveness (see review by Di Marzo, Bifulco, 
& De Petrocellis (2004)). However, over-expression of cb™ receptors on 
haematopoietic precursor cells has been suggested to be associated with, 
and possibly a causative factor of, human acute myeloid leukaemia. 
In summary, we can conclude that endocannabinoid changes accom-
pany a wide variety of disorders, although many changes are still contro-
versial. This is largely due to the physiological complexity of the endo-
immunology – Immunologic disorders for which the endocannabinoid 
system has been investigated include multiple sclerosis, arthritis, sepsis, 
inflammatory bowel disease, pancreatitis, uveitis and peridontitis. 
Studies performed in vitro, preclinically and in humans showed 
an upregulation of the endocannabinoid system in inflammation 
(Richardson et al., 2008) (for an overview of the studies in multiple 
sclerosis, see the review by Pertwee (2007)). For example, aea and 
2-ag have been found in synovial fluid of arthritic patients, whereas 
in the synovial fluid of healthy volunteers, no cannabinoids were 
detected (Richardson et al., 2008). In post-mortem lesioned brain tissue 
from patients with chronic multiple sclerosis, the concentration of 
anandamide was significantly elevated compared to brain tissue from 
healthy controls (Eljaschewitsch et al., 2006). These examples suggest a 
protective role of the endocannabinoid system in inflammation.
endocrinology – Several studies demonstrated that the upregulation 
of endocannabinoids and cb¡ and cb™ stimulation increases food 
intake, obesity-related inflammation and adipogenesis (Gamage and 
Lichtman, 2012) (for an overview, see review by Cluny, Reimer, & Sharkey 
(2012) and Faurholt Bennetzen (2010)). Clinical studies found that obese 
subjects have a decreased subcutaneous cb¡ expression compared to lean 
subjects, and that the endocannabinoid system reduction is normalised 
with weight loss (Faurholt Bennetzen, 2010). This could imply a reactive 
compensation in obese patients.
In line with these observations, mice lacking the cb¡ receptor in 
hepatocytes, although still susceptible to diet-induced obesity, are 
protected against liver steatosis, hyperglycemia, dyslipidemia, and 
insulin resistance (Osei-Hyiaman et al., 2008). Blocking cb¡ function is 
associated with alleviation of hyperglycemia and dyslipidemia. In line 
with these findings, several studies indicate that endocannabinoids 
have negative effects on glucose tolerance and insulin secretion (for 
review, see Doyle (2011)). Studies in patients with advanced diabetic 
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that are involved in endocannabinoid synthesis and degradation is also 
limited. Consequently, there is a shortage of good pharmacological inter-
ventions to manipulate the endogenous cannabinoids, such as inhibitors 
of degradation but also of reuptake or transport.
widespread distribution
The endocannabinoid system is one of the most widely distributed phar-
macological systems in the body (for review, see Pertwee (1997)). This 
complicates systemic or organ-specific targeting. By trying to target a 
specific location, the ubiquitous presence of the system easily causes 
unnecessary or undesirable effects elsewhere, which limits the develop-
ment of therapeutically specific drugs. 
high lipophilicity
To optimise specific targeting of cannabinoids to those parts of the body 
that are involved in a disease, pharmacokinetics of endogenous and ex-
ogenous cannabinoids can be modified, for example by changing admin-
istration routes, dosing quantity and time intervals, or by differentiating 
peripheral and central drug distribution. However, pharmacokinetic 
optimisation is limited by the strong lipophilic character of exogenous 
and endogenous cannabinoids (e.g. Log P values for anandamide and 
2-ag are 6.31 and 8.01 respectively (Stanton et al., 2005). Although lipo-
philic compounds are generally well absorbed gastro-intestinally, they 
carry the risk not to be optimally distributed systemically, due to the rap-
id diffusion from the blood to fatty organs, such as adipose tissue, liver 
and brain. As a consequence, a relatively large concentration is located at 
specific sites, whereas other sites are much less exposed to the compound. 
Also, very lipophilic compounds are often only slowly redistributed from 
fatty organs back into the blood, as a result of which the compounds ac-
cumulate and remain detectable in the blood for long time periods after 
cannabinoid system, which often involves feedback mechanisms at a lo-
cal tissue level, or indirect influences on processes that are also regulated 
by other systems. Changes in signalling sometimes represent an attempt 
to counteract a pathological process, and in other instances could be one 
of the causative factors underlying the disease or its symptoms. Although 
it is premature to view endocannabinoids as markers of pathological 
states, a general conclusion from previous studies is that, endocannabi-
noids seem to have a protective or ameliorating role in many cases. 
Complexities of cannabinoid drug development
Endocannabinoids are involved in complex physiological systems that 
play an important role in a huge number of diseases in almost all areas 
of medicine. In principle, this makes them appealing targets for drug de-
velopment. However, because of this complexity and the relatively recent 
discovery of the endocannabinoid system, endocannabinoid research is 
still in a premature stage. Cannabinoid research and drug development 
is complicated further by a number of factors which are summarised in 
the following paragraphs.
limited subtype specificity
The limited number of receptor subtypes and the limited number of 
endogenous ligands and their ubiquitous presence makes it difficult to 
identify the exact local steering processes. For example, in contrast, the 
gaba-a receptor has at least half a dozen subtypes and the serotonin-
system has over a dozen of 5-ht receptor subtypes. This creates ample 
opportunities for the development of highly selective compounds as re-
search tools or potential drugs, or to develop genetic knock-in or knock-
out models to study the functional role of a specific receptor subtype. In 
the case of the endocannabinoid system, such models and interventions 
generally affect many systems at the same time. The number of enzymes 
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induced changes. Therefore, it is easy to miss relevant effects. This can 
be the case in acute single dosing studies, where the, very often subtle, 
changes in homeostasis can be easily overlooked.
Optimisation of early cannabinoid development
In spite of the complexity of endocannabinoids, many efforts have been 
made to develop drugs that are targeted on this system. In general, 
several options are available to overcome the pharmacologic limitations 
and the problems with effect measurements that are described in the 
previous sections. This section deals with these options, and how they 
were approached in this thesis.
drug design optimisation
pharmacological optimisation – To act on pathological conditions, 
which are often very local or limited to a single physiological system, 
receptor subtypes should be targeted as specifically as possible. thc is the 
most well-known cannabinoid and is generally used as an experimental 
compound in cb¡ agonist studies and thc-challenge studies and is 
a major compound in various registered and experimental medical 
formulations, including medicinal cannabis, Sativex® and Marinol®. 
However, thc lacks cannabinoid receptor specificity and exhibits its 
effects as a partial agonist on both the cb¡ and the cb™ receptor (for a 
review, see Pertwee (2008)). Also, thc is very lipophilic (log P = 6.97) and 
accordingly, after administration, thc is very quickly distributed to the 
peripheral fatty tissues including lungs, adipose tissue and the brain 
(Thomas et al., 1990; Lemberger et al., 1970; Ryrfeldt et al., 1973; Brunet et 
al., 2010). Besides the option of exogenous targeting of the cannabinoid 
receptors, the endogenous cannabinoid levels could be manipulated. 
Options for manipulation of the endogenous cannabinoid levels in-
clude influencing synthesis, transport, release, and degradation. The 
dosing. Furthermore, lipophilic compounds can be rapidly metabolised, 
resulting in fast metabolite exposure. They generally have a high protein 
binding, resulting in a low free drug fraction and thereby more variable 
drug exposure. Also lipophilic compounds generally have a somewhat 
limited specificity, i.e. ‘pharmacological promiscuity’. Consequently, the 
lipophilicity of cannabinoids creates a large complexity for specific dos-
ing in terms of target and time frame.
complex physiological integration 
Due to the ancient phylogeny of the endocannabinoid system and its in-
volvement in primitive systems, it is deeply embedded in basic functions 
and complex physiological systems. Locally, these systems can have very 
diverse signalling pathways, cellular messaging and functions (Figure 
3). Most systems in which endocannabinoids are involved, such as the 
central nervous system or immune system) form highly integrated net-
works, with many layers of feedback and regulation. This makes it enor-
mously difficult for pharmacology to precisely interfere with one specific 
signalling pathway. For the same reasons there are also many uncertain-
ties regarding the exact role of endocannabinoids in pathophysiology, 
which in most diseases has not been unequivocally demonstrated. For 
the few diseases in which consistent involvement of the endocannabi-
noid system has been found, it is still unclear to what extent a deregula-
tion is part of the cause or merely a consequence or sign of dysfunction.
complicated effect measurements
The integration of the endocannabinoid system at subcellular levels of 
complex multicascadic physiological mechanisms and the wide range 
of effects create a major challenge for measurement of changes in their 
activity, which is essential in drug development. The methodology 
currently used in clinical research is unable to track all drug- or disease-
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In order to avoid gut- and liver metabolism, drugs can be administered 
intravenously, directly into the blood stream (i.e. 100% bioavailability). 
This administration route is limited by its invasiveness. Non-invasive 
ways of avoiding hepatic metabolism are for example intrapulmonal, 
sublingual and transdermal administrations. These routes are not suit-
able for each compound. They may give less variable pharmacokinetics 
compared to oral administration, but the administration routes are less 
practical. Another way to enhance the bioavailability of a compound is 
by galenic manipulation. Changing the formulation can improve the re-
sorption of a compound and affect the exposure profile.
In this thesis, we investigated the pharmacokinetics and pharmaco-
dynamics of several different administration routes of thc. In previous 
studies by Zuurman et al. we have optimized the intrapulmonary admin-
istration of thc, using a vaporizer and pure thc rather than the more 
usual method of smoking cannabis extracts (Zuurman et al., 2008). Al-
though inhalation of vaporized pure thc produces reliable pharmacoki-
netic profiles, it is a less convenient mode of administration, which gives 
little control over the exposure profile. This can be improved by the so 
called repeated paced puffing protocol, which uses predetermined dos-
ages and times to achieve a desired exposure profile, however with rela-
tively variable results (Chapter 3, 4, 5 and 6). 
In Chapter 2, we investigate different oral and sublingual administra-
tions of Namisol, a new tablet containing thc. Namisol is manufactured 
with Alitra™, a novel lipophilic compound delivery technology that has 
an improved absorption of poor water soluble compounds in the human 
blood, thereby improving bioavailability with reduced variability. Th 
most favourable administration route was chosen for further develop-
ment of Namisol for the indication of pain and spasms in multiple 
sclerosis. 
pharmacokinetic control of the therapeutic window: dosage 
and time interval – Besides the route of administration, the actual 
most well-known example of current investigation of this type of ma-
nipulation is the development of faah-inhibitors, which inhibit the 
metabolism of aea. Clinical studies with faah-inhibitors for the indica-
tions of several pain and inflammation states are still ongoing. Studies 
with inhibitors of monoacylglycerol lipase (magl) and transporters are 
still in pre-clinical in vitro phase (icrs, 2012). Despite these attempts, the 
options are very limited due to the small number of available compounds 
influencing endogenous cannabinoids and are unlikely to allow enough 
pharmacological selectivity for a wide array of disease-specific cannabi-
noid-targeted treatments. 
Another way to improve the therapeutic window of drugs with limit-
ed pharmacological selectivity is to control their action site penetration. 
This can be achieved by pharmacokinetic optimisation of drug levels and 
tissue penetration. 
pharmacokinetic optimisation
reducing systemic variability: administration route – The ad-
ministration route can influence pharmacokinetic aspects such as time 
of drug absorption or peak concentration and distribution, and thereby 
time of effect onset, and the number and magnitude of concentration-
related therapeutic and undesirable effects. The most common adminis-
tration route is the oral route. Oral administration is generally very easy 
and convenient, however, pharmacokinetically, there are some risks with 
this administration route. Oral administration could result in variable 
plasma concentrations, as absorption to the blood is dependent on gi 
tract activity, pH variations and food interactions. Also, the compounds 
reach the liver before they reach the systemic blood circulation, resulting 
in metabolism and possible modification of the activity of compounds 
that are metabolised by cyp450 enzymes. These enzymes are also situ-
ated in the gut wall, and their activity can vary due to genetic variations 
and interactions with foods and drugs.
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Another option to improve specificity for a specific target or location 
would be to improve the delivery of the compound to a specific location. 
For example, manipulation of the compound’s permeability for the 
blood brain barrier could keep a compound outside of the central 
nervous system. In Chapter 5, we actually tested tm38837, a compound 
that showed peripheral restriction in preclinical studies with the aim to 
demonstrate peripheral activity without central activity. In this study, we 
compared tm38837 with the centrally and peripherally active antagonist 
rimonabant, using biomarkers of peripheral and central cb¡-activity 
that have been previously identified (i.e. feeling high and heart rate) 
(Zuurman et al., 2009). tm38837 is under development for treatment 
of peripherally associated disorders (including hepatic disorders and 
obesity) with reduced central side-effects.
methodological optimisation
General challenges in drug development are to precisely and accurately 
detect and measure relevant (side) effects, and to ensure translatability 
of drug responses from preclinical animals and healthy volunteers 
to patients and vice versa. These challenges particularly apply to the 
development of cannabinoid drugs.
accurate effect measurements – The endocannabinoid system 
is deeply embedded within a variety of physiological networks. When 
endocannabinoid changes are induced in the network, these changes 
can be quickly modified by other homeostatic processes. The complex 
interactions between the networks and their eventual results are not 
always immediately measurable. Consequently, results from acute 
dosing studies cannot always be extrapolated to multiple dose studies in 
which more chronic effects are studied.
Cannabinoids can induce a wide palette of effects which makes 
measuring the relevant effects related to various physiological networks 
dose given and the time interval between multiple doses are essential 
factors to maintain drug concentrations within the therapeutic window 
for the required time periods. Overdosing could lead to unwanted (side) 
effect profiles and even to toxicological effects. It is essential therefore to 
accurately predict the optimal therapeutic window for a new drug. This 
may be problematic if the effects are difficult to measure; either because 
they are part of an integrated system with many homeostatic mecha-
nisms; or because specific tests are lacking; or because the beneficial ef-
fects are chronic (e.g. weight reduction or cardiovascular risk) or infre-
quent (e.g. epileptic seizures or exacerbations of multiple sclerosis). This 
was a problem with the first cannabinoid antagonists like rimonabant, 
where traditional methods like preclinical dose predictions and maxi-
mum tolerability levels in healthy subjects were used to determine the 
doses for clinical trials (Cohen, 2010). Although this approach led to the 
registration of rimonabant for obesity, the drug was withdrawn soon 
after launch because of unacceptable psychiatric side effects in a minor-
ity of patients. It is important therefore to determine the concentration 
range that has an optimal effect on the right pharmacological target: not 
too much or too little inhibition or stimulation; and not at action sites 
that are not involved in the disease. The determination of dose- or con-
centration-effect relationships for different mechanisms of action of can-
nabinoids is an important part of this thesis. In Chapter 2 a first in human 
study with the novel thc tablet Namisol aimed to find the optimal dos-
age for single dose administration by evaluating pharmacokinetics and 
pharmacodynamic effects. In Chapters 4-6 we try to establish the concen-
tration-effect relationships for different cannabinoid agonists and an-
tagonists, with the aim of establishing a dosing regimen with an optimal 
pharmacological effect. 
target specificity – Options for improving specificity in drug 
development are limited due to the limited number of cannabinoid 
receptor subtypes (i.e. two) and their presence all throughout the body. 
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provide sensitive indications for a wide range of cns effects. In Chapter 
3, we examined the novel technique of pharmacological resting state 
functional magnetic resonance imaging (rs-fmri). This technique 
seems very valuable for clinical phases of drug development; however, it 
has not yet been applied for this purpose. Besides better understanding 
the pharmacodynamics of thc, we aimed to bring rs-fmri one step 
closer towards application in drug development. 
optimal study designs
Pharmacological therapies try to achieve a correction of homeostasis 
(i.e. healthy state) by artificially interfering with the disturbed elements 
in a disordered biological system (e.g. stress or pathology). Since early 
phase clinical research investigates cannabinoids in healthy humans, 
one should find possibilities for translating the effects seen in healthy 
volunteers to clinically relevant outcomes in patients. The latter is a 
specific challenge if the acute effects of a pharmacological manipulation 
are not measurable in healthy subjects. It is difficult for instance to 
show the effects of a pharmacological stimulus (e.g. a receptor agonist), 
if the target system is already maximally active. Such ceiling effects 
are well-known for cognitive enhancers in healthy students. It is 
also challenging to show effects of pharmacological inhibition (e.g. 
a receptor antagonist) in case of ‘floor effects’, when the endogenous 
system is dormant under physiological conditions. The low basic activity 
of the endocannabinoid system may be the reason why cannabinoid 
antagonists do not show any effect in healthy volunteers at doses that 
are clearly effective in various disease states (Rodriguez de Fonseca et 
al., 1999). In such cases, pharmacological or functional challenge tests 
can be used to perturb the target system in such a way, that it is possible 
to show correction by the drug. For example, a scopolamine-challenge 
causes cognitive deterioration, which can be improved by procognitive 
drugs (Snyder et al., 2005). To enable detection and quantification of 
quite challenging. It should be tested whether the compound reaches 
the target site and other sites and to what magnitude and in what time 
frame the effects take place. With the availability of a broad range of tests, 
especially of the central nervous system (cns), an adequate set of tests 
should be chosen in order not to miss any relevant effects. 
test selection – Zuurman et al. performed a systematic literature 
review on biomarkers for the effects of cannabis and thc in healthy 
volunteers (Zuurman et al., 2009). Consistently, she found increases of 
heart rate frequency and feeling high, and decreases of motor control. 
This trio of consistent effect measurements are considered as the basic 
cannabinoid responses that were measurable in a consistent way, and 
were therefore applied in all studies in this thesis.
For the detection of these effects in healthy volunteers, the Centre for 
Human Drug Research (chdr) developed the NeuroCart test battery. 
This test battery includes all of the functions mentioned, using non-
invasive tests with a short duration and limited learning effect, which 
allows for repeated measures. The NeuroCart battery include visual 
analogue scales of mood, alertness and calmness by Bond & Lader (1974), 
psychedelic effects by Bowdle et al. (1998), and body sway measurement, 
and was applied to the studies reported in Chapters 2, 4, 5 and 6 and 
partially in Chapter 3.
Even with a battery of tests, effects of the endocannabinoid system 
can be easily missed. There is a need therefore, for methods that provide 
integrated representations of functional activities, which are highly 
sensitive and specific to pharmacological effects. For the immune system 
and metabolism, biochemical analyses have been developed to examine 
specific functional arrays (immunoarrays and metabolic arrays), and the 
more general ‘omic’ approaches (proteomics, metabolomics) can provide 
broad screens of functional changes on an individual level (Powanda and 
Beisel, 2003; Ahmed et al., 2013). Biochemical effects are more difficult 
to determine in the central nervous system, but network analysis could 
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and dynamical systems analysis, which takes into account the specific 
physiological characteristics of a body system (such as blood flow and 
lipophilicity). Also, statistical and technical improvements led to the 
more widespread application of visual predictive checks and objective 
assessments of model complexity (minimal value of objective func-
tion), thereby improving the quality of model predictions. Previously, 
chdr developed pk-pd models for thc effects (Strougo et al., 2008). 
These models were used for the design of all thc challenge studies de-
scribed in this thesis. In this thesis, we tried to expand these models with 
new pk-pd models for the cb¡ antagonists drinabant (ave1625), suri-
nabant (sr147778) and tm38837 and cb¡ inverse agonist rimonabant 
(sr141716) based on inhibition of thc-induced effects (Chapter 6). 
In summary, the aim of this thesis is to improve cannabinoid drug de-
velopment in early phase clinical research, by investigating new canna-
binoid compounds and new formulations to improve pharmacological 
effects, experimenting with new methodologies to optimise effect mea-
surement, and applying new concentration-effect models to improve the 
simulation and prediction of optimal dosing regimens of cannabinoid 
agents for future studies.
effects of cannabinoid antagonists, chdr developed the thc challenge 
test (Zuurman et al., 2008; Zuurman et al., 2010). This test allows indirect 
quantification of agonistic effects by measuring the antagonistic 
inhibition of thc-induced effects. In practice, this means that on one 
study occasion an agonist is used to induce acute effects (e.g. feeling 
high), whereas on another occasion the agonist is dosed together with 
an antagonist, which can now be shown to reduce the agonistic effects. 
This provides unequivocal proof that the antagonist has reached 
pharmacologically active concentrations in relevant parts of the body, 
which is an essential prerequisite for therapeutic activity. Obviously, 
these relevant body parts need to be represented by the measurements 
that are used in the study.
The thc challenge test has been developed as a standard method 
that has been applied in over ten studies, including both antagonist 
studies and studies investigating thc effects only (Zuurman et al., 2008; 
Zuurman et al., 2010) and it was applied for Chapters 4, 5 and 6.
concentration-effect modelling 
Modelling is a very powerful tool to simulate and predict pharmacoki-
netics (pk) and pharmacodynamic effects (pd). These models allow the 
optimisation of a study design by predicting effective dosages and con-
centrations and relevant effects, but they can also be applied to ’trans-
late’ data from experimental animals and healthy volunteers to patient 
groups. 
The mathematical models that relate pk and pd are referred to as pk-
pd models. These models are data driven mathematical models that 
best describe the relationship between the plasma concentration and 
a particular pharmacodynamic effect, based on a relatively simple un-
derlying function (usually an Emax-model). During recent years, the 
field of modelling underwent major improvements with the devel-
opment of new theoretical concepts, including the receptor theory 
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box - thc pharmacokinetics 
As the most well known constituent of cannabis, thc is often used as a 
cannabinoid (partial) agonist in pharmacological studies (Pijlman et al., 
2005). Also, thc is only one of the few cannabinoid agonists available 
for clinical use. Therefore, we chose thc as the agonist of preference in 
this thesis. thc is very lipophilic and its pharmacokinetics are complex. 
In this box, we give an overview of the most important aspects of thc 
pharmacokinetics in clinical trials. 
administration  
intravenous – Intravenous thc administration is a very uncommon 
and merely experimental administration route that was only applied 
in a limited number of clinical experiments (Bhattacharyya et al., 2010; 
Carbuto et al., 2011; Lemberger et al., 1973). Intravenous administration 
has a bioavailability of 100%, and it thereby allows assessment of absolute 
bioavailablity when compared to other formulations.
inhalation – One of the most common administration routes of thc 
is via smoking cannabis. This has several methodological disadvantages 
in addition to the problems of smoking. Cannabis is usually smoked in 
combination with tobacco, resulting in the inhalation of a varied mixture 
of (noxious) compounds which could influence the thc-induced effects. 
When smoked as pure cannabis, the mixture of cannabinoids could as 
well influence the thc-induced effects. For example, cannabidiol (cbd) 
abolishes the well-known thc-induced ‘feeling high’ effect (Dalton 
et al., 1976). Moreover, the lack of dosage control makes smoking less 
suitable for clinical research; the exact amount of thc that is inhaled 
cannot be controlled due to partial combustion of the thc at times when 
the cigarette smoke is not inhaled. Moreover, efficiency of smoking is 
dependent on the experience of cannabis users.
To avoid these disadvantages, a thc inhalation method using a vaporiser 
was developed at the Centre for Human Drug Research (chdr, Leiden). 
Pure thc diluted in 100% ethanol is applied on the Volcano® device. Hot 
air from the vaporiser vaporises the thc dilution into a balloon that is 
attached to the vaporiser. The balloon is closed with a valve that opens 
when the content is inhaled. Using a paced puffing protocol, volunteers 
inhale an exactly known amount of thc from vapour in the balloon 
(Hazekamp et al., 2006; Zuurman et al., 2008). This inhalation method 
is used in several chapters of this thesis. An overview of the average loss 
of thc during the thc administration using the vaporiser, and the 
quantity of thc that is inhaled is given in Figure 5.
oral – Oral thc administration is another very commonly used method 
for both recreational and clinical usage. Cannabis could be processed into 
baked products, such as biscuits and cakes, or decocted and served as ‘tea’. 
The disadvantages of oral administration are the variation of cannabinoid 
composition and the late onset and unpredictable magnitude of effects. 
The cannabinoid composition is dependent on way the cannabis 
is processed. For example, due to the lipophilic character of some 
cannabinoids such as thc, the composition of cannabinoids in tea shifts 
to relatively lower concentrations of thc and higher concentrations of 
thc-acid (thca) (Hazekamp et al., 2007). Also, the temperature during 
processing is of relevance for cannabinoid composition due to conversion 
of cannabinoid acids (Hazekamp et al., 2007).
To avoid the problems of variable cannabinoid composition, several 
oral formulations of cannabis derived medicines (cdm) and thc have 
been developed containing predefined amounts of cannabinoids. These 
formulations include Marinol®, a capsule with a synthetic form of 
thc dissolved in sesame oil, and Cesamet®, a capsule containing thc 
analogue nabilone. 
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oromucosal and sublingual – Sativex® is a cdm that, besides its 
major compounds thc and cannabidiol (cbd), contains a mixture 
of several other cannabinoids (presented during the 20th and 21st 
Symposiums of the International Cannabinoid Research Society, 2010 
and 2011). At present, Sativex® is the only registered cdm that is applied 
for oromucosal and sublingual administration. Sativex® is administered 
by spraying into the oral cavity. 
other – Other thc and cdm administration routes such as dermal 
and rectal have been applied as well in clinical trials (Mattes et al., 1994; 
Callaway et al., 2005). These administration routes are not applied for 
currently registered cannabinoid medicines, and are beyond the scope 
of this thesis. 
absorption
Plasma concentration profiles of thc for different administration 
routes are given in Figure 6. thc profile after inhalation of pure thc is 
comparable to the profile after intravenous administration, with an 
instant time to peak plasma concentration (tmax) within 3 min and a 
steep decline of plasma concentration (Ohlsson et al., 1980). Although 
the oral administration route is more practical, thc absorption is less 
favourable compared to intravenous or intrapulmonary administration 
routes. The oral tmax lies between 60 to 90 min after eating of a 20 mg 
thc-containing chocolate cookie (Ohlsson et al., 1980) and between 2.8 to 
3 h for 5-20 mg Marinol® (Schwilke et al., 2009; Karschner et al., 2011). An 
oromucosal thc-cbd dosage, administered as a spray, gives a relatively 
late thc tmax of 4 h (Karschner et al., 2011). 
Previous pharmacokinetic studies reported that bioavailability of 
thc inhalation was between 10 and 28.7% on average. Frequent cannabis 
users had higher thc plasma levels compared to infrequent users after 
smoking (Ohlsson et al., 1982; Lindgren et al., 1981). However, a study by 
Ohlsson et al. (1982) found that intravenous thc administration resulted 
in only small plasma concentration differences between infrequent and 
frequent users. This indicates that a substantial amount of thc from 
cigarettes is not absorbed and that the amount of thc intake is relatively 
variable. However, the intrapulmonary administration route has advan-
tages over intravenous administration with regards to familiarity and its 
non-invasive character. Therefore, the Centre for Human Drug Research 
developed a standardised thc inhalation protocol that was reported by 
Zuurman et al. This protocol was applied for studies with repeated mea-
surements for the assessment of concentration-effect relationship mod-
elling, and in challenge tests (Zuurman et al., 2008; Strougo et al., 2008; 
Zuurman et al., 2008). 
Oral bioavailability is relatively small, varying on average from 6 to 
20% (Ohlsson et al., 1980; Wall et al., 1983). The relative bioavailability of 
oral thc was 87.2% when compared to sublingual thc+cbd, and 93.9% 
when compared to buccal thc+cbd administration (Guy and Robson, 
2003). A study with oromucosal thc+cbd administration (both sub-
lingual and buccal) found a 92.6 to 98.8% bioavailability of oral thc 
(Karschner et al., 2011). 
distribution
Although extensive data are available from studies in animals, only little 
is reported on the distribution of cannabinoids in humans. Due to its li-
pophilic nature, thc is distributed to peripheral tissues, such as lungs, 
adipose tissue and kidneys. This happens very quickly after central ab-
sorption, as can be seen by the steep concentration decline in Figure 6 
(Lemberger et al., 1970; Ryrfeldt et al., 1973; Brunet et al., 2010). Grone-
wold and Skopp (2011) investigated distribution of thc and its metabo-
lites in five human post mortem cases (Gronewold and Skopp, 2011). Bile 
contained high concentrations of thc and metabolites and muscle tis-
sue also contained high concentrations of thc, although metabolites 
could hardly be detected. In the liver, thc had low concentrations or was 
even undetectable, while 11-nor-9-carboxy-thc glucuronide (thc-
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cooglu) had appreciably concentrations in both liver and kidney. Fur-
thermore, thc was present in lung specimens. Metabolites were largely 
absent in brain tissue, with 11-hydroxy-thc (11-oh-thc) being com-
pletely absent. Gronewold and Skopp (2011) suggested that muscle tissue 
serves as a matrix for detection of cannabis use, and that retention from 
muscle tissue, in addition to retention in fat, could be a source of the pro-
longed elimination period of cannabinoids (Gronewold and Skopp, 2011). 
Findings from bile supported extensive enterohepatic recirculation of 
thc-cooglu (Gronewold and Skopp, 2011). The role of enterohepatic cir-
culation in the distribution pattern of thc has also been described in ani-
mal studies (Garrett and Hunt, 1977; Klausner and Dingell, 1971). In daily 
cannabis users, a previous study on cannabinoids in oral fluid described 
the abundant presence of thc-cooh in 98.2% of the samples (Milman et 
al., 2010). Conversely, 11-oh-thc was not detected in any sample, where-
as thc was present in only 20.7% of plasma samples. Previous studies also 
described the distribution and determination of thc in detail in vitreous 
humour, oral fluid, breast milk and foetuses (Jenkins and Oblock, 2008; 
Milman et al., 2011; Perez-Reyes and Wall, 1982). These aspects are beyond 
the scope of this thesis, and are therefore not described.
metabolism 
In humans, thc is predominantly metabolised by hydroxylation and 
oxi da tion via cytochrome P450 (cyp) enzymes (Yamamoto et al., 1995). 
cyp2C9 and to a lesser extend cyp2C19 play the major roles in humans 
(Watanabe et al., 2007). Metabolism mainly takes place in the liver, and 
to lesser extend in the heart and lungs, as reported from animal studies 
(Nakazawa and Costa, 1971; Widman et al., 1975). Many pre-clinical stud-
ies reported on metabolic rates, but extrapolation of the results is limited 
by interspecies differences that could be explained by differences in cyp 
profiles (Harvey and Brown, 1991). The major metabolism pathway is visu-
alised in Figure 2. The ratios at which the metabolites occur after human 
administration, is largely dependent on the administration route. 
elimination
After reaching the maximum concentration (cmax) for thc inhalation 
and right after intravenous administration, thc plasma concentration 
has a steep decline until the concentration reaches a second phase, 
resembling an equilibrium (Figure 6). This equilibrium occurs between 
approximately 20 minutes and 6 hours after thc administration. After 
6 hours a third phase is reached in which the plasma concentration 
has a flatter slope compared to the second phase. The exact course of 
elimination phases in humans is unknown, but preclinical studies 
reported up to 6 phases (Leuschner et al., 1986). 
The steep decline in the first phase, which could be attributed by a 
combination of rapid distribution and metabolism, has a half-life (ini-
tial half life or t¡/™init) of 30 min (Lemberger et al., 1970). In the second 
and third phase, equilibriums between plasma and tissue are reached 
(Chiang and Rapaka, 1987; Lemberger et al., 1970). The terminal plasma 
t¡/™term was calculated up to 57 hours (Lemberger et al., 1971). It should 
be noted that the actual t¡/™ calculation is difficult and is limited by dif-
ficulties in the quantitative analysis of very low plasma concentrations 
that are found in phase 3. The clearance of thc in the third phase is be-
tween 0.0033 and 0.06 L/h, while the maximum clearance at t = 100 min 
was reported to be 1.2 L/h (Ohlsson et al., 1982; Wall et al., 1983; Hunt and 
Jones, 1980). The slow elimination of thc from the plasma could be ex-
plained by redistribution from peripheral tissues, such as the adipose tis-
sue, into the blood compartment. 
About 15-30% of thc is excreted in urine, mainly as acid metabolites 
with less than 0.05% of unchanged thc. About 30-65% is excreted in 
faeces, less than 5% of an oral dose as unchanged drug (Lemberger et al., 
1970; Hunt and Jones, 1980; Wall et al., 1983). Most of the thc metabolites 
in urine were excreted as polar acidic metabolites during day 1. 
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figure 3  Complexity of intracellular cb¡ receptor signalling. As for G protein coupled receptors in general, the cb¡ 
receptor has the ability to activate multiple G proteins. Consequently, different functions are regulated by a variety of 
pathways. For example, cell survival and cell death are regulated by the mapk cascades, whereas ion currents are directly 
involved in the process of neurotransmitter release. The triggering of the variety of intracellular pathways and thereby 
functional responses elicited by cannabinoid receptors is dependent on several factors, including the type of cells or 
tissue targeted, the type of ligand and the duration of receptor activation (Sanchez et al., 2001; Galve-Roperh et al., 
2000). For example, successive activation might lead to a biphasic concentration-response profile or to tolerance by  
a molecular switch between G proteins (Asimaki and Mangoura, 2011; Sulcova et al., 1998; Paquette et al., 2007).
figure 4  Signalling of endocannabinoids on cb¡ receptors located at the axon terminals is via a retrograde pathway. 
Endocannabinoids, such as anandamide and 2-arachidonoyl glycerol are released post-synaptically. Via the synapse, 
the molecules migrate to the pre-synaptic cell, where they give feedback via stimulation of the cb¡ receptor. Upon 
stimulation, a second messenger pathway influences ion channels (e.g. inhibition of calcium) thereby regulating the 





















































figure 1 Distribution of cannabinoid receptors in the body and brain. cb¡ receptors are widely distributed in areas 
related to metabolism and energy storage, such as the adipose tissue, digestive tract, liver, brain, but also in the kidney, 
lungs and reproductive organs (1a). cb™ receptors are mainly present in the immune system, such as tissues of the spleen, 
tonsils, and thymus gland, and immune cells including glia cells in the brain, monocytes, macrophages, B-cells and 
T-cells and hematopoetic stem cells (1a). figure 1b shows the location of cb¡ receptors in the brain in more detail. 
The cb¡ receptor is predominantly found in the hypothalamus (associated with appetite regulation), hippocampus 
(associated with memory and stress), amygdala (associated with emotion), basal ganglia and cerebellum (associated  
with coordination and movement), medulla (associated with basal functions, including vomiting), spinal cord 
(associated with sensations, including pain) and in the cortex (associated with higher cognitive functions). 
a  (see inside cover for this figure in colour) b (see inside cover for this figure in colour)
figure 2  Structural formulas of the endocannabinoids anandamide and 2-arachydonylglycerolamide (2a),  
and the metabolic pathway of the exogenous cannabinoid ∆9-tetrahydrocannabinol that is metabolised to  
11-nor-9-carboxy-thc glucuronide, a water soluble congener which can be more easily excreted by the body (2b). 




figure 5  Overview of the different steps of the thc administration process where thc loss occurs. The given 
percentages are mean values. Eventually, 25.8% of the thc dose stays in the lungs. The exact percentage of the  
thc that actually reaches the blood stream is unknown, since thc metabolising enzymes are present in the lungs.  
The data are derived from work by Hazekamp et al. (2006).
figure 6  Plasma concentration profiles of 10 mg thc after inhalation, intravenous and oral absorption as simulated 
from a chdr thc model in 2012 (data on file). With this model, we are able to distinguish three elimination phases:  
a steep decline of plasma concentration (phase 1) occurs in all administrations and lasts for a few minutes. Subsequently, 
a less steep decline occurs (phase 2), which changes into a flat phase that could last for over an hour (phase 3). 
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abstract
aim Among the main disadvantages of currently available ∆9-
tetrahydrocannabinol (thc) formulations are dosing difficulties due to 
poor pharmacokinetic characteristics. Namisol® is a novel thc formu-
lation, designed to improve thc absorption. The study objectives were 
to investigate the optimal administration route, pharmacokinetics (pk), 
pharmacodynamics (pd), and tolerability of Namisol®.
methods This first in human study consisted of two parts. Panel I 
included healthy males and females (n = 6/6) in a double-blind, double-
dummy, randomised, cross-over study with sublingual (crushed tablet) 
and oral administration of Namisol® (5 mg thc). Based on these results, 
male and female (n = 4/5) participants from panel I received oral thc 
6.5-, 8.0 mg or matching placebo in a randomised, cross-over, rising 
dose study during panel ii. pd measurements were: body sway; visual 
analogue scales (vas) mood, psychedelic; heart rate. thc and 11-oh-thc 
population pk analysis was performed. 
results Sublingual administration showed a flat concentration 
profile compared to oral. Oral thc apparent t¡/™ was 72-80 min, tmax 
was 39-56 min, and cmax 2.92-4.69 ng ml-1. thc affected body sway 
(60.8%; 95%ci 29.5-99.8), external perception (0.078 log mm; 95%ci 
0.019-0.137), alertness (-2.7 mm; 95%ci -4.5-/-0.9) feeling high (0.256 
log mm; 95%ci 0.093-0.418), and heart rate (5.6 bpm; 95%ci 2.7-6.5). 
Namisol® was well tolerated.
conclusions Oral Namisol® showed promising pk and pd char-
acteristics. Variability and tmax of thc plasma concentrations were 
smaller for Namisol® than reported for studies using oral dronabinol 
and nabilone. This study was performed in a limited number of healthy 
volunteers. Therefore, future research on Namisol® should study clini-
cal effects in patient populations.
introduction
Components of the Cannabis sativa L. plant, or cannabis, have been used 
for medical purposes for thousands of years. Nowadays, cannabis derived 
compounds, or cannabinoids, are registered in several countries for a 
variety of indications, including antinociception and muscle relaxation 
in patients suffering from multiple sclerosis (Ungerleider et al., 1987; 
Zajicek et al., 2003; Zajicek et al., 2005), and anti-nausea and anti-emetic 
effects in cancer patients (Chang et al., 1979; Orr et al., 1980; Sallan et al., 
1975). Cannabis consists of several cannabinoid compounds, some of 
which are still subject of clinical research. For the registered products, 
∆9-tetrahydrocannabinol (thc) is generally considered to be the active 
compound responsible for the clinical effects (Buccellato et al., 2010; 
Baker et al., 2000). 
thc induces its effects via activation of cannabinoid receptor types 1 
and 2 (cb¡ and cb™) (Alexander et al., 2008). cb¡ are mainly located in the 
central nervous system, as well as in peripheral tissues such as the heart, 
adipose tissue and sympathetic ganglions, while cb™ are mainly present 
in immune cells (Engeli et al., 2005; Herkenham, 1992; Ishac et al., 1996). 
The major metabolite of thc is 11-oh-thc (Grotenhermen, 2003). This 
metabolite induces effects via cb¡ and has been described to be equally 
or up to seven times as potent as thc (Wilson and May, 1975; Karler and 
Turkanis, 1987). This could mean that the clinical effects of thc are 
related to the combined activities of thc and 11-oh-thc.
The common medicinal cannabis administration routes are via 
smoking, after vaporising, and orally as tea or in baked goods. After 
smoking, thc plasma levels increase quickly (Huestis et al., 1992). 
However, smoking is not a very practical route and it can lead to 
stigmatisation, which may be limiting factors particularly for non-
smokers. Also, cannabis, especially when co-administered with tobacco, 
contains a mixture of other compounds, some of which interact with 
the effects of thc, and some of which are noxious. Moreover, part of 
the active substances is not inhaled and will be lost. Also, depth and 
novel approaches in clinical development of cannabinoid drugs
– 52 –
chapter ii – pk and pd of namisol®
– 53 –
frequency of inhalations vary considerably between individuals. This 
lack of controlled dosing may reduce clinical efficacy or induce side 
effects and may also occur after vaporisation of cannabis or thc. With 
regards to oral administration of thc using cannabis tea, a previous 
study found tea to have a different cannabinoid composition compared 
to non-decocted cannabis (Hazekamp et al., 2007), affecting the clinical 
effects. To bypass these problems, methods have been developed to 
purify thc from cannabis and to formulate it in a stable dosage form. 
Marinol® and Cesamet® are two oral thc formulations registered 
for anorexia in aids patients, and nausea and vomiting in cancer 
patients. Marinol® contains synthetic thc, or dronabinol, and is 
registered in Germany and the usa. Cesamet® contains nabilone, a 
thc analogue, and is registered in Canada and the usa. An oromucosal 
spray containing mainly thc and cannabidiol, a non-psychoactive 
cannabinoid, is registered in Canada and in some European countries as 
Sativex® against pain and spasms in ms. Disadvantages of the current 
administration forms are the long tmax-values for these formulations, 
ranging from 1 to 4 hours for Marinol® and Cesamet® (Davis, 2008; 
Schwilke et al., 2009), and 3.3 to 4.0 hours for Sativex® (Karschner 
et al., 2011). Long times to reach a maximal concentration can be a 
disadvantage for on demand symptomatic treatment. Oral dronabinol 
formulations, such as Marinol®, have variable pharmacokinetics, as 
peak plasma concentration variations from 150% to 200% were observed 
in previous studies (Naef et al., 2003; Wall and Perez-Reyes, 1981). This is 
unfavourable for accurate dose regulation.
In the current study, Namisol® was examined, a novel tablet 
formulation of pure thc that was produced using Alitra™ (Echo 
Pharmaceuticals b.v., Nijmegen), an emulsifying drug delivery 
technology. This technology was designed to improve the uptake 
of poorly soluble lipophilic compounds, using less surfactant (less 
than 10% w/w). This is a first in human trial investigating the optimal 
administration route of Namisol®, the safety, pharmacokinetics, 
pharmacodynamics and tolerability. The first objective was to compare 
the sublingual and oral dosing routes of Namisol® tablets with 
respect to pharmacodynamic effects and pharmacokinetics of thc and 
its active metabolite 11-oh-thc and to choose the most favourable 
administration route. This was decided on factors such as a short time 
to maximal thc concentration, and a high maximal concentration. 
The second objective was to use the most favourable administration 
route in a subsequent dose-ranging study, in order to evaluate the 
pharmacokinetics and pharmacodynamic effects of different doses. 
With these objectives, which intend to explore the pharmacokinetic 
and pharmacodynamic properties of Namisol®, no registered cannabis 
based medicines were taken as an additional treatment arm in at this 
early stage of development.
chapter ii – pk and pd of namisol®
– 55 –




The study consisted of two parts. In the first part of the study, 
the pharmacokinetic differences between oral and sublingual 
administration, and the most favourable administration route were 
determined, referred to as ‘Panel I’. Panel I had a double blind, double 
dummy, two-way cross-over design. Panel ii referred to the dose-ranging 
part of the study, which was a randomized, double blind, placebo-
controlled, 3-way dose-escalation trial. For both panels, the wash-out 
period between two treatments was at least two weeks. Subjects were 
medically screened within 3 weeks before dosing. Subjects had a follow-
up visit after the 24-hour pk sample of the last visit of Panel ii.
Sample size
This was an explorative study for which no sample size calculation 
was performed. For Panel I, 12 healthy subjects (6 male, 6 female) were 
included, and for Panel ii, 9 subjects (mixed gender) were included. 
These numbers are usually sufficient to demonstrate significant dose-
related pharmacodynamic effects of thc after inhalation (Zuurman et 
al., 2008; Bossong et al., 2009). Participants from Panel I were allowed to 
continue in Panel ii.
Inclusion and exclusion criteria
After signing the informed consent form, subjects were medically 
screened. Subjects were between 18 and 55 years old and had a body 
mass index between 18.0 and 28.5 kg m-2 (extremes included). They 
had to be cannabis users for at least one year, to minimise the risk of 
oversensitivity to thc in naive subjects. To prevent pharmacokinetic 
and pharmacodynamic tolerance, the maximal use was limited to once 
per week, and subjects were not allowed to have used cannabis from at 
least two weeks prior to the first treatment period to the end of the last 
study day. Subjects were not allowed to smoke more than ten cigarettes 
per day and had to refrain from smoking during study days. Subjects 
using more than six units of (methyl)xanthine products (e.g. coffee, 
tea, cola, chocolate) were not included, and subjects had to stop using 
xanthine containing products from 12 hours prior to dosing until 
discharge. An irregular diurnal rhythm and consumption of grapefruit 
(juice) were not allowed from two weeks prior to the first dose until the 
last study day. quinine and alcohol use were not allowed from two days 
prior to dosing until discharge. Use of medication was not allowed from 
one week prior to dosing until the last study day. Use of illicit drugs 
were not allowed during the study, and each study day prior to dosing, 
illicit drug (including cannabis) use was tested using drug screening 
urine tests. In order to keep a consistent level of sex hormones, female 
subjects were only included if they used the Nuvaring® or one of the 
monophasic oral contraceptives, and were able and willing to skip the 
pill or ring-free week from screening until the end of the study. Pregnant 
and/or breastfeeding women were excluded, and urinary pregnancy 
tests were performed prior to study drug administration. The study 
was approved by the Ethical Review Board of Leiden University Medical 
Center.
Treatments
Namisol® and matching placebo (Echo Pharmaceuticals b.v., Nijmegen) 
were administered as 1.5 mg and 5 mg tablets. In Panel I, one tablet (5.0 
mg thc), and in Panel ii, three tablets (one 5.0 mg and two 1.5 mg tablets 
active or matching placebos) were used for the administration of 6.5 mg 
or 8.0 mg thc or placebo respectively. Oral administrations were done 
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with 200 ml mineral water. Namisol® tablets were not designed for 
sublingual use. Due to a relatively long in vitro disintegration time of 
up to 15 minutes of this experimental formulation, tablets were crushed 
before sublingual administration using Pillmaster (Sell-Plan, Weesp) to 
increase the surface area of the tablet, and, as a result, improve sublingual 
absorption. The crushed tablet was then placed under the tongue using 
cigarette rolling paper.
In Panel I, the following treatments were administered within one 
minute of t = 0: (1) oral Namisol® 5 mg + sublingual matching placebo, 
(2) sublingual Namisol® 5 mg + oral matching placebo. After Panel I, 
an interim analysis of safety, pharmacokinetic and pharmacodynamic 
data was performed. Based on this analysis, the most favourable 
administration route of Namisol® was selected for Panel ii. The dose 
levels for Panel ii were also based on the interim results of Panel I, leading 
to an oral dose selection of 6.5 mg, 8.0 mg or matching placebo.
Pharmacokinetics
For determination of the plasma concentration of thc and its active 
metabolite 11-oh-thc, venous blood was collected in edta tubes of 4 
ml at the following time points: pre dose, 0h11m, 0h30m, 0h45m, 1h00m, 
1h30m, and at 2, 3, 4, 6, 8, 12 and 24 hours. The 24-hour blood sample 
was only drawn in Panel I. After blood collection the tubes were put in 
ice water in light-shielded containers and were centrifuged within one 
hour (10 min, 2000g, 40C). The handling of thc samples was done at 
low ambient lighting. Plasma samples were stored at a temperature of 
at least –70 0C and analysed by Analytisch Biochemisch Laboratorium 
b.v., (Assen) using liquid chromatography/mass spectrometry/mass 
spectrometry (lc-ms/ms) according to good laboratory practice 
procedures. The lower limit of quantification for both thc and 11-oh-
thc was 0.100 ng/ml.
Pharmacodynamics
Pharmacodynamic measurements were performed in ‘test-blocks’, in a 
quiet room with subdued lighting, with only one subject in the same room 
per session. Test-blocks were performed at the following time points: 
twice pre-dose, 0h15m, 0h32m, 0h47, 1h02m, 1h32m, and at 2 minutes 
past 2, 3, 4, 6, and 8 hours. Within three weeks before the first occasion, 
subjects had a training session in order to get acquainted with the phar-
macodynamic tests and to minimise learning effects during the study.
body sway methodology 
Two-minute measurements of postural stability were performed using a 
body sway meter as described previously (Zuurman et al., 2008).
visual analogue scales 
The Bond and Lader visual analogue scales (vas) were used to measure 
subjective alertness, mood, and calmness (Bond and Lader, 1974). The 
Bowdle vas of psychedelic effects were performed in order to measure 
subjective feeling high, and clustered scales that quantify effects on inter-
nal and external perception (Bowdle et al., 1998; Zuurman et al., 2008). 
Internal perception reflects inner feelings that do not correspond with 
reality, including mistrustful feelings, whereas external perception re-
flects a misperception of external stimuli or changes in the awareness of 
the subject’s surroundings. The data were clustered and log transformed, 
and are expressed as units as described previously (Zuurman et al., 2008).
heart rate 
Electrocardiogram (ecg) measurements (Cardiofax V equipped with 
ecaps12 analysis program, Nihon Kohden) were taken in triplicate after 
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having been in a supine position for at least 5 min at the following time 
points: pre-dose, 1h15m and 24h08m (Panel ii only). The qt-intervals 
were corrected for heart rate according to Bazett and Fridericia’s 
qt correction. Blood pressure and heart rate measurements were 
performed using Nihon-Kohden (bsm-1101K) or Colin (Pressmate bp 
8800) automated device after sitting for at least 5 min. Safety heart rate 
and blood pressure measurements were performed at the following 
time points: pre-dose, 1h03m and 23h58m (Panel ii only). Heart rate 
measurements that were also recorded as pharmacodynamic endpoints, 
at time points described in that pertaining section.
Data analysis
As the first part of the study was not placebo-controlled, statistical 
analysis of safety and pharmacodynamics was performed for both study 
panels separately. For the pharmacokinetic parameters, all treatments 
were analysed together. After Panel I, an interim analysis was performed 
for adverse events, pharmacokinetics and pharmacodynamics, to adapt 
the design of Panel ii. 
Non-compartmental pharmacokinetic analysis
Descriptive statistics were calculated for the plasma concentrations 
of thc, 11-oh-thc, and unbound active moiety (thc + 11-oh-thc) at 
each time point and for peak plasma concentration (cmax), time to peak 
plasma concentration (tmax), apparent terminal half-life (t¡/™), and area 
under the curve from t = 0 to infinity (auc0-∞). Dose-proportionality 
was assessed for cmax and auc0-∞. Pharmacokinetic parameters were 
compared with a mixed model analysis of variance and reported with 
95% confidence intervals around the estimated differences. All effects 
were considered significant at the 5% level.
Compartmental pharmacokinetic analysis
A population pharmacokinetic model was developed for the most fa-
vourable Namisol® formulation, in order to make predictions of phar-
macokinetic profiles for further clinical development. Pharmacokinetic 
modelling was conducted using nonmem (version 7.1.2). Pharmacoki-
netics of thc and 11-oh-thc were described using a sequential com-
partmental modelling approach, which was used previously (Strougo et 
al., 2008; Zhang et al., 2003). The model part of 11-oh-thc was linked 
to the individual empirical Bayes estimates determined for the thc 
pharmacokinetic parameters. Different absorption models were tested, 
including first-order absorption and transit models, as well as different 
elimination models, including linear elimination and Michaelis-Menten 
elimination, which was used in a previous model (Strougo et al., 2008). 
Model discrimination was performed using the likelihood ratio test, us-
ing a difference in objective function values of 6.64 as significance cri-
terion (chi-square test, α = 0.01, df = 1). All models were also graphically 
evaluated using goodness of fit plots, depicting individual and popula-
tion predicted versus observed. Potential model misspecification was as-
sessed using plots of residuals versus time and the dependent variable. 
Predictive performance of the final models for internal validation was 
evaluated using a visual predictive check depicting the model simulated 
distribution together with the observed values versus time. 
Pharmacodynamic analyses
Average baseline values per subject and visit for each variable were 
obtained by calculation of the mean of two baseline assessments. Body 
sway was log transformed to correct for the log normal distribution. All 
pharmacodynamic parameters were analysed by mixed model analyses 
of variance (using sas proc mixed) with subject, subject by treatment 
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and subject by time as random effects, with gender, treatment, occasion, 
time, treatment by gender and treatment by time as fixed effects, and the 
average baseline value was included as covariate. For panel I the contrast 
oral thc 5 mg versus sublingual thc 5 mg was calculated. For panel ii 
the calculated contrasts were: placebo versus oral 6.5 mg, placebo versus 
oral 8.0 mg, oral 6.5 mg versus oral 8.0 mg. All effects were considered 
significant at the 5% level.
results
Subjects
For Panel I, 14 subjects (7 males and 7 females) were included in order to 
get 12 complete data sets. Data sets from 13 subjects were used for phar-
macodynamic and pharmacokinetic analysis. One subject dropped out 
after a vasovagal collapse, and one subject for personal circumstances. 
Four males and five females from Panel I continued the study in Panel ii. 
On average, the subjects were 21.4 years old, and had a body mass index of 
21.7 kg m-2. Demographic details per panel can be found in Table 1.
Adverse effects
All adverse events were of mild to moderate intensity and transitory in 
nature. A vasovagal syncope occurred during the first occasion, 32 min-
utes after administration of Namisol® oral 5 mg + Placebo Namisol® 
sublingual, which was considered to be possibly related to treatment 
and led to the subject’s withdrawal. In Panel I, the frequencies and types 
of adverse events were similarly distributed over sublingual and oral 
administration. In Panel ii, compared to placebo, more subjects in thc 
treatment groups had adverse events that were classified as nervous sys-
tem disorders, especially in the 8.0 mg thc treatment group (9/9 sub-
jects; 6.5 mg thc, 7/9 subjects; placebo, 4/9 subjects), with dizziness as 
the most frequent adverse event. The same trend was found for the psy-
chiatric disorder class (8.0 mg thc, 5/9; 6.5 mg thc, 3/9; placebo, 0/9), 
which mainly concerned self reported euphoric mood (‘feeling high’). 
No clinically relevant changes in blood pressure, body temperature, 
haematology, biochemistry, urinalysis or any of the ecg intervals were 
found. Heart rate increase after treatment was analysed as a pharmacody-
namic parameter.
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Noncompartmental pharmacokinetic analysis
Noncompartmental pharmacokinetic parameters of sublingual and oral 
thc are summarised in Table 2 and the concentration profiles of thc 
and 11-oh-thc are given in Figure 1. Based on the interim pk analysis, 
the oral administration route was chosen above the sublingual route. A 
shorter tmax and a higher cmax of oral thc indicated a possibly larger 
effect with a faster onset compared to sublingual administration. These 
differences in tmax and cmax between oral and sublingual administra-
tion were not statistically significant. Sublingual administration showed 
a significant longer apparent t¡/™ compared to oral administration (+122 
min; 95% ci 64 / 181; p = 0.0002). auc0-∞ and cmax of oral thc were dose 
proportional and tmax and t¡/™ were similar for all doses. 
The difference between pharmacokinetic parameters for oral and 
sublingual thc 5 mg administration were not significantly different for 
11-oh-thc, except for the dose corrected peak concentration (0.30 ng/
ml/mg; 95% ci 0.10/0.49; p = 0.0047). Pharmacokinetic profiles for oral 
5.0-, 6.5-, and 8.0 mg thc were also not different, except for t¡/™, where 
5 mg was shorter than both 6.5- and 8.0 mg (115 min; 95% ci 8 / 222; p = 
0.0366; and 110 min; 95% ci 3 / 217; p = 0.0441 respectively). 
Compartmental pharmacokinetic analysis
The two-compartment model for thc pharmacokinetics had first-order 
absorption, linear elimination and a lag time. A proportional model was 
used for the residual error. The estimates for clearance and volumes are 
apparent values, i.e. cl F-1 and V F-1, since this study had no intravenous 
administration and therefore absolute bioavailability (F) could not be de-
termined. Peripheral volume of distribution of thc was approximately 
two times larger than central volume (1780 L vs. 889 L), while the periph-
eral volume of 11-oh-thc was approximately 19 times larger than the 
central volume of distribution (1010 L vs. 52.6 L). Inter-individual vari-
ability was estimated for clearance and central volume. thc clearance 
had a variability of 28.4%. 11-oh-thc had a large variability of clearance 
of 70.4%. Inter-individual variability of the central volume of distribu-
tion was large for thc with 56.3%, and was especially large for 11-oh-
thc with 413%. Almost all parameters showed a relative standard error 
(rse) that was smaller than 30%. An overview of the pharmacokinetic pa-
rameters after oral administration of Namisol® is given in Table 3. Visual 
predictive checks demonstrated that the predictive performance of the 
thc and 11-oh-thc models slightly overestimated the variability dur-
ing wash-out. The visual predictive checks can be found in Figure 2. 
The pharmacokinetic model of thc was used for a stochastic simula-
tion of thc and 11-oh-thc concentrations during a multiple dose de-
sign of two daily 5 mg thc doses. The graphical representation of this 
simulation can be found in Figure 3. In this simulation the plasma con-
centration of thc and 11-oh-thc will not drop below the lower limit 
of quantification (0.100 ng/ml for both thc and 11-oh-thc) in steady 
state before the next dose is administered. The accumulation factor of the 
plasma concentration is 1.02 for thc, and 1.11 for the active metabolite as 
based on this single dose study. 
Pharmacodynamics
Contrasts of pharmacodynamic parameters are summarised in Table 4. 
As an example of the graphical representation of the pharmacodynamic 
parameters, the effect of Namisol® on body sway is given in Figure 4. In 
panel I, oral thc administration gave a statistically significant increase 
in vas calmness, compared to sublingual administration. This difference 
was not considered clinically relevant, as the absolute peak difference 
was 3 mm on a 100 mm scale. Between oral and sublingual administra-
tion, no clinically relevant differences in pd parameters were observed. In 
panel ii, significant increases were found between thc 6.5 mg and pla-
cebo on vas external perception, vas feeling high, and heart rate. thc 8.0 
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mg produced a decrease on vas alertness, and increases on body sway, vas 
external perception, vas feeling high, and heart rate compared to place-
bo. The thc-effects changed in a dose-dependent way, which was signifi-
cant for body sway when comparing thc 6.5 mg and 8.0 mg. 
discussion
Available oral thc formulations and cannabis based medicines gener-
ally show disadvantageous pharmacokinetics that cause difficulties in 
dose regulation. Namisol® is a new thc formulation that was devel-
oped to achieve a more favourable pharmacokinetic profile. Since phar-
macokinetic characteristics of thc ultimately determine its pharma-
codynamic features, a fast onset of action and less variable response, as 
found in this study, are expected to lead to a more rapid and consistent 
clinical response. This study was designed to investigate two administra-
tion routes of Namisol® and three different oral doses of Namisol® in 
healthy volunteers.
Route of administration
The pharmacokinetic differences after oral and sublingual administra-
tion were small. Sublingual administration showed more flat concentra-
tion profiles of thc and 11-oh-thc, compared to oral administration, a 
late and small maximal concentration and a long apparent terminal half-
life. This could be explained by a relatively small absorption constant of 
thc from the oral mucosa into the blood, with an absorption that could 
be slower than the elimination or distribution. The slow absorption from 
the oral mucosa after sublingual administration could be caused by the 
lipophilic character of thc. Furthermore, no in-vitro data are available that 
support a slow absorption. The more favourable pharmacokinetic pro-
file of the oral tablet compared to the sublingual route implies beneficial 
pharmacodynamic properties of oral Namisol®, such as an improvement 
of speed and accuracy of the onset and of the extent of the effects. There-
fore, combined with the practical convenience of the administration pro-
cedure, the oral administration route was found to be most optimal.
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Pharmacokinetics
Oral Namisol® showed a short time to reach maximal thc 
concentration (39-56 min) compared to reported values in previous 
studies using oral thc (60-240 min), nabilone (120-240 min), or oral-
mucosal thc+cbd (Sativex®, 198-240 min) (Valeant Pharmaceuticals 
International, 2006; Davis, 2008; Schwilke et al., 2009; Karschner et al., 
2011; Naef et al., 2003). Namisol® also had a shorter time to maximal 
concentration of the active metabolite 11-oh-thc (46-84 min) compared 
to what has been published for dronabinol (120-204 min) and Sativex® 
(216-234 min) (Naef et al., 2003; Karschner et al., 2011). Although direct 
comparative studies are needed to corroborate these findings, the 
differences seem large enough to be realistic, and to be clinically relevant 
if the therapeutic effects follow the plasma concentrations reasonably 
directly. If so, Namisol® could give faster clinical effects compared to 
other oral formulations with thc or cannabis based medicines that 
are currently in clinical use. The short time to reach maximal thc and 
11-oh-thc concentrations could be explained by a fast absorption 
of Namisol®. Inter-individual variability of Namisol® parameters 
was relatively large when compared to thc inhalation, as shown by 
compartmental analysis on thc pharmacokinetic parameters (Strougo 
et al., 2008). However, variability of thc maximal concentration was 
two to five times smaller than reported previously for dronabinol, which 
was based on non-compartmental analysis (Naef et al., 2003; Wall et al., 
1983). This first in human study was primarily intended to explore the 
pharmacokinetic and pharmacodynamic properties of Namisol®. At 
this early stage of development therefore, no registered cannabis based 
medicines were taken as an additional treatment arm. Although there 
are clear limitations to comparisons with literature data, in summary, 
the pharmacokinetic properties suggest that thc from Namisol® might 
have a faster absorption and a less variable maximal concentration. 
Therefore, pharmacokinetics of Namisol® could be more favourable 
than currently registered oral dronabinol formulations and cannabis 
based medicines.
The pharmacokinetic model that was developed for thc and 11-oh-
thc can be used to predict concentration-time profiles of alternative 
dosing scenarios. Hence, ’what-if’ questions that are related to phar-
macokinetics can be answered in further clinical development of this 
compound. Compartmental pharmacokinetic analysis assessed that the 
apparent terminal half-life of 11-oh-thc was shorter for oral 5.0 mg 
compared to 6.5 and 8.0 mg. This could be explained by the fact that the 
concentration after 5.0 mg drops below the lower limit of quantification 
more rapidly than for higher doses, and this does not necessarily imply 
that the actual half-life is different for oral than for sublingual adminis-
trations. A previous study administering 5 mg of labelled thc intrave-
nously found that thc was still detectable in plasma 72 h after adminis-
tration (Ohlsson et al., 1982), while in the current study no thc or 11-oh-
thc was detected in plasma at 24 h after administration. This confirms 
our implication that the limitations of the limit of quantification and the 
time frame of sampling in the current study thwarted an accurate estima-
tion of the half-life of oral and sublingual Namisol®.
Compared with intravenous administration and inhalation, the 
concentration of the 11-oh metabolite after oral thc administrations 
from Namisol® was relatively high (Committee for medicinal products 
for human use, 2010; Valeant Pharmaceuticals International, 2006; 
Wilson and May, 1975). The ratio of 11-oh-thc:thc (based on peak 
plasma concentrations) was 1:30 for intravenous administration and 1:7 
for inhalation, while this ratio was 1:0.6-0.8 for Namisol® (Naef et al., 
2004; Grotenhermen, 2003; Strougo et al., 2008). Previous studies with 
oral dronabinol and Sativex® also gave a lower metabolite concentration 
compared to Namisol® (11-oh-thc:thc was 1:1.2-2.0) (Schwilke et al., 
2009; Karschner et al., 2011). The relatively high levels of 11-oh-thc 
compared to the parent compound thc could be explained by several 
concomitant or alternative factors that could not be identified in this 
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study. High concentrations of the metabolite suggest that considerable 
first-pass metabolism is taking place. Considering the absorption rate 
constant of 0.04 per minute suggested by the pk-model, it is possible that 
thc stays in the gastro-intestinal tract for a relatively long time where 
much of it is locally metabolised to 11-oh-thc. The metabolite is then 
absorbed from the gastrointestinal tract to the blood, where it is not as 
rapidly distributed to fatty tissues as thc, due to the metabolite’s less 
lipophilic character. At the same time, thc could rapidly disappear from 
blood into more fatty tissues, leading to low plasma concentrations. Long 
blood sampling schedules and very low detection thresholds for thc and 
its metabolites in plasma or mass balance studies would be needed to 
resolve the complex pharmacokinetics of thc in more detail.
Pharmacodynamics
Although the thc plasma concentrations after oral Namisol® 
administration were relatively low after completion of Panel I, the 
pharmacodynamic effects were larger than we had expected, and 
comparable to those observed in a thc inhalation study in which 
high peak thc plasma concentrations were found (Zuurman et al., 
2008). This could reflect a large pharmacological effect of the 11-oh-
metabolite. Preclinical studies have found 11-oh-thc to be a highly 
potent cb¡-agonist (Karler and Turkanis, 1987; Wilson and May, 1975), 
and clinical studies also reported more rapid and larger effects after 
11-oh-thc administration compared to thc (Lemberger et al., 1972; 
Lemberger, 1973; Lemberger et al., 1973). In itself, this would have 
allowed us to predict the pharmacodynamic effects of higher doses 
in Panel ii, by reference to the results of other oral thc formulations 
in the literature which also produce high concentrations of 11-oh-
thc. However, quantitative comparisons were quite difficult to make 
because of differences in methodology and study designs (Curran et al., 
2002; Zuurman et al., 2009). Moreover, it was impossible to exclude the 
alternative (or additional) explanation that the large pharmacodynamic 
effects are due to a more efficient absorption of thc from the Namisol® 
formulation, with rapid redistribution to the cns during the absorption 
phase. Since after Panel I we could not be certain about the dose 
proportionality of Namisol® at higher doses, we decided to continue 
the study in Panel ii with two conservatively small dose increases (to 6.5 
and 8 mg) for reasons of safety and tolerability, and to increase the dose 
further if necessary and possible. 
The first pharmacodynamic effects of Namisol® 6.5 and 8.0 mg 
were already observed during the first assessments, 15 min after dosing. 
Namisol® had a faster onset of action than reported in a previous 
study with oral dronabinol (Marinol®), which had an onset of action 
between 0.5 and 1 hour, and peak effects that were reached between 
2 and 4 hours (Solvay Pharmaceuticals, 2004). The time profile of the 
pharmacodynamic effects was more similar to the concentration curve 
of 11-oh-thc than that of thc. A previous study reported that 11-oh-
thc induces a quicker onset of the pharmacodynamic effects compared 
to thc (Lemberger et al., 1972; Lemberger, 1973; Lemberger et al., 1973). 
These results in this study are quite promising for a fast onset of the 
clinical effects in a patient population, although future studies should 
carefully investigate the relation between pharmacodynamic effects in 
healthy volunteers and clinical effects in patients. Also, a more detailed 
analysis of the cns-effects of thc and 11-oh-thc should be done in 
humans to separate the contributions of both compounds to the effects. A 
future study where the effects of thc are compared with those of 11-oh-
thc alone could provide meaningful information about the relative 
contributions of 11-oh-thc to the cns-effects of thc and cannabis. 
In conclusion, Namisol® is a novel formulation of thc that is well-
tolerated and absorbed quickly after ingestion, and reaches peak plasma 
concentrations within one hour and maximal effects between 1 to 2 
hours after Namisol® administration. Compared to the literature on 
registered dronabinol formulations and cannabis based medicines, these 
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results imply that Namisol® may also have favourable pharmacokinetic 
and pharmacodynamic characteristics in patients. Further clinical 
studies are needed to show that these apparent advantages are also 
therapeutically relevant.
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table 1  Summary of subject demographics of Panel i and Panel ii
Variable N Mean Std Min Max
panel i Gender (M:F) 7:7
Age (yrs) 14 21.4 3.3 18 27
bmi (kg m-2) 14 21.71 1.52 18.4 24.5
Height (m) 14 1.783 0.103 1.62 1.96
Weight (kg) 14 69.09 10.13 55.3 90.1
panel ii Gender (M:F) 4:5
Age (yrs) 9 21.9 3.8 18 27
bmi (kg m-2) 9 22.31 0.97 21.1 24.5
Height (m) 9 1.766 0.099 1.62 1.91
Weight (kg) 9 69.70 8.91 55.3 80.6
      
table 2  Pharmacokinetic parameters of thc and 11-oh-thc after sublingual and oral administration of Namisol®. 
All data are presented as means with coefficient of variation (%).
Panel I (n=13) I (n=13) II (n=9) II (n=9)
Parameter 5.0 mg sublingual 5.0 mg oral 6.5 mg oral 8.0 mg oral
thc
Cmax (ng ml-1) 2.30 (44) 2.92 (51) 4.43 (42) 4.69 (62)
Tmax (min) 74.5 (52) 56.0 (73) 39.3 (20) 43.6 (26)
auc0-∞ (ng.min ml
-1) 235.8 (47) 188.7 (40) 286.6 (36) 377.2 (46)
t¡ /™ (min) 252.9 (98) 71.9 (24) 80.0 (22) 78.8 (21)
11-oh-thc
Cmax (ng ml-1) 3.08 (42) 4.68 (42) 5.94 (44) 6.10 (53)
Tmax (min) 83.6 (63) 74.1 (68) 46.1 (28) 78.4 (63)
auc0-∞ (ng.min ml
-1) 522.9 (50) 648.1 (49) 848.7 (42) 1087.3 (50)
t¡ /™ (min) 279.0 (51) 196.0 (33) 318.7 (54) 314.1 (58)
* Cmax and aucº-∞ were dose-corrected for treatment p-value calculation
 Cmax=peak plasma concentration; Tmax=time to peak plasma concentration; 
 aucº-∞=area under the curve from t=0 to infinity; t¡/™= apparent terminal half-life.
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table 3 thc population pharmacokinetic parameters after oral Namisol®.
thc 11-oh-thc
Parameter Estimate (rse) iiv Estimate (rse) iiv
Clearance/F (L min-1)* 26.5 (10.6) 28.4 9.53 (25) 70.4
Central volume of distribution/F (L)* 889 (22.5) 56.3 52.6 (47.9) 413
Peripheral volume of distribution/F (L)* 1790 (21.9) - 1010 (15.3) 21.1
Intercompartmental clearance/F (L min-1)* 13.3 (17) - 4.46 (34.5) 50.7
Absorption rate constant (min-1) 0.0401 (22) - - -
Proportional residual error (sd mean-1) 0.509 (8) - 0.461 (6.2) -
Absorption lag time (min) 11.5 (0.9) - - -
* This parameter is an apparent parameter as bioavailability could not be calculated. 
 rse = relative standard error (%); iiv=inter-individual variability (coefficient of variation, %).
table 4  Pharmacodynamic effects after Namisol® dosing. Treatment differences are given in estimated differences 
of least square means with 95% confidence intervals and p-values. Log transformed vas (scores in mm + 2) are given in 
units (U).
Panel I (n=13) II (n=9) II (n=9) II (n=9)
Parameter 5.0 mg oral vs  
5.0 mg sublingual
6.5 mg oral vs 
placebo
8.0 mg oral vs 
placebo
8.0 mg vs  
6.5 mg oral
Body sway (%) 7.66 (-4.62, 21.53) 
p=0.2037
22.06 (-1.05, 50.57) 
p=0.0610
60.82 (29.46, 99.79) 
p=0.0003*
31.76 (6.53, 62.96) 
p=0.0145*
vas Alertness (mm) -0.3 (-2.0, 1.5) 
p=0.7124
-1.4 (-3.2, 0.4) 
p=0.1161
-2.7 (-4.5, -0.9) 
p=0.0057*
-1.3 (-3.1, 0.5) 
p=0.1390
vas Mood (mm) 0.8 (-0.1, 1.6) 
p=0.0653
0.1 (-0.3, 0.5) 
p=0.5357
0.2 (-0.2, 0.6) 
p=0.3686
0.1 (-0.4, 0.5) 
p=0.7815
vas Calmness (mm) 1.8 (0.1, 3.5) 
p=0.0443*
0.7 (-0.1, 1.4) 
p=0.0665
0.5 (-0.2, 1.2) 
p=0.1246
-0.1 (-0.9, 0.6) 
p=0.7080
vas Feeling high (U) 0.111 (-.042, 0.265) 
p=0.1347
0.229 (0.073, 0.384) 
p=0.0071*
0.256 (0.093, 0.418) 
p=0.0044*
0.027 (-.129, 0.183) 
p=0.7145
vas External  
perception (U)
0.037 (-.017, 0.090) 
p=0.1482
0.061 (0.002, 0.121) 
p=0.0446*
0.078 (0.019, 0.137) 
p=0.0141*
0.017 (-.042, 0.076) 
p=0.5507
vas Internal  
perception (U)
0.006 (-.014, 0.026) 
p=0.5247
0.013 (-.003, 0.029) 
p=0.1057
0.002 (-.015, 0.019) 
p=0.8312
-0.011 (-.028, 0.005) 
p=0.1632






0.3 (-2.7, 3.2) 
p=0.8524
* Statistically significant values
figure 1  thc (A) en 11-oh-thc (B) concentrations after sublingual 5.0 mg and oral 5.0-, 6.5- and 8.0 mg Namisol® 
administration as estimated with a mixed model. Closed circles are sublingual thc 5 mg, open circles are oral thc  
5.0 mg, triangles are oral thc 6.5 mg, and squares are oral thc 8.0 mg. Error bars represent standard deviations.
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figure 3  Stochastic simulations (n=2000) of concentrations of thc after a single 5 mg dose (A), and after 21 dosages,  
5 mg two times per day (B) and simulations of 11-oh-thc concentrations after a single 5 mg dose (C), and after 21 dos-
ages, 5 mg two times per day (D). Sd = single dose; bid = two doses per day.
figure 2  Visual predictive checks of thc concentrations after thc 5.0-, 6.5-, and 8.0 mg (figures A, B and C), and  
of 11-oh-thc concentrations (figures D, E, and F). Lower limit of quantification for thc and 11-oh-thc is 0.1 ng/ml.
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figure 4  Effect-time profiles of baseline corrected body sway least square means in %, with 95% confidence 
interval error bars. Figure A shows the results from Panel i of the study, including sublingual thc 5.0 mg as closed 
circles, and oral thc 5.0 mg as open circles. Figure B has the results of Panel ii, with oral thc 6.5 mg as triangles, 
and oral thc 8.0 mg as squares.
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abstract
aim Resting state-functional magnetic resonance imaging (rs-fmri) 
is a neuroimaging technique that allows repeated assessments of func-
tional connectivity in resting state. While task-related fmri is limited 
to indirectly measured drug effects in areas affected by the task, resting 
state can show direct cns effects across all brain networks. Hence, rs-fm-
ri could be an objective measure for compounds affecting the cns. Sev-
eral studies on the effects of cannabinoid receptor type 1 (cb¡)-receptor 
agonist ∆9-tetrahydrocannabinol (thc) on task-dependent fmri have 
been performed. However, no studies on the effects of cannabinoids on 
resting state networks using rs-fmri have been published. Therefore, 
we investigated the effects of thc on functional brain connectivity using 
rs-fmri.
methods Twelve healthy volunteers (9 male, 3 female) inhaled 2, 6 
and 6 mg thc or placebo with 90-minute intervals in a randomized, 
double blind, cross-over trial. Eight rs-fmri scans of 8 minutes were ob-
tained per occasion. Subjects rated subjective psychedelic effects on a vi-
sual analogue scale after each scan, as pharmacodynamic effect measures. 
Drug-induced effects on functional connectivity were examined using 
dual regression with fsl software (fmrib Analysis Group, Oxford). Eight 
maps of voxel-wise connectivity throughout the entire brain were pro-
vided per rs-fmri series with eight predefined resting-state networks of 
interest. These maps were used in a mixed effects model group analysis 
to determine brain regions with a statistically significant drug-by-time 
interaction. Statistical images were cluster-corrected, and results were 
Bonferroni-corrected across multiple contrasts.
results thc administration increased functional connectivity in the 
sensorimotor network, and was associated with dissociable lateralised 
connectivity changes in the right and left dorsal visual stream networks. 
The brain regions showing connectivity changes included the cerebel-
lum and dorsal frontal cortical regions. Clear increases were found for 
feeling high, external perception, heart rate and cortisol, whereas prolac-
tin decreased.
conclusions This study shows that thc induces both increases and 
(to a lesser extent) decreases in functional brain connectivity, mainly in 
brain regions with high densities of cb¡-receptors. Some of the involved 
regions could be functionally related to robust thc-induced cns-effects 
that have been found in previous studies (Zuurman et al, 2008), such as 
postural stability, feeling high and altered time perception.
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introduction
Ideally, early clinical phase drug development for neurological and psy-
chiatric indications should use tests that measure effects in an objective 
way and repeatedly over time across different species. These tests should 
also be able to distinguish unique effect profiles for different classes of 
drugs. Traditionally, measurements of drug effects on the central ner-
vous system (cns) in healthy volunteers include cognitive tasks, various 
questionnaires, neurophysiological measurements, and increasingly 
also neuroimaging. The wide diversity of these tests and their numerous 
variations limits their applicability for decision making in clinical prac-
tice or drug development. In addition, pharmacological studies can only 
include a limited number of pre-defined pharmacodynamic tests, which 
can easily miss drug effects in cns domains that are not tested. Moreover, 
most cns effects are influenced by various functions like attention and 
motor coordination, and therefore do not provide direct information on 
an exact site of drug action. 
Imaging techniques have the advantage of objectively assessing direct 
effects in the body. However, positron emission tomography (pet) stud-
ies have radiation dose restrictions that limit repeated measurements 
within subjects, and the targeted pharmacological or functional system 
is restricted by the availability of an appropriate imaging agent. Func-
tional magnetic resonance imaging (fmri) on the other hand is a non-
invasive imaging technique based on blood-oxygen-level-dependent 
(bold) measurements that represent brain activity. Until recently, fmri 
was applicable in task-related designs only, in which pharmacologically 
induced changes in bold signals were measured in response to a specific 
task. The application of fmri in drug development has several restric-
tions, imposed by the need for a pre-defined hypothesis about how the 
drug affects the task, and by limitations related to the scanning environ-
ment and to repetitive testing.
Resting state (rs) fmri is a recently developed imaging technique 
that measures spontaneous bold changes of subjects who are in a rest-
ing state, without the interference of any task or specific stimulus. This 
means that rs-fmri can be applied in studies without a priori hypotheses 
on action site. The fact that rs-fmri is non-invasive and not affected by 
variability or limitations of task performance and that it can be frequent-
ly and rapidly repeated, could make it a highly valuable technique in cns 
drug development. Although experience is still limited, rs-fmri could 
be applied in pre-clinical animal studies, healthy volunteers and pa-
tients, which could make it a suitable translational instrument in drug 
development.
Previous studies found that coherent resting state bold fluctuations 
form spatially correlated brain maps, or resting-state networks (rsns) 
(Beckmann et al., 2005; Biswal et al., 2010). rsns have shown to be consis-
tently present across human subjects, and could represent brain regions 
that are anatomically and functionally connected, and related to behav-
ioural outcomes and clinical conditions (De Luca et al., 2006; Greicius et 
al., 2004; Fox et al., 2007; quigley et al., 2003; Smith et al., 2009; Damoi-
seaux et al., 2006). A previous study by Mennes et al. suggested that inter-
individual differences in rs-fmri could predict the response to task-in-
duced bold activity (Mennes et al., 2010). Only a few studies investigated 
the effects of pharmacologically active cns compounds on the functional 
topography of rsns. We recently conducted a study where rs-fmri was 
repeated while plasma levels of morphine and alcohol were kept stable 
(Khalili-Mahani et al., 2011). In order to develop a broad basis for this 
technique by investigating reliability and reproducibility, more studies 
using different drug classes should be performed. This would provide 
important methodological information and reference data for the use of 
rs-fmri as a biomarker for cns drug research (Wise and Preston, 2010).
In the current study we investigated the effects of ∆9-tetrahydroc-
annabinol (thc) on the brain using rs-fmri. thc is a major pharmaco-
logically active constituent of the plant Cannabis sativa L. In the body, thc 
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binds to two cannabinoid receptors (cb¡ and cb™) of which cb¡ receptors 
are predominantly present in various brain areas (Herkenham, 1992). The 
action of thc on the cb¡ receptors is generally considered responsible for 
the commonly known pharmacodynamic effects, such as feeling high 
and postural instability (Zuurman et al., 2008). 
Previous pet and fmri studies with thc that investigated regional 
cerebral blood flow and bold signal fluctuation found thc-induced 
effects on the limbic system (thalamus, amygdala, hippocampus, 
parahippocampal gyrus, cingulate cortex) and connected areas (basal 
ganglia, frontal cortex), which are involved in reward, emotion, memory, 
awareness, pain, and executive functions (Bhattacharyya et al., 2009; 
Mathew et al., 1998; Mathew et al., 1999; Mathew et al., 2002; Stokes et 
al., 2010; van Hell et al., 2011). thc also affects areas of sensory (insula, 
postcentral gyrus, superior temporal gyrus), and motor coordination 
systems (cerebellum). The functions associated with these regions are 
related to the behavioural effects after thc or cannabis use (Zuurman et 
al., 2009). 
The primary aim of this study was to investigate the effects of thc on 
task-independent rs-fmri functional connectivity patterns using re-
petitive measures in healthy volunteers. Based on previous studies us-
ing other psychopharmacological manipulations (Khalili-Mahani et al., 
2011) we hypothesised that thc would induce changes in brain connec-
tivity compared to placebo. In addition, we measured the plasma concen-
trations of thc and its active metabolite 11-hydroxy-thc (11-oh-thc) 
as well as a number of well-known thc-related cns effects. Based on our 
previous studies, we expected to measure clear thc and metabolite plas-
ma concentration profiles, and prominent pharmacodynamic effects, 
other than rs-fmri (Strougo et al., 2008; Zuurman et al., 2008).
methods
Design
This was a double-blind, randomized, placebo-controlled, two-way 
cross- over study with a wash-out period of at least 2 weeks.
Subjects
Healthy, right-handed male and female volunteers aged 18 to 45 years 
with a body mass index of 18.0 to 28.5 kg/m2 were included in the study. 
Subjects with a history of psychiatric or neurological illness, or with a 
history of hereditary psychiatric illness in first degree relatives or neu-
rological illness in first- or second degree relatives were excluded from 
participation. Subjects had to be cannabis users for at least 1 year with 
use frequency of no more than once a week, and had to be able to refrain 
from using cannabinoids from at least 2 weeks prior to the first treatment 
period up to the end of the study. They had to refrain from nicotine and 
caffeinated products on study days. Subjects were excluded if they used 
medication other than contraceptives, and if they were pregnant (as as-
sessed by hcg urine test). They were not allowed to have a positive alco-
hol breath test or drug urine test at the screening visit or at the start of 
a study day, neither a history of alcohol or drug dependence. Subjects 
could not participate if they had metal body implants or claustrophobia.
As this was an explorative study, no sample size calculation could 
be performed. We planned a sample size of 12 volunteers (6 male and 6 
female) who completed two occasions, since in all drug studies that we 
have performed so far, numbers of 12 subjects were found to be sufficient 
(Strougo et al., 2008; Desmond and Glover, 2002), and a similar number 
was also mentioned in a study about the power of fmri and rs-fmri. 
Subjects who were not able to complete two occasions would be replaced.
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Procedure
Subjects gave written informed consent before any study-specific pro-
cedure was performed. Eligible subjects were enrolled in the study af-
ter a general health screen within three weeks before the first study day. 
Subjects were acquainted with the visual analogue scales questionnaire 
and the inhalation procedure using thc vehicle. At each study day, thc 
or placebo was administered at 0m, 1h30m and 3h00m. Pharmacody-
namic (pd) and pharmacokinetic (pk) measurements were frequently 
performed on all study days at fixed time points, as chronologically in-
dicated in Figure 1. At the beginning of each study day a venflon cannula 
was inserted intravenously for all blood samples that were drawn on both 
study days. Subjects were fasted for at least 4 hours at arrival, and stan-
dardized meals were provided pre-dose, and at 3h40m and after the last 
study day activity at 6h47m. The wash-out period between study days 
was at least two weeks. The study protocol was approved by the Medical 
Ethics Review Board of Leiden University Medical Center and complied 
with the principles of ich-gcp, the Helsinki declaration and Dutch laws 
and regulations.
Treatments
Each study day, subjects received three doses of thc (2-, 6-, and 6 mg) or pla-
cebo via inhalation with 1.5 h intervals. Two mg purified thc was dissolved 
in 200 µl 100% ethanol. The thc dosages were selected to reach and main-
tain clear central nervous system effects as predicted by pk-pd models that 
were based on a previous study (Strougo et al., 2008). Procedures for vapor-
izing the solution and inhalation of the vapour were done according to a 
method as previously described (Zuurman et al., 2008). In addition to this 
procedure, the current study used a nose clip during the thc or placebo ad-
ministrations to prevent nasal exhalation, in order to reduce pharmacoki-
netic variability by minimizing undetected loss of thc vapour.
Outcome measures
A schematic representation of the time points of the study day activities 
is given in Figure 1. The precision of all activities is imposed by the tight 
time schedule.
pharmacokinetic measurements and  
bio-analysis
To determine thc plasma concentration, venous blood samples were col-
lected in 4 ml edta tubes at 5, 20 and 88 min after each administration 
and at 178 min after the third administration only. After collection, the 
tubes were kept on ice water in aluminium foiled containers and centri-
fuged within one hour for 10 minutes at 2000G at 4 0C. thc samples were 
handled sheltered from light. Plasma samples were stored at –20 0C and 
sent to Analytisch Biochemisch Laboratorium (abl, Assen) for analysis. 
Plasma thc as well as metabolite concentrations (11-hydroxy-thc and 
11-nor-9 carboxy-thc) were determined using tandem mass spec-
trometry with a lower limit of quantification of 1.00 ng/ml. 
pharmacodynamic assessments
imaging – Resting state functional magnetic resonance imaging (rs-
fmri) scans were made pre-dose and at 10 and 70 min after the first 
and second thc administrations, and 10, 100 and 190 min after the 
third administration. The differences in time points of measurements 
performed after the first and second administration versus after the 
third thc administration were chosen to investigate a more extended 
time course of thc and metabolite plasma concentrations, and 
pharmacodynamics. As the interval of the thc dosing schedule was 90 
minutes, the time frame in which measurements could be performed 
that were related to the previous thc administration was limited 
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to 90 minutes. Subjects were asked not to move or talk and to look at a 
fixation cross during scanning to improve the subject’s comfort in thc 
conditions, and to minimize the risk of falling asleep during scanning. 
Four chest electrodes and the scanner’s flexible pressure belt were used 
to record heart rate and respiration rate during scanning. A 3T Achieva 
scanner (Philips Medical System, Best) was used for image acquisition. 
rs-fmri scans were T2*-weighted and consisted of 220 gradient echo 
‘echo planar imaging’ (epi) volumes (repetition time interval = 2180 ms; 
echo time interval = 30 ms; flip angle = 800; 38 axial slices; 64x64x38 
isotropic resolution 3.44 mm; scan time = 8.1 min). For anatomical 
registration, a T1-weighted scan was obtained for each subject at the end 
of each study day.
visual analogue scales (vas) – vas by Bond and Lader is a 16-item 
subjective assessment of subjective effect on alertness (composition 
of items alert/drowsy, strong/feeble, muzzy/clear-handed, well 
coordinated/clumsy, lethargic/energetic, mentally slow/quick-
witted, attentive/dreamy, incompetent/proficient, and interested/
bored), on mood (composition of items contended/discontented, 
troubled/tranquil, happy/sad, antagonistic/amicable, and withdrawn/
gregarious), and calmness (composition of items calm/excited, and 
tense/relaxed) (Bond and Lader, 1974). The adapted version of vas by 
Bowdle et al. (1998) is a 13-item assessment of subjective effects on 
item ‘feeling high’ and on factors ‘internal perception’ and ‘external 
perception’, which are both compositions of items that are affected 
differently by thc as previously described (Zuurman et al., 2008). vas 
were included in this study to provide a positive control for thc-induced 
pharmacodynamic effects, as previous studies showed clear effects on the 
vas (Zuurman et al., 2008; Zuurman et al., 2008; Zuurman et al., 2009). 
The measurements were taken twice pre-dose, and at time points: 29 
and 59 min, 1h23min, 1h59min, 2h29min, 2h53min, 3h35min, 4h29min, 
4h57min, 5h59min, and 6h42min.
heart rate and blood pressure – Heart rate and blood pressure 
were taken as safety measurements using a Nihon-Koden (Lifescope ec, 
Tokyo, Japan) blood pressure apparatus. Heart rate measurements were 
used as an objective measure for treatment effects, as previous studies 
showed clear heart rate effects (Zuurman et al., 2008; Zuurman et al., 
2008; Zuurman et al., 2009). Heart rate measurements were taken 3 
minutes after each time point of vas measurements as mentioned in 
the previous paragraph. Blood pressure was measured pre-dose, and at 
6h45min.
hormones – Prolactin levels (µgr/l) were measured as a biomarker 
for dopaminergic activity (de Visser et al., 2001). Cortisol (µmol/ml), 
luteinizing hormone (lh, ng/ml) and follicle-stimulating hormone 
(fsh, U/l) were measured as exploratory biomarkers of hypothalamic-
pituitary activity (Chen et al., 2010). Due to the diurnal rhythm of 
cortisol, the two study days of each subject were consistently scheduled 
at the same time of the day. Blood samples for lh, fsh, prolactin and 
cortisol were collected twice pre-dose, at 20 and 1h28min after each 
thc administration and an additional sample was taken at 5h58min. 
Serum was separated by centrifugation (2000g at 40C for 10 min) within 
1 h of collection. The samples were analyzed by the Central Clinical 
Chemistry Laboratory (Leiden University Medical Center, Leiden) using 
an electrochemoluminiscence-immunoassay for prolactin and cortisol, 
and a fluoro-immunoassay for lh and fsh.
metabolic blood measures – The study was also used to perform 
an exploratory analysis of several metabolic effects of thc. Glucose 
(mmol/l), high-density lipoprotein (hdl) cholesterol (mmol/l), leptin 
(µg/l) and triglycerides (mmol/l) serum samples were analyzed by the 
Central Clinical Chemistry Laboratory (Leiden University Medical 
Center, Leiden). For description of serum collection and time points, see 
‘hormones’ section.
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For vital signs [heart rate (hr) in beats per minute (bpm) and blood pres-
sure (mmHg)], raw data and changes from baseline were analyzed by type 
of measurement and parameter and treatment using descriptive statis-
tics. hr and pr-, qrs-, and qt-intervals, corrected qt (qtc) (all in ms) from 
automatic reading were analyzed as raw parameter value and change from 
baseline (for hr and qtc only). Adverse events were coded according to the 
Medical Dictionary for Regulatory Activities (Meddra version 13.0).
pharmacokinetics 
All concentrations and maximal concentration (cmax), time of maxi-
mal concentration (tmax), area under the curve from zero to infinity 
(auc0-∞), and terminal half-life (t¡/™) of thc and its metabolites 11-oh-
thc, and thc-cooh were summarized by mean, standard deviation 
(sd), standard error of the mean (sem), coefficient of variation (cv%), and 
number of available observations. Also, a population pharmacokinetic 
analysis was performed based on a previously described two-compart-
mental model (Strougo et al., 2008), with the addition of the active me-
tabolite 11-oh-thc in a separate compartment. A post hoc analysis on 
gender differences was performed using a linear mixed effect model with 
treatment, period, time and treatment by time as fixed effects, subjects 
and subject by treatment as random effects and with baseline value as co-
variate (sas for windows V9.1.2 ; sas Institute, Inc., Cary, nc, usa).
pharmacodynamics
Resting State fmri data processing was carried out using the Functional 
Magnetic Resonance Imaging of the Brain (fmrib) Software Library (fsl 
4.1, Oxford, uk), using the same analysis techniques for pharmacological 
rs-fmri as reported previously (Khalili-Mahani et al., 2011).
For preprocessing the following standard procedure was performed: 
head motion correction, brain extraction, Gaussian smoothing with a 5 
mm fwhm kernel, grand-mean scaling of each bold fmri dataset by a 
single multiplicative factor; high-pass temporal filtering (fwhm = 100s). 
After preprocessing, the epi data were affine-registered to the anatomi-
cal T1-weighted scan, and the anatomical scan was subsequently affine-
registered to the mni 152 standard space (Montreal Neurological Insti-
tute, Montreal, Canada). fmri images in mni space were interpolated to 
2x2x2 mm voxels.
rsn functional connectivity was determined as similarity of the bold 
fluctuations in each brain voxel in relation to characteristic fluctuation 
in eight predefined networks of interest (nois). These networks were 
obtained from a published model-free analysis of the spatio-temporal 
structure of the resting-state bold fluctuations (Beckmann et al., 2005). 
The template nois include over 80% of the total brain volume and com-
prise the following networks: medial and lateral visual (nois 1 and 2, re-
spectively, including primary visual areas), auditory and somatosensory 
(noi 3, including areas involved with hearing), sensorimotor (noi 4), de-
fault mode [noi 5, of which is hypothesized that these regions are associ-
ated with the representation of the world around us and spatial attention 
(Miller and Cohen, 2001)], executive control (noi 6, these areas have been 
hypothesized to provide bias signals to other areas of the brain in order 
to implement cognitive control), and right and left-lateralized fronto-
parietal dorsal visual [nois 7 and 8, probably representing information 
relevant for (visual) attention, but related to visuospatial and verbal at-
tention respectively] (Beckmann et al., 2005; Laird et al., 2011). The pre-
defined networks, as determined by the weighted template nois, were 
calculated for the study sample.
Connectivity to each of the 8 nois, for each voxel, was measured using 
dual-regression (Filippini et al., 2009; Beckmann et al., 2005) followed by 
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a mixed effects model group analysis. Dual-regression analysis gene-
rated whole-brain statistical maps of z-scores representing voxel-wise 
functional connectivity across all regions with the characteristic activity 
in each of the nois (12 subjects x 8 scans x 2 occasions x 8 nois). The 
higher the absolute value of the z-score, the stronger the connectivity to 
a given noi.
Variations in heart rate and respiratory rate could be induced phar-
macologically by thc administrations (Zuurman et al., 2008; Zuurman 
et al., 2008), and these fluctuations could induce variance in the resting-
state bold signal unrelated to functional cns-effects (Beckmann and 
Smith, 2005; Birn et al., 2008; Chang et al., 2009). It has been shown that 
bold signal fluctuations measured in the white matter (wm) and cere-
brospinal fluid (csf) are reliable representations of non-neuronal physi-
ological noise in rs-fmri data (Birn, 2012). Therefore, we included sepa-
rate wm and csf confounds, as well as six motion parameters, as nuisance 
variables in the second stage of the dual regression analysis for each scan. 
These separate wm and csf confounds were measured for each scan by 
calculating tissue-specific segmentations of each subject’s high-resolu-
tion T1 structural scan (segmented using fsl fast) (Zhang et al., 2001), 
transforming the resulting wm and csf maps to the corresponding sub-
ject’s epi space and subsequently extracting mean time series from that 
functional scan within the space of each of these tissue-specific maps.
For group analyses, treatment and time were used as fixed factors 
and subject was used as a random factor. Average respiration and heart 
rates per rs-fmri scan were also added as nuisance covariates (Khalili-
Mahani et al., 2011). Within-subject average z-maps were modelled with 
separate fixed factors, to allow the model to estimate the correlation be-
tween z-maps. Permutation-based statistical inference was used (5000 
repeated permutations) on the treatment by time interactions (Nichols 
and Holmes, 2002). Higher-level analyses were restricted to study pop-
ulation-specific grey matter regions by registration of the grey matter 
volumes resulting from fast segmentation to mni space and subsequent 
summing across subjects. Significant thc effects on functional connec-
tivity were defined using threshold-free cluster enhancement (p ‹ 0.05, 
family-wise error-corrected) (Smith and Nichols, 2009). Correction for 16 
multiple comparisons was done using Bonferroni correction. The multi-
ple comparisons consisted of 2 comparisons (either connectivity increase 
or decrease after thc administration) for 8 nois.
vas and heart rate were analyzed using a linear mixed effect model 
with treatment, period, time and treatment by time as fixed effects, sub-
jects and subject by treatment as random effects and with baseline value 
as covariate (sas for windows V9.1.2; sas Institute, Inc., Cary, nc, usa). 
From this model, pair wise differences and corresponding 95% confi-
dence intervals were estimated to verify the effects of thc. Measure-
ments from vas Bowdle (e.g. feeling high, external and internal percep-
tion) were log (vas score+2) transformed for statistical analysis and re-
ported in ‘units’ (U).
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Twenty-two healthy volunteers (eleven male, eleven female) were 
randomized and treated, twelve of whom completed two occasions and 
were included in the pharmacodynamic and pharmacokinetic analysis. 
One of these subjects missed the last two scans on the placebo occasion 
due to nausea and vomiting. For safety analysis, all treated subjects were 
included. Eight female subjects and one male subject dropped out from 
the study due to adverse events during thc occasions. Details on the 
nature of the adverse events can be found in section 0. One male subject 
discontinued the study after the first occasion with thc treatment, 
for personal reasons. Also, this subject had an incomplete first thc 
administration (2 mg) due to leakage of the vaporizer. Details on subject 
demographics can be found in Table 1.
Adverse effects
Nine subjects dropped out due to adverse effects during thc occasions 
only. Two subjects dropped out due to a vasovagal collapse, one female 
22 min after the first thc inhalation, and one male 27 min after the 
second thc inhalation. One female subject discontinued due to nausea 
that started 4 min after the second thc inhalation, and another female 
became nauseous after the third thc inhalation. One female dropped 
out because of nausea and anxiety that started 12 min after the second 
thc inhalation. Four other females discontinued due to anxiety: two at 
12 and 21 minutes after the first thc administration, and two at 10 and 12 
minutes after the second. Most adverse events that were observed in this 
study were typically related to thc use. The most occurring treatment 
related adverse effects were feeling high (7/22 subjects), nausea (7/22), 
and anxiety (6/22).
Pharmacokinetics
Five minutes after each thc administration, a peak plasma concentra-
tion was observed (Figure 2). Mean peak plasma concentrations were: 
29.5 ng/ml (sd 11.6) after the first administration (2 mg thc), 139.9 ng/
ml (sd 42.1) after the second administration (6 mg thc) and 109.1 ng/
ml (sd 55.3) after the third administration (6mg thc). After each peak, a 
rapid decline in plasma concentration was observed. An overview of the 
pharmacokinetic parameters of thc and 11-oh-thc is given in Table 2. 
gender
The unexpectedly large number of thc-related adverse events in females 
raised questions about potential sex-related pharmacokinetic differenc-
es. Therefore, a post hoc analysis of thc and metabolite plasma concen-
trations was performed in males and females. In Figure 3 the thc concen-
tration curves of males and females are given. When compared graphical-
ly, the average plasma concentration for females was higher compared to 
males. A reliable statistical analysis could not be performed for subjects 
who completed the entire study, since only three females received all 
treatments. However, thc concentrations were significantly higher in 
the eleven females who inhaled the first dose of thc 2 mg (42.3 ng/ml), 
than in the nine males (26.3 ng/ml; difference 61.0%, 95% ci 13.3-128.7, 
p = 0.0087).
Resting State Connectivity
Each of the 8 nois showed treatment effects on connections with several 
brain regions (Table 3). After Bonferroni correction, treatment-related 
connectivity differences were observed within the sensorimotor and 
right and left dorsal visual stream networks (noi 4, 7, 8), which are 
depicted in Figure 4. Most changes occurred in connectivity patterns of 
the right dorsal visual stream network (noi 7). After thc administration, 
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connectivity of this network increased with the left and bilateral frontal 
pole and dorsomedial prefrontal cortex, and with the left superior 
pre-frontal cortex (t = 5.69 with 149 voxels; t = 4.97 with 130 voxels 
respectively, Bonferroni corrected), with an extension into the left 
superior frontal gyrus. Also, a connectivity decrease (t = 5.44; 53 voxels) 
was found in the right and dorsal visual stream network (noi 7). This 
decrease was observed in the area covering the superior frontal pole, 
middle and inferior frontal gyrus, and dorsolateral prefrontal cortex, 
with all regions being lateralized to the right hemisphere. An increase 
of connectivity was found between the cerebellum and the sensorimotor 
network (noi 4) after thc administration (t = 6.36; 6101 voxels, 
Bonferroni corrected). The area including the occipital pole and lateral 
occipital cortex showed an increased connectivity (t = 5.01; 52 voxels) 
with the left dorsal visual stream network (noi 8). 
Other pharmacodynamic parameters
Graphs of feeling high and heart rate plotted against time are given 
in Figure 5. Treatment comparison of the pharmacodynamic effects 
other than fmri measurements demonstrated significant increases 
after thc administration on vas external perception (0.225 (U); 95%cv 
0.054 - 0.396; p = 0.0149), feeling high (0.768 (U); 95%cv 0.578 - 0.957; 
p = ‹.0001), and heart rate (10.3 bpm; 95%cv 4.4 - 16.2; p = 0.0026). 
The centrally mediated external perception and feeling high scores 
increased after the first and second thc administration, but not after 
the third thc inhalation. The decrease of these effects was relatively 
slow. Heart rate remained stable during placebo treatment; whereas 
thc induced acute heart rate elevations that declined relatively rapidly 
after each dose (Figure 5B). Stress-hormone cortisol showed a 32.2% 
increase (95%cv 11.9 - 56.3; p = 0.0051) after thc, whereas prolactin 
decreased with 21.0% (95%cv -33.0 -/-7.0; p = 0.0100). The thc effect on 
cortisol was maximal around the third thc administration. The first 
prolactin measurement after the first thc administration showed no 
significant differences between thc and placebo treatment, however, as 
time progressed, concentration differences increased by a continuously 
decreasing prolactin concentration after thc compared to placebo. 
The mean glucose concentration over time increased by 7.2% after thc 
treatment (95%cv 0.1 – 14.8; p = 0.0468). Visual inspection indicated that 
this difference was solely caused by a larger glucose increase in the thc 
arm after a standardized meal (at t = 4.28 h, 48 min after lunch and 1h28m 
after the third thc administration) (6.19 mmol/l in the placebo group 
and 8.34 mmol/l in the thc treated group). No significant changes were 
seen for hdl cholesterol, leptin and triglycerides. An overview of the 
pharmacodynamic parameters can be found in Table 4.
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discussion 
This study demonstrated that thc induced changes in rsn functional 
connectivity. As predicted by the pk-pd models that were based on a pre-
vious study (Strougo et al., 2008) the thc and 11-oh-thc concentrations 
were within the effective range, inducing significant effects on external 
perception and feeling high from vas Bowdle and on heart rate mea-
sures.
Connectivity and function
thc induced significant effects on functional connectivity between 
various brain areas and the sensorimotor and right and left dorsal visual 
stream networks. In general, an increase of network connectivity was 
found after Bonferroni-correction, with one area showing decreased 
connectivity in the left dorsal visual stream cortex. The areas that 
were found to be most affected by thc in this study were comparable 
to findings from previous thc studies using pet, in which changes 
in resting-state blood flow or [11C]-raclopride binding potential were 
found, including the cerebellum, frontal pole, left superior frontal gyrus, 
right middle frontal gyrus (Mathew et al., 1998; Stokes et al., 2010). 
noi 4
The areas displaying thc-induced connectivity changes in the 
sensorimotor network could be associated with the functional changes 
that are observed after thc administration, such as the increase of 
external perception as seen in this study. The cerebellum, which showed 
connectivity increase, is associated with motor coordination and time 
perception (which is one aspect of external perception) and has high cb¡ 
receptor density (Nyberg et al., 2010; Stoodley and Schmahmann, 2009; 
Romero et al., 2002). A previous study with thc reported a correlation 
between altered time perception and cerebellar blood flow (Mathew et 
al., 1998). Also, the cerebellum is likely to be involved in thc-induced 
postural stability changes as previously observed (Zuurman et al., 2008; 
Zuurman et al., 2008; Zuurman et al., 2009). A possible correlation 
between the increase of external perception (a composite scale including 
the item ‘altered time perception’) and cerebellar connectivity changes 
should be further explored in a future study using pk-pd modelling. 
noi 7
The bilateral and left dmpfc, and the left frontal pole and left superior 
frontal gyrus (sfg) had an increased connectivity to the right dorsal vi-
sual stream network, whereas the right superior frontal pole, right dor-
solateral pfc (dlpfc), and the right inferior and middle frontal gyri had 
a decreased connectivity. The dmpfc and frontal pole are functionally as-
sociated with decision making and cognitive control, such as subserving 
the monitoring of action outcomes and cognitive branching, the ability 
to put on hold an alternative course of action during the concurrent per-
formance of the ongoing one (Venkatraman et al., 2009; Daw et al., 2006; 
Koechlin et al., 1999). We have not studied these functions in our study, but 
the literature includes a few studies of the effects of thc/cannabis on com-
plex problem solving and planning tasks (Tinklenberg et al., 1972; Crock-
ett et al., 1976), which could be attributed to fronto-polar pfc changes. 
The sfg is involved in higher cognitive functions, such as the execu-
tive functions of working memory processing, and is suggested to be 
associated with the excitatory and inhibitory influences on craving, as 
found in a lesion study and a study with tobacco cigarettes (du Boisgue-
heneuc et al., 2006; Rose et al., 2011). In human brain tissue, cb¡ receptors 
are present in the sfg (Eggan and Lewis, 2007), suggesting effects of can-
nabinoids on the higher cognitive functions. However, in healthy sub-
jects, thc demonstrated no effects on cognitive functions such as plan-
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ning and reasoning in the very limited available literature (Ramaekers 
et al., 2009; Morrison et al., 2009). The right inferior and middle frontal 
gyri are involved in risk attitudes and contingency awareness (Carter et 
al., 2006). These behaviours are affected by thc (Foltin et al., 1990), but 
are much dependent on the exact type of behaviour that is tested (Mc-
Donald et al., 2003; Zuurman et al., 2009). One fmri-study, for example, 
showed that thc attenuated activity in the right inferior frontal and an-
terior cingulate gyri when performing the Go/No-Go task for response 
inhibition, but no difference was seen on the task performance itself 
(Borgwardt et al., 2008). The dlpfc is involved with organization of 
working memory (Jha et al., 2006), which can also be affected by thc use 
(Bocker et al., 2010).
noi 8
This study showed that the right posterior pole and lateral occipital 
cortex had an increased connectivity with the left visual dorsal stream 
network. The occipital regions are functional visual areas (Hine, 1918; 
Kolmel, 1988). Previous studies found that thc influences several aspects 
of vision that could be attributed to visual cortex changes (Koethe et al., 
2006; Emrich et al., 1991; Winton-Brown et al., 2011). In this study, thc 
had clear effects on vas external perception, which includes several scales 
of changes of colours and shapes. 
In summary, the different nois show significant connectivity effects 
on brain areas that are functionally related and that have been found 
to be significantly affected by thc administration in previous studies. 
This suggests that connectivity changes that are found with rs-fmri 
could be related to functional alterations. Since similar conclusions were 
previously reached with morphine and ethanol (Khalili-Mahani et al., 
2011), rs-fmri can possibly be a useful technique for prediction of drug 
effects, although more studies are needed to understand the potential 
role of this technique in drug development.
Other pharmacodynamic parameters and  
 gender effects
cortisol
The cortisol increase, or reduced decrease (which occurs during daytime 
due to the diurnal rhythm), is consistent with previous findings (Good-
win et al., 2011; Ranganathan et al., 2009). Pre-clinical studies found that 
the cannabinoid-induced hypothalamic-pituitary axis activity increase 
is caused by cannabinoid action in the paraventricular nuclei in the hypo-
thalamus and the pituitary gland, where cb¡ and corticotrophin releas-
ing hormone receptors are co-expressed (Corchero et al., 1999; Dewey et 
al., 1970; Wenger et al., 1999). No clear connectivity changes were found 
in hypothalamic regions. The question whether connectivity changes 
could be expected between, for example, the hypothalamus and limbic 
regions after a thc-induced cortisol increase remains unanswered, as the 
relationship between connectivity changes and functional changes is un-
known and should be further investigated. Possibly, the thc-induced en-
hancement of postprandial glucose elevations was due to a thc-induced 
cortisol increase, which may have induced gluconeogenesis. No compa-
rable studies to our study have been reported, but similar findings have 
been reported in pre-clinical studies and a clinical study in fasting condi-
tions (Kim et al., 2011; Benowitz et al., 1976). As the subjects were served a 
standardized meal, glucose elevation due to larger carbohydrate intake 
is unlikely. Future studies may reveal interesting information about the 
circuitry involved in adaptive regulation of the brain-body function.
feeling high
Most subjects experienced the familiar feelings of subjective ‘high’ 
after administration of thc. This raises the question of which networks 
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could be associated with these psychomimetic effects. The answer to this 
question cannot be given easily, since thc causes many different effects 
with very similar time profiles (Strougo et al., 2008). Consequently, it is 
difficult if not impossible to distinguish the network activities that are 
uniquely associated with feeling high, from those related to other thc-
effects like upright postural instability or sedation. As our database 
of similar pharmacological studies with other psychomimetic drugs 
expands, we may be able to address the question of neural correlates of 
‘feeling high’ by integration and, for example, factor analyses of data 
from different drugs in the future.
physiological variations
We have found a significant effect of thc on heart rate. Because 
physiological pulsations may cause movement of large vessels, various 
retrospective processing techniques are proposed to correct for 
correlated physiological noise. As recently recommended in (Birn, 2012) 
we have used the bold fluctuations within individual’s csf and wm 
masks as an indirect measure of physiological noise. Furthermore, we 
have used average physiological variables as covariates at the higher-
level group analysis. Previously, it has been shown that the functional 
connectivity of the default mode network (noi 5) in particular is 
susceptible to heart pulsations (Chang et al., 2009). However, the impact 
of such corrections is likely to vary depending on the method used for 
estimating functional connectivity (e.g. ica, dual-regression or seed-
based) without any significant impact at the group level analysis (Starck 
et al., 2010). Because the aim of our study is to localize drug effects in the 
brain, we have refrained from performing any physiological correction 
that assumes a hemodynamic response function for the respiration and 
heart rate variations. Therefore, our results should be interpreted with 
the caveat that some of the regional drug effects might be confounded 
with signal change due to vascular motion.
Gender
The post-hoc analysis on pharmacokinetic gender differences showed 
a higher thc plasma concentration in females compared to males 
after the 2 mg dose. This study did not anticipate gender differences, 
which have rarely been examined in the literature. We administered 
a fixed dose using a nose clip to prevent surreptitious exhalation, 
whereas during recreational use (as cannabis), individual titration 
to the subjective effect could easily obscure most gender differences. 
Possible explanations for the pharmacokinetic gender differences 
found in this study are differences in height, weight, body composition, 
metabolism, hormones, or frequency of habitual cannabis use. This 
could not be explored further in this study, which was not designed to 
examine pharmacokinetic or pharmacodynamic gender differences. 
This would require future studies with a larger sample size and adequate 
considerations of other sex-associated confounders.
Concluding remarks and future directions
In line with previous findings, this study confirms that rs-fmri seems 
a promising technique for clinical pharmacological studies and drug 
development (Khalili-Mahani et al., 2011; Cole et al., 2010). The possible 
thc concentration-effect relationship including the active metabolite 
11-oh-thc needs to be further studied using pk-pd modelling. This 
would allow the quantitative examination of thc-induced effects on 
connectivity, including changes at low concentrations that might be 
observed without pronounced behavioural effects. 
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table 1  Demographics of the subjects that were included for pharmacodynamic and pharmacokinetic analyses.  
sd = standard deviation
Gender Variable N Mean SD
All Age (year) 12 22.17 2.95
bmi (kg/m2) 12 22.36 2.55
Height (m) 12 1.82 0.09
Weight (kg) 12 74.33 13.17
Female Age (year) 3 23.33 2.52
bmi (kg/m2) 3 22.07 0.32
Height (m) 3 1.70 0.06
Weight (kg) 3 63.83 4.93
Male Age (year) 9 21.78 3.11
bmi (kg/m2) 9 22.46 2.97
Height (m) 9 1.86 0.05
Weight (kg) 9 77.82 13.32
table 2  Pharmacokinetic parameters of thc as assessed by non-compartmental pharmacokinetic analysis.  
cv = coefficient of variation, iiv = interindividual variability, Cl = clearance, F = bioavailability, V = distribution volume, 
q = intercompartmental clearance, t¡/™ = initial half-life, NA = not applicable. 
Parameter Units Median Uncertainty (%cv) iiv (%cv)
CL/F (L/hr) 145 11.2 37.4
V/F (L) 20.1 12.5 37.4
V peripheral (L) 78.6 15.8 37.4
Q (L/hr) 95.6 15.1 37.4
t¡ /™ (hr) 0.986 4.91 NA
table 3  Overview of the significant decreases and increases of connectivity (p‹0.05, threshold-free cluster 
enhancement corrected). The areas in grey are significant regions after Bonferroni correction.




no11: Medial visual L Superior and medial frontal 
gyrus (premotor cortex)
5.32 -24 -2 46 26 -
B Dorsal acc 5.02 2 12 34 20 -
L Temporal occipital fusiform 
cortex
4.9 -30 -48 -18 17 -
no12 : Lateral visual L Temporal occipital fusiform 
cortex (extending into para-
hippocampal gyrus & hippo-
campus)
4.91 -30 -48 -12 163 +
L Ventromedial cerebellum 5.03 -22 -60 -44 36 +
R Temporal occipital fusiform 
cortex (extending into parahip-
pocampal gyrus)
4.16 26 -38 -18 22 +
R Middle frontal gyrus, dlpfc 5.34 28 20 44 14 +
B Posterior precuneous cortex 4.8 2 -74 42 203 -
R occipital pole, lateral occipital 
cortex
4.3 34 -92 -10 27 -
R Precentral gyrus 5.54 46 -10 58 12 -
no13: Auditory R Parahippocampal gyrus  
 (extending into hippocampus)
4.66 40 -34 -10 132 +
B pcc, retrosplenial cortex 5.04 0 -46 2 20 +
R Caudate 5.86 20 32 2 16 +
B Supramarginal gyrus, superior/
medial/inferior temporal gyri, 
temporal pole, parahippo campal 
gyrus, lateral ofc
6.07 62 -30 28 25075 -
B Superior frontal gyrus, dmpfc 4.83 0 50 28 262 -
R Frontal pole, dmpfc 4.13 10 60 22 104 -
L Precentral gyrus, superior  
parietal cortex
3.85 -10 -16 64 52 -
B Mid-cingulate cortex 4.26 -4 -8 34 38 -
L Precentral gyrus, superior  
mid-cingulate cortex
4.11 -4 -20 50 30 -
R vmpfc 4.12 16 54 6 28 -
R Middle frontal gyrus 3.36 46 10 40 19 -
R Precentral gyrus, superior mid-
cingulate
4.12 6 -26 54 17 -
(Table continues on next page)
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L Midbrain 3.92 -8 -28 -18 22 +
B Cerebellum (more extensive in 
right hemisphere)
6.36 14 -70 -50 6101 +
L Cerebellum (antero-ventral) 5.53 -20 -48 -54 47 +
L Cerebellum (ventromedial) 5.15 -10 -64 -50 5.15 +
R Postcentral gyrus 5.09 40 -32 62 184 -
R Precuneous cortex 4.28 14 -46 44 169 -
R Superior posterior parietal cortex 4.39 20 -56 62 142 -
L Superior posterior parietal cortex 3.73 -22 -54 50 99 -
L Postcentral gyrus, superior 
parietal cortex
4.39 -18 -40 64 71 -
R Superior posterior parietal cortex 
(mid-superior)
4.24 30 -42 64 57 -
no15: Default mode L Frontal pole, dorsal pfc 5.17 -28 46 16 35 +
L Intracalcarine (visual) cortex 5.63 -18 -80 10 17 +
no16: Executive/ 
salience
L Precuneous Cortex. 5.19 -8 -58 36 17 -
no17: Right dorsal 
visual stream
B Frontal pole, dmpfc 5.69 -12 66 10 149 +
L Frontal pole, dmpfc 4.97 -12 54 30 130 +
L dmpfc, frontal pole, superior 
frontal gyrus
4.53 -2 52 30 15 +
R Superior frontal pole, middle 
frontal gyrus, dlpfc, inferior 
frontal gyrus
5.44 38 38 24 53 -
R Superior frontal pole, inferior 
and medial frontal gyrus, dlpfc
5.44 38 38 24 324 -
R Superior frontal pole, inferior 
frontal gyrus (partial)
4.16 32 50 14 138 -
R Frontal pole (inferior),  
ventrolateral pfc
4.61 44 52 -6 109 -
no18: Left dorsal 
visual stream
R Occipital pole, lateral occipital 
cortex
5.01 42 -92 2 770 +
L Pre and post-central gyrus, 
central sulcus
4.74 -44 -16 40 29 +
R Occipital pole, lateral occipital 
cortex
5.01 42 -92 2 52 +
B pcc 4.7 -2 -38 24 105 -
a Uncorrected peak t-value
b The minus (-) indicates a connectivity decrease after thc, and the plus (+) an increase.
Abbreviations: L - left, R - right, B - bilateral, acc/pcc - anterior/posterior cingulated cortex, pfc - prefrontal cortex,   
dlpfc - dorso-lateral pfc, dmpfc - dorso-medial PFC, vmpfc - ventro-medial pfc, ofc - orbito-frontal cortex
table 4  Overview of the non-fmri pharmacodynamic parameters
 lsm Treatment Contrasts lsm change from 
baseline
Parameter Placebo thc P-value thc vs Placebo Placebo thc
vas Alertness (mm) 52.5 45.9 0.0646 -6.6 (-13.7, 0.5) 1.3 -5.3
vas Calmness (mm) 53.9 55 0.2248 1.1 ( -0.8, 3.0) 0.3 1.4
vas Mood (mm) 55 55 0.9787 0.1 ( -4.6, 4.8) -0.6 -0.5
vas External log (mm) 0.32 0.545 0.0149* 0.225 (0.054, 0.396) 0.008 0.233
vas Internal log (mm) 0.308 0.346 0.0718 0.037 (-.004, 0.079) 0.004 0.041
vas feeling high log (mm) 0.285 1.053 ‹.0001* 0.768 (0.578, 0.957) -0.02 0.748
Heart rate (bpm) 66.7 77 0.0026* 10.3 (4.4, 16.2) -1.8 8.4
fsh (U/L) 2.327 2.291 0.5601 -1.56% (-7.11%, 4.33%) -3.87 -5.37
lh (ng/ml) 4.16 3.15 0.0935 -24.20% (-45.9%, 6.12%) 2.02 -22.71
Cortisol (µmol/ml) 0.36 0.47 0.0051* 32.21% (11.87%, 56.25%) -29.24 -6.45
Prolactin (µgr/l) 8.41 6.64 0.0100* -21.00% (-33.0%, -7.01%) -28.68 -43.69
Glucose (mmol/l) 4.7 5.1 0.0468* 7.2% (0.1%, 14.8%) -4.64 2.25
hdl cholesterol (mmol/l) 1.12 1.12 0.8933 0.63% (-9.21%, 11.53%) 0.93 1.57
Leptin (µg/l) 3.6 3.7 0.8328 1.95% (-16.6%, 24.62%) -2.94 -1.04
Triglycerides (mmol/l) 0.98 0.97 0.9086 -0.70% (-13.2%, 13.64%) 3.47 2.74
* Statistically significant values
figure 1  Visual representation of the chronological study day activities after each thc inhalation. The horizontal 
axis represents the time line and should be read from left to right. The vertical lines connected to the dots represent 
the relative time points for the activities indicated in the boxes. The grey lines represent measurements that were 
only performed after the third thc inhalation. The time points are given in hours and minutes relative to the thc 
administration, and refer to thc administration and rs-mri measurements. At the first blood sample (1) for each cycle, 
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figure 2  Mean thc plasma concentration (+ standard deviation) graph. thc was administered at 0 min (2 mg), 90 
min (6 mg), and 180 min (6 mg).
figure 3  Mean thc plasma concentration (+ standard deviation) graph by gender. Dots = males; Circles = females. 
figure 4  Brain regions showing clusters of significant differences (Bonferroni corrected) in noi functional 
connectivity following thc relative to placebo. Spatial maps (right): Axial and coronal slices are displayed in 
radiological convention such that left=right. Green = noi, Red = Connectivity increase after thc relative to placebo, 
Blue = Connectivity decrease after thc relative to placebo; crosshairs indicate position of displayed slices. Connectivity 
changes across time (left): plots visualise z-scores resulting from each significant contrast (Bonferroni corrected) 
only, split by scan time point and averaged across clusters and subjects, separately for placebo (grey) and thc (black) 
conditions. Error bars represent the standard error of the mean. Vertical green dotted lines indicate the three points at 
which a dose was inhaled. Red and blue arrows link the associated spatial and temporal information.
 (see inside cover for this figure in colour)
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figure 5  Graphs of pharmacodynamic effects, with vas feeling high (figure A) average scores of log (mm) + standard 
deviations (sd), and mean heart rate + sd (figure B). Open circle: thc, closed circle: placebo. thc inhalations were given 
at time points 0, 90, and 180 min.














































Surinabant, a selective 
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abstract
aim Cannabinoid receptor type 1 (cb¡) antagonists are developed 
for the treatment of obesity and associated risk factors. Surinabant is a 
high affinity cb¡ antagonist in vitro. The aim of this study was to assess 
the magnitude of inhibition by surinabant of cns effects and heart rate 
induced by ∆9-tetrahydrocannabinol in humans. 
methods This was a double blind, placebo-controlled, randomized, 
four-period six-sequence cross-over study. Thirty healthy young male 
occasional cannabis users (‹1/week) were included. A single oral dose 
of surinabant (5, 20 or 60 mg) or placebo was administered followed 
1.5 hours later by four intrapulmonary thc doses (2, 4, 6 and 6 mg) or 
vehicle, administered at 1h intervals. The wash-out period was 14-21 
days. Subjective and objective pharmacodynamic (pd) measurements 
were performed. A population pk-pd model for thc and surinabant 
quantified pk and pd effects. 
results Surinabant 20 and 60 mg inhibited all thc-induced pd ef-
fects in a similar range for both doses with inhibition ratios ranging from 
68.3% (95%ci = 32.5, 104.2; heart rate) to 91.1% (95%ci = 30.3, 151.8; body 
sway). ic∞º ranged from 22.0 ng/ml (relative standard error = 45.2%; body 
sway) to 58.8 ng/ml (rse = 44.2%; internal perception). Surinabant 5 mg 
demonstrated no significant effects. 
conclusions The dose-related inhibition by surinabant, without any 
effect of its own, suggests that this compound behaves as a cb¡ receptor 
antagonist in humans at these concentrations. A single surinabant dose 
between 5 to 20 mg and above was able to antagonize thc-induced 
effects in humans.
introduction
Research on the cannabinoid system started several decades ago with the 
isolation of ∆9-tetrahydrocannabidiol (thc) from the plant Cannabis 
Sativa (Mechoulam and Gaoni, 1965). Since the 1990s, when cannabinoid 
receptors type 1 (cb¡) and type 2 (cb™) (Alexander et al., 2008) were cloned, 
the number of studies on the cannabinoid system and its application 
to the medical practice increased rapidly (Munro et al., 1993; Matsuda 
et al., 1990b). Modulators of cb¡ receptors became of special interest 
for medical indications. cb¡ receptors are mainly located in brain areas 
such as the cortex, basal ganglia, hippocampus, hypothalamus, and 
cerebellum, in the spinal cord, and in peripheral tissues such as adipose 
tissue, the heart, and intestines (Bermudez-Silva et al., 2010). thc is the 
most well-known agonist of the cb¡ receptor and induces a wide range 
of effects corresponding to the widespread location of cb¡ cb¡ receptors. 
These effects include involvement in feeding behaviour and pain 
(Bermudez-Silva et al., 2010; Ravinet et al., 2003; Van Gaal et al., 2005; 
Pertwee, 2009).
In the 1990s, the alimentary effects led to the theory that if appetite 
enhancement is regulated by cb¡ receptors, then antagonism of these 
receptors would suppress appetite, resulting in weight loss. With the 
increasing global problem of obesity and related factors, this topic 
became of special interest for pharmaceutical companies. From 1994, 
the first cb¡ inverse agonist rimonabant (at that time believed to be an 
antagonist) was discovered and developed by Sanofi (Rinaldi-Carmona et 
al., 1994). Besides efficacy in obesity and associated risk factors (Ravinet 
et al., 2003; Van Gaal et al., 2005), results from pre-clinical and clinical 
research also showed the beneficial effects of cb¡ antagonists on alcohol 
and nicotine abuse (Rodriguez de Fonseca et al., 1999; Centre for Reviews 
and Dissemination, 2004; Cohen et al., 2005; Cohen et al., 2002). In 
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2006, the European Commission granted a marketing authorisation 
for rimonabant as an adjunct to diet and exercise for the treatment of 
obese patients, or overweight patients with associated risk factors such 
as dyslipidaema, diabetes mellitus type 2, or cardiovascular risk factors 
(Wathion, 2009). 
However, after a recommendation of suspension of rimonabant’s 
marketing authorisation by the European Medicines Agency (emea) in 
2008, rimonabant was withdrawn from the market (The European Medi-
cines Agency (emea), 2008). The emea had drawn the conclusions that 
the weight loss did not outweigh the psychiatric side effects, especially 
depression (The European Medicines Agency (emea), 2008). At around 
the same time, Merck announced the withdrawal of their cb¡-antagonist 
taranabant from phase ii and iii studies for the indications of smoking 
cessation and obesity, also due to psychiatric side effects including de-
pression, irritability, anxiety, and suicidality (Merck & Co., 2008; Aronne 
et al., 2010; Kipnes et al., 2010; Proietto et al., 2010; Morrison et al., 2010). 
The results of clinical studies on rimonabant and taranabant showed 
that both the desired and undesired effects were dose related, with great-
er efficacy and more adverse events in the highest doses (Aronne et al., 
2010; Kipnes et al., 2010; Merck & Co., 2008; Van Gaal et al., 2005). While 
the significant weight loss effects can only be measured after a few weeks, 
Morrison et al. reported that with taranabant, the largest percentage of 
psychiatric adverse events occurred within the first four days of treat-
ment (Morrison et al., 2010). 
These clinical findings with cb¡ antagonists do not invalidate at-
tempts to address obesity treatment or smoking cessation via antago-
nism of the cb¡ receptor. However, careful attention should be paid to 
potentially harmful effects as clearly explained by Kirilly, Gonda & Bagdy 
(2012). The clinically effective level might be found in a lower dose range 
of the cb¡ antagonist compared to doses that cause psychiatric side ef-
fects (Cohen, 2010). In the available literature on cb¡ antagonists, there 
is a lack of information on different dose or plasma concentration ranges, 
and the relation between the various pharmacodynamic parameters, i.e. 
efficacy parameters and safety profile. Therefore, for future cb¡ antago-
nist studies a possible safety window between clinically effective dose 
levels and doses with undesirable effects should be examined carefully. 
For example, rimonabant 20 mg demonstrated a reduction of both 
weight gain and smoking cessation in humans, whereas Tonstad and 
Aubin found, that cb¡ antagonist surinabant 5 mg did not improve 
smoking cessation, but had a small effect on reducing weight gain 
(Tonstad and Aubin, 2012; Cahill and Ussher, 2011). 
Acute administration of cb¡ antagonists does not give measurable ef-
fects in healthy volunteers, which hampers the accurate determination 
of dose-response relationships and prediction of minimal pharmaco-
logical effect levels in early drug development. Therefore, we previously 
developed the thc-challenge test (Zuurman et al., 2008; Zuurman et al., 
2008). This test is used to quantify the displacement of the concentration 
effect curve of cb¡ agonist thc, by different doses of a cb¡ antagonist for 
various pharmacodynamic parameters. The thc-challenge test showed 
clear dose-related effects of cb¡ antagonist drinabant (ave1625) in a pre-
vious study, after single doses that did not cause any detectable effect of 
their own, and which were lower than predicted from preclinical experi-
ments (Zuurman et al., 2008). As a consequence, the dose range for subse-
quent phase ii-trials was reduced. A very recent study on smoking cessa-
tion found that another cb¡ antagonist surinabant had a small effect on 
weight gain, whereas it had no effect on smoking cessation (Tonstad and 
Aubin, 2012). 
After repeated-dose oral administration for 14 days in young subjects, 
surinabant was rapidly absorbed with a median tmax of ~2 h. After a 
single-dose administration of 20 to 80 mg, cmax and auc increased 
less than dose-proportionally (2.0-and 2.9-fold respectively). The 4-fold 
dose increase in a repeated dosing study had a 2.1- and 2.1-fold increase 
of cmax and aucº-™¢ . The terminal half-life was not dose-proportional 
and ranged between 161 and 183 hours for 14-day multiple doses (20 to 80 
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mg/day). Steady state was achieved by Day 13 and the mean accumulation 
ratios were 1.3 (cmax) and ‹2.6 (aucº-™¢) (sanofi-aventis, 2006). A 
previous pharmacokinetic trial in humans found that surinabant 
elimination took place primarily through the faeces (sanofi-aventis, 
2006c). An in vitro study identified cyp3A4 as the major cyp isoform 
involved in the metabolism of surinabant (sanofi-aventis, 2006). 
The aim of this study was to investigate the pharmacodynamic/
pharmacokinetic relationships of surinabant using the thc-challenge 
test in healthy volunteers.
methods
Study design 
This was a single-centre double-blind, placebo-controlled, randomized, 
6-treatment, 4-period, 6-sequence incomplete balanced cross-over study 
with a wash-out period of at least 2 weeks. 
Subjects and power calculation
Healthy male volunteers aged 18 to 45 years were included in the study. 
Subjects had to be cannabis users for at least 1 year with a frequency of 
use of no more than once a week to minimise the risk on adverse effects 
from naive subjects, as well as to avoid tolerance. Subjects had to be able 
to refrain from using cannabinoids from at least 3 weeks prior to the first 
treatment period up to the end of the study. 
Thirty-six subjects were planned to be randomised and treated in or-
der to obtain at least 24 subjects completing the 4 periods (4 subjects per 
sequence, each treatment given to a total of 16 subjects). A sample size of 
16 subjects per treatment group was to provide a power of at least 90% to 
demonstrate a 50% inhibition of thc-induced effect on body sway, alert-
ness and feeling high, using a two-sided paired t-test at 5% alpha level. 
These parameters gave consistent and robust thc effects in previous stud-
ies, and were therefore chosen for power calculation (Strougo et al., 2008; 
Zuurman et al., 2008; Zuurman et al., 2008). Calculations were based on 
cb¡ antagonist placebo + thc effects and within-subject standard devia-
tions as demonstrated in a previous study (Zuurman et al., 2008).
Procedure
Subjects gave written informed consent after full explanation of what 
was involved, and before any study-specific procedure was performed. 
chapter iv – effects of cb1 antagonist surinabant
– 123 –
novel approaches in clinical development of cannabinoid drugs
– 122 –
Eligible subjects were enrolled in the study after a general health screen 
within three weeks before the first study day. Subjects were acquainted 
with the experimental methods and conditions in a training session 
including the inhalation procedure using thc vehicle. Alcohol 
breath test and urine drug screen had to be negative on each study day. 
Pharmacodynamic (pd) and pharmacokinetic (pk) measurements were 
frequently performed on all study days. A follow-up visit was scheduled 
between 12 and 18 days after the last study day. The study protocol was 
approved by the Medical Ethics Review Board of Leiden University 
Medical Center and complied with the principles of ich-gcp, the 
Helsinki declaration and Dutch laws and regulations. 
Treatments
Subjects received randomised administration of 4 out of the following 6 
treatments: surinabant 5 mg or 20 mg or 60 mg + thc, surinabant 60 mg 
+ placebo thc, placebo surinabant + thc, and placebo surinabant + pla-
cebo thc. Starting from the expected tmax of surinabant at 1.5 hours, 4 
doses of inhaled thc (2, 4, 6 and 6 mg) or placebo were administered at 
1-hour intervals. 
Surinabant was administered as oral capsules (Sanofi-Synthélabo Re-
cherche, Toulouse, France). The soft gelatine capsules contained 5 mg, 10 
mg, or 20 mg surinabant or placebo and the following excipients: poly-
oxyl 40 hydrogenated castor oil, propylene glycol monolaurate type ii, 
triglycerides medium-chain (caprylic-capric acid 60-40), caprylocaproyl 
macrogolglycerides type 400, gelatine, glycerol, titanium dioxide, and 
purified water.
thc 2, 4, and 6 mg was diluted in 200 µl 100% ethanol (Farmalyse 
b.v., Zaandam) or thc vehicle, which consisted of ethanol only. This 
amount of ethanol was considered too small to cause any effects that 
would interfere with thc effects. The thc was vaporised into a balloon 
using a Volcano vaporizer® (Storz & Bickel GmbH & co. kg, Tuttlingen, 
Germany). Subjects inhaled the full contents of the balloon within 2 
minutes using a standard paced puffing protocol as previously described 
by Zuurman et al (Zuurman et al., 2008).
Surinabant dosages were selected in order to obtain sub-effective 
and effective plasma concentrations, based on phase 2 efficacy results in 
obesity, and on pk data from a phase 1 study (study numbers dri5029 and 
tdr 5736, data on file). thc dosages were selected in order to reach and 
maintain clear, sub-maximal central nervous system effects, based on pk-
pd model simulations that were based on a previous study (Strougo et al., 
2008). Procedures to evaporate the solution and inhalation of the vapour 





For surinabant and thc pk analysis, venous blood samples were taken 
via a cannula that was inserted at the start of the study day thirty minutes 
after arrival, before any measurements were performed. Surinabant 
samples were drawn pre-dose and at fixed time points after dosing from t 
= 0h45m up to t = 24h. thc samples were taken pre-dose and three times 




The choice of the pd endpoints was based on a previous review 
and previous studies by Zuurman et al. (2008; 2008; 2009). The pd 
measurements were performed twice pre-dose, twice after surinabant 
administration before the first thc inhalation, three times after each 
of the first three thc inhalations and nine times after the fourth thc 
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inhalation up to t = 9h16m. Vital signs (heart rate and blood pressure) 
were measured ten times per study day of which twice pre-dose.
body sway – The body sway meter (André Ibelings, tno/ict, Delft) is an 
objective assessment of antero-postural sway in mm per two minutes. 
The antero-postural sway is regulated by different factors, such as 
attention and motor coordination, involving the central and peripheral 
nervous system and vestibular processes. Visual feedback was eliminated 
by closing the eyes. Measurements were performed according to a 
procedure previously described (Zuurman et al., 2008).
visual analogue scales (vas) – vas by Bond and Lader is a 16-item as-
sessment of subjective effect on alertness (composition of items alert / 
drowsy, strong / feeble, muzzy / clear-handed, well coordinated / clumsy, 
lethargic / energetic, mentally slow / quick-witted, attentive / dreamy, in-
competent / proficient, and interested / bored), on mood (composition of 
items contended / discontended, troubled / tranquil, happy / sad, antago-
nistic / amicable, and withdrawn / gregarious), and calmness (composi-
tion of items calm / excited, and tense / relaxed) (Bond and Lader, 1974). 
The adapted version of vas by Bowdle (1998) is a 13-item assessment of 
subjective effects on feeling high and on factors of internal and external 
perception, which are both compositions of items that are affected differ-
ently by thc as previously described (Zuurman et al., 2008). 
heart rate and blood pressure – Heart rate and blood pressure were 
measured using Nihon-Koden (Lifescope ec, Tokyo, Japan) blood pres-
sure apparatus. All heart rate measurements were used for pd analysis. 
Adverse events and concomitant medication were continuously 
recorded from screening until follow-up period.
Bioanalyses
surinabant samples
Venous blood was collected in 4.5 ml edta tubes. The blood samples were 
kept on ice and centrifuged within 30 min of collection at 2000xg at 40C for 
10 minutes. The plasma was transferred into 2 ml Sarstedt polypropylene 
tubes and stored at –200C. Samples were analysed by the Global Metabo-
lism and Pharmacokinetics department of Sanofi (Malvern, pa, usa) using 
liquid chromatography coupled with tandem mass spectrometry (lc-
ms/ms) method with a lower limit of quantification (lloq) of 1.0 ng/ml.
 
thc samples
For determination of the concentration of plasma thc and its 
metabolites 11-hydroxy-thc (11-oh-thc) and 11-nor-9-carboxy-
thc (thc-cooh) venous blood was collected in 4 ml edta tubes. As 
cannabinoids are photosensitive compounds, samples were protected 
from light at all times. The tubes were kept on ice and centrifuged 
for 10 minutes at 2000xg at 40C. The plasma was transferred into 2 
ml brown Sarstedt polypropylene tubes and stored at –200C. Plasma 
samples were analysed by pra International (Zuidlaren). Plasma thc 
as well as metabolite concentrations (11-oh-thc and thc-cooh) were 
determined using lc-ms/ms method with a lloq of 0.5 ng/ml.
Statistical Analyses
adverse effects
Evaluation of the safety data was based on the review of individual values 
and descriptive statistics. Vital signs (heart rate and blood pressure were 
analysed using descriptive statistics. Adverse events were coded according 
to the Medical Dictionary for Regulatory Activities (Meddra version 9.0). 
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noncompartmental pharmacokinetics
pk parameters of surinabant, thc, 11-oh-thc, and thc-cooh were 
determined for each period by noncompartmental analysis of plasma 
concentrations and real time values using pkdms Version 1.3 with 
WinNonlin Professional Version 4.01. 
 
pharmacodynamics
pd parameters were analyzed using a linear mixed effect model with 
treatment, period, time and treatment by time as fixed effects, subject 
and subject by treatment as random effects and with baseline value 
as covariate. The baseline value was defined as the calculated mean of 
pre-dose assessments for each occasion. From this model, pairwise 
differences and corresponding 95% confidence intervals were estimated 
to verify the effects of thc and to assess the intrinsic and inhibitory 
activity of surinabant. This analysis was conducted on data measured 
from the third thc inhalation up to three hours after the fourth 
inhalation to measure at maximum thc effects. The model was fitted by 
estimated generalized least squares (gls) using sas proc mixed. 
Inhibition ratios as defined in percentages were estimated (with 
95% confidence interval) within the mixed model framework for each 
surinabant dose separately using the following formula below. Each 
parameter in the formula represents the effect that was measured at a 
certain time point for the indicated treatment:
Surinabant dose + thc challenge versus placebo + thc challenge
Placebo surinabant + thc vehicle versus placebo + thc challenge
Body sway data and item ‘feeling high’ on the vas Bowdle were analyzed 
after log (vas score+2) transformation.
Population pk-pd modelling
Population pk and pk-pd modelling was performed using the nonlinear 
mixed effect modelling package nonmem (version 5, icon Development 
Solutions, Ellicott City, Maryland, usa) (nonmem project group, 1992) 
running on a Linux cluster (Speth, 2004). Model development was 
guided by visual (goodness-of-fit plots) and statistical criteria based on 
minimisation of the objective function value, uncertainty of parameter 
estimates, and biologically plausible values. The first order conditional 
estimation method with interaction (foce-I) was used throughout the 
analysis.
Population pk-models were developed to describe the time course of 
surinabant- and thc concentrations. Subsequently, pk-pd models were 
developed for the separate pd measures that quantify the relationship 
between the plasma concentrations of surinabant and thc and the 
observed effects, using an agonist-antagonist interaction model, as 
shown in Equation 1:
 (1)
 (2)
Equation 2 models the effect at a specific time point and occasion. The 
empirical Bayes estimates of the individual pk parameters were used to 
develop separate pk-pd models for the evaluated pd parameters. 
The pk-pd relationship for thc was described using an effect 
compartment model in which the effect compartment rate constant 
(Keo) accounts for the delay between pk and pd (i.e. hysteresis). 
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This parameter can also be expressed as the effect compartment 
equilibrium half-life (T∞º), which was calculated by the following 
equation: 
 (3)
The relation between the effect compartment concentration and the 
observed effect was initially modelled using a maximal effect model, in 
terms of baseline, ec∞º and Emax. When the data showed no maximal 
effect relationship, a linear slope function was estimated. 
As all subjects had pk sampling on more than one occasion for 
thc, interoccasion variability (iov) was evaluated for the relative 
bioavailability. A thc dose was defined as an occasion. Interindividual 
variability (iiv) and iov in a pk parameter, P, were included in the model 
and assumed to be log-normally distributed, according to Equation 4: 
 (4) Pjk = tvp • e (ηj+τk) 
where Pjk is an individual pk parameter for the jth individual and the 
kth occasion, tvp is the typical value of the pk parameter, and ~j and ~k 
are the independent and normally distributed between- and within-
subject random variability with mean of zero and variance ωp and πp, 
respectively. Different combinations of ~ correlation (~-block) and ~ fixed 
at zero were evaluated. The selection of an ~-block, if any, was made 
on the basis of the decrease of the objective function value (ofv). The 
residual variability was evaluated using a proportional error model for 
the population pk analysis and using an additive error model for the 
population pk-pd analysis according to Equations 5 and 6, respectively: 
 (5) Cobs = Cpred • (1+ ε) 
 (6) Cobs = Cpred + ε
where Cobs was the observed concentration or effect; Cpred was the 
corresponding model predicted concentration or effect; and ~ was the 
departure of the observed from the predicted concentration or effect, 
which was assumed to follow a random normal distribution with a mean 
of 0 and variance.
results 
Subject demographics
Thirty healthy young males were randomised and treated, and 28 
subjects completed 4 occasions. One subject discontinued from the 
study after the first study occasion (surinabant 5 mg + thc) due to 
personal reasons, and one subject discontinued due to an adverse event 
during the second visit (placebo surinabant + thc). Thirty subjects were 
evaluated for pharmacodynamic and pharmacokinetic analysis. Subject 
demographics were balanced for all treatment arms (mean age = 23.2 
years, sd = 5.3; weight = 78.94 kg, sd = 8.23; height = 187.7 cm, sd = 6.7; 
bmi = 22.39 kg/m2, sd = 1.94). All subjects were of Caucasian ethnicity 
(one subject was of half Asian, half Caucasian origin).
Adverse effects
Adverse events were of mild to moderate intensity and transitory in 
nature, and no serious adverse events were reported during the study. 
One subject discontinued his second occasion with placebo + thc 
challenge treatment due to vasovagal syncope, which occurred 8 minutes 
after the second thc inhalation (4 mg). The safety profile of adverse 
events was similar in the surinabant 60 mg group (10 out of 18; 56% of the 
subjects had adverse events) compared with the placebo group (8 out of 
19; 42%). The most frequent adverse events in the surinabant 60 mg + thc 
vehicle group were headache (28%), somnolence (17%), and nausea (17%). 
A higher incidence of psychiatric, nervous system and gastrointestinal 
disorders was observed during thc treatment (95%), which were 
dose dependently decreased by surinabant co-treatment (90% in the 
surinabant 5 mg group; 82% in the surinabant 20 mg group, and 63% in 
surinabant 60 mg + thc treatment group). These adverse events include 
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euphoric mood (feeling high, collected after spontaneous reporting 
independent from the vas feeling high scores, 45%), dizziness (50%), 
somnolence (45%), headache (30%), dry mouth (20%), and nausea (15%). 
No clinically relevant changes were found for blood pressure, haema-
tology, biochemistry, urinalysis or any of the ecg intervals. Heart rate 
changes were analysed as pd parameters.
pk analysis  
surinabant
Mean surinabant plasma concentration-time profiles are shown in 
Figure 1 and an overview of surinabant pk parameters is given in Table 
1. Mean surinabant exposure was generally similar with or without 
thc challenge after surinabant 60 mg (Figure 1). Median tmax was 
1.58 hours for all surinabant dosages, corresponding to the start time 
of the thc challenge. Surinabant exposure increased in a less than dose 
proportional manner. A twelve-fold increase in surinabant dose (from 5 
mg to 60 mg) gave a 6.91-fold increase of cmax (p‹0.0001) and an 8.08-
fold increase of auc0-™¢ (p‹0.0001).
Population pk analysis showed that surinabant pk was best described 
with a two-compartment model with first-order elimination and 
first-order absorption with a lag time. Population pk parameters 
were estimated with good precision (relative standard errors ‹22.0). 
Population pk parameters estimates are given in Table 2.
thc
Mean thc plasma concentration-time profiles are shown in Figure 2. 
thc peak plasma concentration increased for the fourth inhalation, as 
co-administration of surinabant increased (Figure 2, p = 0.0006). A simi-
lar increase was observed for 11-oh-thc and to a lesser extent for thc-
cooh (data not shown).
A two-compartmental model with linear elimination best described the 
thc pk data. A model with Michaelis-Menten elimination, as was used 
in a previous study (Strougo et al., 2008), did not significantly improve 
the model (data not shown). pk parameter estimations were relatively 
good, with a relative standard error up to 14.6%. Relative bioavailability 
fractions were implemented for each dose within an individual allowing 
the estimation of intra-individual variability in absorption. Inter-occa-
sion variability of bioavailability was shown to significantly improve the 
model, and was estimated to be 55.8%. Inter-individual variability was es-
timated for central clearance and central volume of distribution. An over-
view of population pharmacokinetic parameters is given in Table 2.
Pharmacodynamics
thc-induced significant effects on all pharmacodynamic measurements, 
except for vas calmness, compared with the placebo surinabant + placebo 
thc condition. Surinabant 20 and 60 mg were able to significantly reduce 
all thc-induced effects on the central nervous system and heart rate com-
pared to surinabant placebo + thc challenge. The inhibition ratios for 
surinabant 20 mg and 60 mg did not differ significantly. Surinabant com-
pletely or almost completely (›80% inhibition) inhibited thc-induced ef-
fects, except on heart rate and feeling high where submaximal inhibition 
was observed (Table 3). Surinabant 5 mg was not able to inhibit any of the 
thc-induced effects significantly. By itself, 60 mg surinabant did not in-
duce any significant effect on the central nervous system parameters nor 
on heart rate, compared with surinabant placebo + thc placebo treatment. 
A graph with the observed effects of feeling high can be found in Figure 3.
Population pk-pd
A schematic representation of the basic structure of the pk-pd model is 
visualised in Figure 4. The effect of thc on body sway and feeling high 
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were best described by maximum effect models, relating the effect to 
the concentration in the effect compartment (Ferron et al., 2008). These 
models included inter-individual variability on the baseline value, 
Emax and Keo (Table 4). The effect by surinabant on thc-induced 
feeling high was best described using a partial antagonism model. 
Internal and external perception and alertness were best described by 
a linear response model, relating the effect to the concentration in the 
effect compartment. These models included variability on the baseline 
value along with inter-individual variability on baseline, slope and 
Keo (Table 4). As some subjects appeared not to show any changes in 
internal perception following the thc challenge, a model excluding 
non-responders was evaluated, but no improvement was seen. The effect 
compartment equilibrium half-lives for alertness (120 min) and body 
sway (89 min) were larger compared to feeling high (40 min), internal 
(44 min) and external perception (48 min). This means that thc-induced 
effects on alertness and body sway have a later onset than effects on 
feeling high, internal, and external perception and that they last longer. 
For heart rate, no pk-pd model was developed. In the placebo group, the 
sampling scheme during the postprandial period in which heart rate 
increase was observed was too sparse for accurate pk-pd modelling.
The ec∞º of thc for body sway was similar to that of feeling high (7.24 
ng/ml and 6.98 ng/ml respectively). No ec∞º could be calculated for the 
other pd parameters, as a linear model best described these parameters. 
The ic∞º of surinabant for body sway was approximately half of the ic∞º 
value for internal perception (22.0 ng/ml vs. 58.8 ng/ml). This means that 
50% inhibition of thc-induced body sway increase is established with a 
surinabant concentration that is approximately half of the concentration 
needed to reduce the effects on internal perception by half. ic∞º values for 
feeling high, alertness, and external perception were similar (30.5 ng/ml, 
33.6 ng/ml and 37.1 ng/ml respectively). A summary of population pk-pd 
model parameters can be found in Table 4. 
discussion
The objective of this study was to investigate the interaction of oral 
surinabant and inhaled thc on central nervous system effects and heart 
rate in healthy subjects. We have demonstrated that doses of 20- and 60 
mg surinabant are able to inhibit thc-induced effects on central nervous 
system parameters and heart rate by 68.0% to 91.6%, whereas surinabant 
5 mg was unable to antagonize any thc-effect. Surinabant 60 mg alone 
had no acute effects, particularly not on mood. 
Pharmacokinetics
With increasing doses of surinabant, maximum plasma concentration 
(cmax) and area under the plasma concentration curve from time 0 to 24 
hours (aucº-™¢) increased in a less than dose-proportional manner. This 
was also found in the population pk model; a negative dose effect on the 
absorption rate constant improved the model. Physiologically, this could 
be explained by saturation of absorption of surinabant, poor dissolution, 
or an increase of transit time from the blood. The exact mechanism is 
unknown.
thc peak plasma concentration increased as co-administration 
of surinabant increased, which was represented in the population pk 
model by a relatively high inter-occasion variability on bioavailability 
of 55.8%. Rather than representing a pk interaction, this could be due 
to a pharmacodynamic compensation in this group of experienced 
cannabis users. Subjects who received surinabant in combination 
with thc experienced less of their familiar subjective effects while 
inhaling thc. Consequently, they may have tried to inhale maximally 
thc during concomitant surinabant treatment. On the other hand, 
less thc was required to induce the desired high feelings, while 
on surinabant placebo. The standardized paced puffing inhalation 
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protocol should have prevented this type of variability. However, it is 
possible that some subjects were able to regulate the amount of thc by 
breathing out through the nose. Therefore, the inhalation protocol has 
since been adapted by adding the use of a nose clamp during future 
studies. 
Pharmacodynamics
In contrast to a paced puffing protocol, complete self-regulation of thc 
administration would allow subjects to titrate for the expected or desired 
pd effects. This would lead to inaccurate estimations of the antagonistic 
effects, which could explain the differences in the effect size between 
our study and a previous study by Huestis et al. In the latter study in 
which a cannabis challenge was applied, rimonabant doses up to 90 mg 
gave 43% inhibition on subjective feeling high of and 59% inhibition on 
heart rate increase (Huestis et al., 2001; Huestis et al., 2007), whereas for 
surinabant, reductions were 70% and 75% respectively. The rimonabant 
doses produced plasma concentrations in the upper range of the 
therapeutic window, suggesting that the levels of inhibition that were 
found in the current study could be over the therapeutic range. Although 
this cannot be excluded without a comparison with the results of clinical 
studies, it is perhaps more likely that the disparate estimates are related 
to differences in inhalation methodology. In Huestis’ study, subjects 
inhaled thc from cannabis cigarettes, which allows a certain freedom to 
self-regulate the amount of inhaled thc by the deepness and the number 
of the inhalations. thc cmax was 130 ng/ml in the study by Huestis et al., 
and 83.48 ng/ml in the current study. With self-regulated titration for 
pd effects, subjects compensate for a certain amount of effect inhibition, 
leading to an underestimation of rimonabant’s antagonistic potency. 
This is more difficult if thc is administered with an evaporation device 
and subjects are instructed to inhale the full contents of the balloon. 
In view of these differences, it seems more likely that the suppression 
caused by surinabant is in the same range as the effects of rimonabant. 
Furthermore, the variety of active compounds from cannabis could 
interfere with the thc and antagonist effects. The time period from 
which the inhibition ratios were calculated was different for both studies 
(1 hour vs. 4.5 hours). 
Another study using the cb¡ antagonist drinabant (ave1625) had 
a similar design as the current study (Zuurman et al., 2008). Drinabant 
20 mg and 60 mg induced maximal inhibition on heart rate, vas feeling 
high, internal and external perception, but not on body sway and vas 
alertness. Surinabant caused suppression of all these thc-responses, 
including near-complete inhibition of body sway and vas alertness, 
but it had sub-maximal effects on heart rate and high feeling. This 
indicates possible differences in clinical efficacy between surinabant 
and drinabant. We have argued that thc-induced tachycardia is 
(primarily) mediated peripherally, based on a previous pk-pd study in 
which the equilibration half-life of heart rate was significantly shorter 
compared to the other centrally mediated effect parameters (Strougo et 
al., 2008). In line with this conjecture, pre-clinical studies also suggest 
that surinabant and drinabant have different central and peripheral 
mediated effects. Conversely, effects on food intake, which could be 
peripherally mediated (Gomez et al., 2002), are found at 0.3 mg/kg oral 
drinabant, while the effective dose of oral surinabant was 3.0 kg/mg 
(unpublished data). No plasma concentrations or pk-pd-relations were 
determined in these preclinical experiments. These findings could 
be explained by a larger or faster brain penetration for surinabant 
compared to drinabant, whereas drinabant appears to have a relatively 
larger peripheral effect. If so, the effect of surinabant on feeling high 
seems small (around 70%) compared to drinabant (up to 101%), but the 
reliability of this inhibition ratio may have been diminished by a fairly 
large intra-individual variability (124%).
Surinabant 5 mg was unable to significantly inhibit any of the thc-
induced central nervous system effects and heart rate, which were 
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suppressed by surinabant 20 mg and 60 mg. This implies that surinabant 
effects are dose-dependent. Inhibition ratios of surinabant 20 mg were 
similar to 60 mg, indicating that 20 mg is able to induce maximal effects. 
pk-pd
The pk-pd models adequately described the time-course of pk and pd 
effects of thc and the antagonism of these pd effects by surinabant. 
The thc models of body sway, feeling high and alertness are generally 
comparable with the thc model that was constructed in a previous study 
by Strougo et al. (2008). The maximal effect of thc on feeling high was 
smaller in the current study compared to the previous study by Strougo 
et al. (0.713 log mm vs. 1.68 log mm). A linear response model best fit 
the external perception data in this study, while Strougo et al. found a 
maximal effect model to best describe their data. The difference observed 
in this study might be explained by the thc dose range, which could 
have been insufficient for detecting a maximal effect.
For surinabant, various ic∞º values were found for central nervous 
system parameters, with a smaller ic∞º value for body sway, which 
may be regulated by central as well as peripheral processes, compared 
to the purely centrally mediated measures. This variability of pk-pd 
parameters implies that surinabant has a variety of effect compartments, 
even within the central nervous system, which could be functional or 
kinetic. Also, the effect compartment equilibrium rate constant, or Keo, 
showed differences among the various pharmacodynamic measures, 
which means that some effects have a later onset and longer duration 
than other effects. This could be caused by several factors that could 
not be determined in this study, such as a difference in penetration rate 
between the different effect compartments. These findings also support 
the hypothesis that the clinically effective level of surinabant might be 
found at different concentrations compared to the levels that are needed 
to induce adverse side effects. 
This agonist-antagonist pk-pd interaction model can be used for predic-
tion of surinabant concentration-effect profiles in future studies, even if 
these studies have a different design or dosing regimen. As surinabant 
and rimonabant are very similar in structure and action, the popula-
tion pk-pd model of surinabant could also be used to estimate concen-
tration-effect profiles of rimonabant to a certain extent. Conversely, as 
rimonabant has been used extensively in patient studies, a patient popu-
lation pk-pd model could theoretically be used to predict concentration-
effect profiles for surinabant in patients, with the aim of finding an op-
timal therapeutic window, ranging between the dose-dependent desired 
and undesired effects. Currently however, such quantitative predictions 
are hampered by the as yet unknown relationships between the pharma-
codynamic (central and peripheral) biomarkers and the clinical (metabol-
ic and psychiatric) endpoints. At any rate, surinabant was found to be a 
potent cb¡-antagonist, at single doses that did not cause any adverse sys-
temic or central nervous system effects in healthy subjects. However, this 
information is insufficient to draw conclusions on the effects after a mul-
tiple dose regimen. Therefore, future studies should investigate the opti-
mal surinabant dose and its effects after long term use, with a particular 
focus on the occurrence of psychiatric side effects.
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table 1  Non-compartmental pk parameters for surinabant (5, 20 and 60 mg), Mean (cv%) ± sd of surinabant  
pk parameters
Surinabant 5 mg +  
thc challenge (n=20)
Surinabant 20 mg +  
thc challenge (n=19)
Surinabant 60 mg +  
thc challenge (n=19)
Surinabant 60 mg +  
thc vehicle (n=18)
Cmax (ng/ml) 104 (31) ± 32.6 334 (24) ± 79.0 719 (26) ± 190 749 (21) ± 157
Tmax* (h) 1.58 (0.750,1.58) 1.58 (0.750, 2.58) 1.58 (0.750, 2.58) 1.58 (0.750, 2.58)
auc0-24 (ng.h/ml) 543 (50) ± 271 1860 (30) ± 557 4390 (32) ± 1420 4870 (28) ± 1380
*  median (minimum, maximum)
table 2  Population pk parameters for surinabant and thc. F=Bioavailability; cv=Coefficient of variation (%); 
rse=Relative Standard Error (%); iiv=inter-individual variability (%).
Parameter Surinabant thc
Estimate (rse) iiv (rse) Estimate (rse) iiv (rse)
Clearance/F (L/h) 4.69 (13.0) 72.1 (27.7) 293 (7.58) 11.8 (25.0)
Central volume of distribution/F (L) 3.74 (22.0) 74.8 (34.9) 43.6 (8.03) 15.2 (36.0)
Peripheral volume of distribution/F (L) 491 (6.27) 30.6 (23.9) 136 (8.97) -
Intercompartmental clearance/F (L/h) 15.3 (3.70) 16.3 (30.8) 166 (8.01) -
Absorption rate constant (ka; h-1) 0.406 (3.18) 6.40 (115) - -
Lag time (h) 0.591 (5.91) - - -
Dose effect on ka* -0.00164 (16.4) - - -
Interoccasion variability on relative  
bioavailability (cv%)
- - 55.8 (12.6) -
Proportional residual error (cv%) 18.2 (10.0) - 15.9 (14.6) -
* Dose effect on k1 (α): ka (dose) = ka (5 mg) + α • (dose-5) 
table 3  Ratios and 95% confidence intervals of inhibition by surinabant (5, 20 and 60 mg) on thc-induced effects, 
measured from the third thc inhalation until three hours after the fourth inhalation.
pd assessment Surinabant dose (mg) % Inhibition (estimate) 95% CI
Body Sway 5 13.6  (-32.6, 59.7)
20 93.1  (31.9, 154.3)
60 91.1  (30.3, 151.8)
vas alertness 5 -8.9  (-54.9, 37.0)
20 72.5  (18.3, 126.7)
60 82.5  (25.7, 139.4)
vas feeling high 5 10.0  (-20.9, 40.9)
20 68.0  (31.6, 104.4)
60 70.0  (33.2, 106.9)
vas External Perception 5 17.1  (-18.3, 52.6)
20 88.7  (43.2, 134.3)
60 89.0  (43.3, 134.7)
vas Internal Perception 5 37.9  (-5.1, 80.9)
20 89.9  (37.0, 142.8)
60 91.6  (38.3, 145.0)
Heart rate 5 17.6  (-13.0, 48.1)
20 75.4  (38.4, 112.3)
60 68.3  (32.5, 104.2)
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figure 1  Mean and predicted plasma concentration-time curve of surinabant with standard deviations. Surinabant 
was administered at time point zero, and the first blood sample for bio-analysis was taken pre-dose. The open circles 
are surinabant concentrations after surinabant 5 mg + thc, the open triangles are surinabant 20 mg + thc, the open 
squares are surinabant 60 mg + thc treatment and the closed squares are after surinabant 60 mg + placebo thc treat-
ment. The dotted lines with plus signs represent the predicted surinabant plasma concentration-time curves.
figure 2  Mean plasma concentration-time curve of thc with standard deviations. The arrows indicate the time 
points of thc administration. The closed circles are the thc concentrations after placebo surinabant + thc treatment, 
the open circles are surinabant 5 mg + thc, the triangles are surinabant 20 mg + thc, and the squares are surinabant 
60 mg + thc treatment. The graph shows a rather repetitive pattern after each thc administration: the blood samples 
were taken at 5, 30 and 57 minutes after the 1st, 2nd and 3rd inhalation, and at 5, 20, 89 and 130 minutes after the 4th 
thc inhalation.
table 4  Population pk-pd parameter estimates for body sway, vas feeling high, alertness, external perception, and 
internal perception







Baseline (ln mm) 5.46 (1.26) 6.66 (24.3) 3.00 (32.2)
emax (log mm) 0.829 (24.5) 68.8 (40.2) -
ec50 (ng/ml) 7.24 (42.8) - -
keo (h
-1) 0.466 (17.9) 73.4 (33.6) -
ic50 (ng/ml) 22.0 (45.2) - -
Residual variability (sd of additive error) 0.212 (10.5) - -
Feeling high
Baseline (log mm) 0.321 (3.96) 21.6 (38.5) -
Emax (log mm) 0.713 (31.6) 124 (39.6) -
ec50 (ng/ml) 6.98 (33.5) - -
keo (h
-1) 1.04 (17.4) 71.6 (32.4) -
ic50 (ng/ml) 30.5 (61.6) - -
Maximum inhibition 0.751 (20.6) - -
Residual variability (sd of additive error) 0.254 (19.1) - -
Alertness
Baseline (mm) 49.4 (1.10) 5.13 (47.9) 180 (37.0)
Slope (/ng/ml) 0.547 (45.2) 98.1 (53.5) -
keo (h
-1) 0.347 (33.7) 4.64 (26.0) -
ic50 (ng/ml) 33.6 (45.8) - -
Residual variability (sd of additive error) 3.30 (18.3) - -
External perception
Baseline (log mm) 0.367 (0.529) - 3.86 (46.1)
Slope (/ng/ml) 0.00258 (41.9) 154 (29.4) -
Keo (h
-1) 0.868 (16.9) 69.9 (30.1) -
ic50 (ng/ml) 37.1 (59.6) - -
Residual variability (sd of additive error) 0.0182 (19.1) - -
Internal perception
Baseline (log mm) 0.366 (0.508) 2.68 (68.2) 1.46 (36.9)
Slope (/ng/ml) 0.000869 (38.2) 151 (35.1) -
keo (h
-1) 0.955 (20.1) 71.4 (45.5) -
ic50 58.8 (44.2) - -
Residual variability (sd of additive error) 0.0123 (22.8) - -
 * ec50 of thc effect. rse = Relative Standard Error (%); cv = Coefficient of variation (%); Emax = Maximal effect; ec50 
= Concentration producing 50% of Emax; Keo = effect compartment equilibration rate constant; ic50 = Concentration 
producing 50% of inhibition of thc Emax; sd = standard deviation.
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figure 3  Graph with observed feeling high effects and standard deviations. Two baseline measurements were re-
corded before surinabant administration. The closed triangles are feeling high scores after placebo surinabant + placebo 
thc administration, the closed circles are after placebo surinabant + thc treatment, the open circles are surinabant 5 
mg + thc, the open triangles are surinabant 20 mg + thc, the open squares are surinabant 60 mg + thc treatment and 
the closed squares are after surinabant 60 mg + placebo thc treatment.
figure 4  Schematic overview of pk-pd model (for detailed background information, see ref. (Mager, Wyska, & Jusko, 
2003)). The central compartment refers to the central circulation. C = compartment, ka = absorption rate constant, Keo = 
effect compartment equilibration rate constant, q = intercompartmental clearance, Cl = clearance
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abstract
aim Cannabinoid receptor type 1 (cb¡) antagonists show central side ef-
fects, whereas beneficial effects are most likely peripherally mediated. In 
this study, peripherally selective cb¡ antagonist tm38837 was studied in 
humans.
methods This was a double-blind, randomized, placebo-controlled, 
cross-over study. In occasion 1-4, 24 healthy subjects received 5x4mg thc 
with tm38837 100 mg, 500 mg, or placebo, or placebos only. During occa-
sion 5, subjects received placebo tm38837+thc with rimonabant 60 mg 
or placebo in parallel groups. Blood collections and pharmacodynamic 
effects (pd) were assessed frequently. Pharmacokinetics (pk) and pd were 
quantified using population pk-pd modelling.
results tm38837 plasma concentration profile was relatively flat 
compared to rimonabant. tm38837 showed an estimated terminal half-
life of 771 hours. thc induced effects on vas feeling high, body sway, 
and heart rate were partly antagonized by rimonabant 60 mg [-26.70% 
(95%ci -40.9-/-12.6%); -7.10%, (95%ci -18.1-5.3%); -7.30%, (95%ci -11.5%-/-
3.0%) respectively] and tm38837 500 mg [-22.10% (95%ci -34.9-/-9.4%); 
-12.20% (95%ci -21.6%-/-1.7%); -8.90% (95%ci -12.8%-/-5.1%) respectively]. 
tm38837 100 mg had no measurable feeling high or body sway effects, 
and limited heart rate effects.
conclusions Rimonabant showed larger effects than tm38837, how-
ever, heart rate effects were similar. tm38837 100 mg had no impact on 
cns-effects, suggesting that this dose does not penetrate the brain. This 
tm38837 dose is predicted to be at least equipotent to rimonabant with 
regard to metabolic disorders in rodent models. These results provide 
support for further development of tm38837 as a peripherally selective 
cb¡ antagonist for indications such as metabolic disorders, with a re-
duced propensity for psychiatric side effects.
introduction
Research on the cannabinoid system has largely increased in the last de-
cades, since the discovery of cannabinoid receptors type 1 and 2 (cb¡ and 
cb™) and endogenous cannabinoids from 1988 onwards (Devane et al., 
1988; Matsuda et al., 1990; Munro et al., 1993; Sugiura et al., 1995; Alexan-
der et al., 2008). The endogenous cannabinoid system, or endocannabi-
noid system, is located throughout the body. cb¡ receptors are present in 
the central nervous system and at peripheral sites such as the heart, liver, 
pancreas and adipose tissue (Bermudez-Silva et al., 2010; Bermudez-Silva 
et al., 2008), whereas cb™ receptors are mainly present in immune cells 
(Munro et al., 1993; Galiegue et al., 1995; Schatz et al., 1997).
Although the exact functions of the endocannabinoid system are un-
known, the widespread presence suggests that the system could have a 
variety of functions, which could be studied for various clinical indica-
tions. Obesity and associated diseases are among the major medical con-
ditions for which involvement of the endocannabinoid system is cur-
rently studied. Obesity, or severe overweight, is a condition that affects 
approximately 500 million adults worldwide, and the World Health 
Organization estimates this number to increase to 700 million adults in 
2015 (World Health Organization, 2011). 
Rimonabant was the first cb¡ receptor antagonist that was registered 
in 2006 as an adjunct to diet and exercise for the treatment of obese 
patients, or overweight patients with associated risk factors such as 
dyslipidaemia, diabetes mellitus type 2, or cardiovascular risk factors 
(Wathion, 2009). However, two years later, rimonabant was withdrawn 
from the market due to adverse psychiatric effects such as depression 
(The European Medicines Agency (emea), 2008; The European 
Medicines Agency (emea), 2008). The beneficial effects of rimonabant 
in patients included decrease of appetite, weight loss, and weight 
loss independent improvement of metabolic parameters such as hdl 
cholesterol, triglycerides, fasting glucose and insulin levels (Van Gaal et 
al., 2008; Pan et al., 2011; Van Gaal et al., 2005). 
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cb¡-receptors are widely distributed throughout the brain, including 
central nervous system areas that are involved in the regulation of food 
intake and metabolism (for review, see Pertwee (1997)). Nevertheless, 
there is considerable evidence to suggest that the beneficial metabolic 
effects of cb¡ antagonists are mediated by cb¡ receptors that are present 
at locations which are specifically associated with metabolic regulation, 
such as the liver, the pancreas, and fat cells (Bermudez-Silva et al., 2010; 
Bermudez-Silva et al., 2008). A study in rats demonstrated that centrally 
administered rimonabant did not affect feeding behaviour, whereas 
peripheral rimonabant inhibited food intake (Gomez et al., 2002). Other 
studies found that peripheral, but not central, cb¡ antagonism induced 
beneficial effects on metabolism and feeding behaviour (Nogueiras 
et al., 2008; Cluny et al., 2010). A recent study by Tam et al. suggests 
that peripheral cb¡ inverse agonism reduces obesity by reversing 
obesity-related leptin resistance (Tam et al., 2012). This suggests that 
the beneficial metabolic effects of rimonabant might be regulated by 
peripheral cb¡ receptors, whereas the psychiatric side effects could be 
regulated by centrally located cb¡ receptors. 
tm38837 is a new peripheral-acting cb¡ antagonist that demon-
strated efficacy in pre-clinical studies (7tm Pharma A/S, 2009). tm38837 
showed 30 times less potency on centrally induced body temperature ef-
fects compared to rimonabant, whereas tm38837 was only 3 to 10 times 
less potent than rimonabant on gastro-intestinal effects (7tm Pharma 
A/S, 2009). In a first in human trial, dosages up to 900 mg were well toler-
ated in healthy subjects, obese patients, and liver fibrotic patients (7tm 
Pharma A/S, 2009). 
In the current study the central and peripheral effects of tm38837 and 
rimonabant in healthy subjects were investigated. Since acute adminis-
tration of cb¡ antagonists does not have measurable effects in healthy 
volunteers, the ∆9-tetrahydrocannabinol (thc)-challenge test was used 
in this study (Zuurman et al., 2008; Zuurman et al., 2008). The thc-chal-
lenge test is able to quantify the displacement of the concentration effect 
curve of the cb¡ agonist thc by different doses of a cb¡ antagonist for 
various pharmacodynamic parameters. These parameters include mea-
sures that are mediated via the central nervous system, such as the sub-
jective effect ‘feeling high’, measures that could be affected by processes 
at multiple locations, such as postural stability, and heart rate, which is 
likely to be peripherally mediated (Strougo et al., 2008). In this way, the 
central and peripheral characteristics of the effect profile in healthy sub-
jects can be assessed. Rimonabant was used as a positive control for both 
central and peripheral effects. quantification of modulation of the con-
centration-effect curve of thc by cb¡ antagonists was done by building a 
population pk-pd model for thc, tm38837, and rimonabant. 
Our hypothesis was that tm38837 would show no effects or small 
effects on central nervous system parameters, while showing clear effects 
on biomarkers that are more likely to be peripherally mediated, such as 
heart rate. 
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This was a double-blind, double dummy, partially randomized, placebo 
controlled, cross-over, partial parallel study with a washout period of at 
least 12 days.
Subjects
Healthy male volunteers aged 18 to 45 years were included in the study. 
Subjects had to be cannabis users for at least 1 year with using frequency 
of no more than once a week, and had to be able to refrain from using 
cannabinoids from at least 3 weeks prior to the first treatment period 
up to the end of the study. Previous studies reported that black subjects 
have different rimonabant pharmacokinetics compared to subjects from 
other races (sanofi, 2008; Martinez et al., 2007). Therefore, black people 
were excluded from the study.
Twenty-four healthy male volunteers were planned to complete five 
periods. The study was powered as a bio-equivalence study (Committee 
for medicinal products for human use (chmp), 2010). This was based on 
the hypothesis that there is no or small difference in central nervous 
system response between thc alone and thc + tm38837, which 
could be defined as a lack of effects when comparing tm38837 with 
thc alone treatment, or bio-equivalent effects according to the bio-
equivalence guideline (Committee for medicinal products for human 
use (chmp), 2010). At the time of study performance, these guidelines 
included the criteria that the 90% confidence intervals of the rate ratios 
for the main effects of the two treatments would lie within the range 
0.80-1.25.
Procedure
Subjects gave written informed consent before any study-specific proce-
dure was performed. Eligible subjects were enrolled in the study after a 
general health screen within three weeks before the first study day. Sub-
jects were acquainted with the experimental methods and conditions in 
a training session including the inhalation procedure using thc vehicle. 
At all treatment visits, subjects stayed at the clinic for 2 days. Alcohol 
breath test and urine drug screen had to be negative on each treatment 
visit. Pharmacodynamic (pd) and pharmacokinetic (pk) measurements 
were frequently performed on all study days (indicated in Table 1). A fol-
low-up visit was scheduled approximately 14 days after the last study day. 
The study protocol was approved by the Medical Ethics Review Board of 
Leiden University Medical Center and complied with the principles of 
ich-gcp, the Helsinki declaration and Dutch laws and regulations.
Treatments
The treatments that were administrated can be found in Table 2. Each 
cb¡ antagonist or placebo administration was followed by 5 inhaled 
doses of vaporised thc 4 mg diluted in 400 µl 100% ethanol or thc 
vehicle, which consisted only of vaporised ethanol. thc was vaporised 
using a Volcano vaporizer® (Storz & Bickel GmbH & co. kg, Tuttlingen, 
Germany). Procedures for vaporising the solution and inhalation of 
the vapour were done according to a method previously described 
by Zuurman et al. (2008). The tmax of tm38837 was expected at 
approximately 4 hours after administration, whereas rimonabant had 
a tmax of 2 hours (sanofi, 2008; 7tm Pharma A/S, 2009). Therefore, oral 
tm38837 was dosed at time point 0h, oral rimonabant was dosed 2 hours 
later to account for expected differences in tmax, and three subsequent 
intrapulmonary thc doses were given from t = 4 hours with 2.5-hour 
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intervals. In this way, the first thc inhalation would be administered at 
the expected tmax of tm38837 and rimonabant. Twenty-four hours 
after tm38837 administration, two thc doses were administered with 
2.5-hour intervals. A schematic overview of the administrations and 
other study day procedures can be found in Table 1. 
Rimonabant has a terminal half-life of 6-9 days after multiple 
ascending doses in healthy volunteers (Turpault et al., 2006). To 
minimize the risk of long-lasting carry-over effects that could complicate 
the interpretation of the effects of tm38837, each rimonabant treatment 
arm was always scheduled at the fifth occasion, thereby splitting the 
study design into a 4-way cross-over part and a parallel part (Table 2). 
tm38837 dosages were based on preclinical and clinical studies (7tm 
Pharma A/S, 2009). The 100 mg dose was selected in order to explore 
exposure of the anticipated therapeutic level. A 500 mg dose in fed state 
was expected to give similar exposure to that seen after the highest dose 
(900 mg) explored in the fasted state, as examined in the first in man 
single ascending dose study (7tm data on file). This exposure was well 
tolerated by all subjects. Rimonabant 60 mg dosage was selected in order 
to obtain plasma concentrations in the clinically effective range. The 
recommended therapeutic dose of rimonabant was 20 mg; however, 
as steady state exposures are 3.3-fold higher than those observed after a 
single dose (sanofi, 2008), a single dose of 60 mg rimonabant per subject 
was administered in this study in order to achieve a maximum plasma 
concentration that was comparable to the steady state concentration 
with therapeutic dosages. Based on previous cannabinoid challenge 
studies with cb¡ antagonists such as rimonabant, we expected that a 
dose of 60 mg rimonabant would be sufficient to suppress thc-induced 
effects (Huestis et al., 2001; Huestis et al., 2007; Zuurman et al., 2010). 
thc dosages and dosing schedules were selected in order to obtain and 
maintain clear, sub-maximal central nervous system effects as predicted 
by pk-pd models that were based on previous studies (Zuurman et al., 
2008; Zuurman et al., 2010).
Outcome measures
pharmacokinetic assessments  
and bio-analyses
Time points of venous blood sampling for pharmacokinetic analyses of 
tm38837, rimonabant and thc can be found in Table 1.
tm38837 and rimonabant – Venous blood was collected in 4 ml Li-
Hep tubes. The blood samples were kept on ice and centrifuged within 
30 min of collection at 2000G at 40C for 10 minutes. The supernatant 
plasma was divided into three or four 2 polypropylene tubes. Samples 
were stored at –800C and sent to quotient Bioresearch (Fordham, uk) 
for analysis. Measurements of tm38837 and rimonabant concentrations 
in human plasma samples were performed according to bioanalytical 
methods that were validated. Concentrations of tm38837 and 
rimonabant were measured by liquid chromatography with tandem 
mass spectrometry method with a lower limit of quantification of 0.1 ng/
ml for tm38837, and 1.0 ng/ml for rimonabant. For tm38837 analysis 
precision was 4.3% accuracy was -1.3% and for rimonabant precision was 
4.5% and accuracy -1.3%.
thc – For determination of the concentration of plasma thc and its 
metabolites 11-oh-thc and 11-nor-9-carboxy-thc venous blood 
was collected in 2 ml edta tubes. As cannabinoids are photosensitive, 
samples were protected from light at all times. After blood collection 
the tubes were put in ice water in aluminium foiled containers, and 
were centrifuged within one hour for 10 minutes at 2000G at 40C. The 
supernatant plasma was divided into two 2 ml brown polypropylene 
tubes. Plasma samples were stored at a temperature of –200C and 
sent to abl (Assen) for pk analysis. Plasma thc as well as metabolite 
concentrations (11-hydroxy-thc and 11-nor-9 carboxy-thc) were 
determined using tandem mass spectrometry with a lower limit of 
quantification of 0.1 ng/ml.
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pharmacodynamic assessments
The choice of the pharmacodynamic (pd) endpoints was based on a pre-
vious review and prior studies by Zuurman et al. (2008; 2010). Pharma-
codynamic measurements were performed at time points indicated in 
Table 1.
body sway – The body sway meter (André Ibelings, tno/ict, Delft) is an 
objective assessment of antero-postural sway in mm per two minutes. 
The antero-postural sway is regulated by different factors, such as atten-
tion and motor coordination, involving the central and peripheral ner-
vous system and vestibular processes. Visual feedback was eliminated by 
closing the eyes. Measurements were performed according to a proce-
dure previously described (Zuurman et al., 2008).
visual analogue scales (vas) – vas by Bond and Lader is a 16-item 
subjective assessment of subjective effect on alertness (composition of 
items alert / drowsy, strong / feeble, muzzy / clear-headed, well coordi-
nated / clumsy, lethargic  /  energetic, mentally slow / quick-witted, atten-
tive / dreamy, incompetent / proficient, and interested / bored), on mood 
(composition of items contended / discontended, troubled / tranquil, 
happy / sad, antagonistic / amicable, and withdrawn / gregarious), and 
calmness (composition of items calm / excited, and tense/relaxed) (Bond 
and Lader, 1974). The adapted version of vas by Bowdle (1998) is a 13-item 
assessment of subjective effect on item feeling high and on factors inter-
nal perception and external perception, both compositions of items that 
are affected differently by thc as previously described (Zuurman et al., 
2008). 
beck’s depression inventory ii (bdi) – The bdi is a 21-item self-report 
questionnaire for measuring the severity of depression with a four-point 
Likert scale for each question (Beck et al., 1996). The questionnaire was 
included in the study to check for possible mood changes, since previous 
multiple dose studies with rimonabant reported a larger incidence of 
subjects suffering from depression (Van Gaal et al., 2005; Van Gaal et 
al., 2008). The bdi was performed one time per occasion at 9h30m after 
tm38837 or placebo tm38837 administration.
heart rate and blood pressure – Heart rate and blood pressure were 
measured using Nihon-Koden bsm-1101K monitor (Lifescope ec, Tokyo, 
Japan) blood pressure apparatus. All heart rate measurements were used 
for pd analysis. Adverse events and concomitant medication were record-
ed from screening until follow-up period.
Data analysis
For the direct clinical effect, pk and pd comparisons of tm38837 and 
rimonabant, data were used only from subjects who received rimonabant 
60 mg + thc treatment during the fifth study occasion.
clinical effects
Evaluation of the safety data were based on the review of individual 
values and descriptive statistics. Analysis of laboratory parameters was 
performed using screening and end-of-study assessments. For vital signs 
(heart rate and blood pressure), raw data and changes from baseline were 
analyzed by type of measurement and parameter and treatment using 
descriptive statistics. Heart rate, pr-, qrs-, and qt-intervals, corrected 
qt (qtc) from automatic reading were analyzed as raw parameter value 
and change from baseline (for hr and qtc only). Adverse events were 
coded according to the Medical Dictionary for Regulatory Activities 
(Meddra version 13.0).
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pharmacokinetics
All concentrations and maximal concentration (cmax), time of maximal 
concentration (tmax), area under the curve from zero to infinity (auc0-
∞), and terminal half-life (t¡/™) of tm38837, rimonabant, thc, and its 
metabolites 11-oh-thc, and thc-cooh were analysed using noncom-
partmental analysis (sas proc mixed 9.1.3).
Pharmacodynamics
To study the effect of repeated doses of thc on the pharmacodynamic 
measures or other carry-over effects, the fifth occasion of the twelve sub-
jects receiving only thc was compared graphically and statistically with 
the previous occasion in which subjects only received thc. If no signifi-
cant period effect could be established, the fifth occasion would be used 
for a 5-way cross-over analysis. For this 5-way partial cross-over subanaly-
sis, and for the 4-way cross-over part of the study, the pharmacodynamic 
variables were analysed with a mixed model analysis of variance (using 
sas proc mixed 9.1.3) with treatment, time, and treatment by time as 
fixed effects, with subject, subject by treatment and subject by time as ran-
dom effects, and the average baseline value was included as covariate. The 
parallel part was analysed with subject as random effect, with treatment, 
time, and treatment by time as fixed effects, and the average baseline val-
ue as covariate. A 90% confidence interval around the ratio was used for 
statistical comparison between tm38837 + thc and placebotm38837 + 
thc treatment with α = 0.05 two-sided (Committee for medicinal prod-
ucts for human use (chmp), 2010). Graphs of the Least Squares Means esti-
mates over time by treatment were presented with 95% confidence inter-
vals as error bars. Body sway was log transformed before analysis to cor-
rect for the log-normal distribution. All pharmacodynamic effects were 
statistically compared with heart rate effects. We assumed that heart rate 
primarily represents a peripheral cb¡-effect and that beneficial effects 
mediated by cb¡-antagonists are peripherally mediated.
Population pk and pk-pd modelling
Population pk and pk-pd modelling was performed using nonlinear 
mixed effect modelling (nonmem version 7.1.0, GloboMax llc, Ellicot 
City, md). The pre-dose samples that were taken at an occasion follow-
ing a study day where tm38837 was administered were also used for the 
pharmacokinetic model of tm38837. The compartmental population pk 
analysis was based on the results of previous chdr studies with multiple 
thc inhalations, which used a two-compartment model with bolus ad-
ministration (Strougo et al., 2008). The empirical Bayes estimates from 
the thc pharmacokinetic analysis were used to describe the thc profile. 
Parameter estimation for population pk modelling of thc, Rimonabant 
and tm38837 was performed under advan 5, and the pk-pd modelling 
of all pd parameters was performed under advan6 tol 5. First order con-
ditional estimation with interaction was the standard method of estima-
tion, with exception for vas feeling high, for which laplace was used. 
Within each model, additive- and proportional residual error models 
were compared.
For pk-pd modelling, an effect compartment was incorporated to ac-
count for delay in response, in which the concentration-effect was mod-
elled as a linear- and a maximal effect relationship. The drug-effect rela-
tions were assumed to cause a horizontal shift on the concentration-ef-
fect profile, therefore the drug effects relationships were only applied to 
the parameter describing the concentration at which half the maximum 
effect is reached (ec∞º). Internal model selection and validation was per-
formed using minimum objective function value, goodness of fit plots 
and visual predictive checks (vpc). For the vpc, 1,000 replications of the 
model were simulated and the median, 5th and 95th percentiles were cal-
culated for each simulated time-point and compared visually with the ac-
tual data (Post et al., 2008).
The inhibition ratios are defined in percentages and quantify the 
maximum inhibition of the thc-induced effect (defined as 100%) by 
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either rimonabant, tm38837 100 mg or 500 mg. The median of the 
inhibition ratios was calculated with their 90% confidence intervals 
(90%ci) by using the pk-pd models, simulated for 1000 individuals. 
To minimize the effect of over- and under-dispersion due to the 
subjectivity of the vas scale, and to include non-response in the 
model, the vas feeling high scale was translated to a binary scale, to 
accommodate the possibility to construct a probability model for feeling 
high. The anchor point for this translation was the median of all scores 
higher than 0. 
results
Subject demographics
Thirty-six healthy young males were randomised and treated, and 24 
subjects completed five occasions. Concerning the parallel part of the 
study, 10 subjects received rimonabant + thc treatment, and 14 subjects 
received placebo rimonabant + thc treatment. Four subjects dropped 
out for personal reasons (i.e. time schedule conflict and not liking the 
study days), two after the first and two after the second occasion. Three 
subjects dropped because of adverse events: two during the first occasion 
(occasion with thc alone treatment) and one during the second (occasion 
1 was placebo, occasion 2 thc alone). The adverse events were thc related 
(i.e. derealisation, pre-syncope and anxious feeling). One subject was 
not compliant and dropped out after the third occasion. Four subjects 
suffered study schedule delays and could eventually not complete five 
occasions because of irremediable expiry dates of rimonabant and thc: 
one subject after occasion three and three subjects after occasion four. All 
36 subjects’ completed occasions were included in the analyses. Subject 
demographics were balanced for all dose arms; the average age was 21.2 
years (sd 3.8 years), the average bmi was 22.9 kg/m2 (sd 2.1 kg/m2), height 
was 183.42 cm (sd 6.99 cm) and the average weight was 77.25 kg (sd 10.18 
kg).
Adverse effects
Adverse events were of mild to moderate intensity and transitory in 
nature. No serious adverse events were reported during the study. One 
subject discontinued during his first occasion with placebo tm38837 
+ thc treatment due to a pre-syncope and anxiety, which occurred 11 
minutes after the first thc inhalation. Another subject discontinued 
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the first occasion with placebo tm38837 + thc due to anxiety that 
started 1h29m after placebo tm38837 administration. During the 
second occasion with placebo tm38837 + thc, one subject decided to 
discontinue due to derealisation that started 14 minutes after the first 
thc inhalation.
The total number of subjects that had an adverse event was similar 
for all treatment groups (90.0%-96.9%), except for the placebo 
tm38837 + placebo group (63.3%). Most of the adverse events were 
classified as psychiatric and nervous system disorders, and mainly the 
psychiatric disorders were considered to be probably thc-related. 
Euphoric mood (‘feeling high’) was by far the most frequently reported 
psychiatric effect, especially in the treatment groups that received thc 
in combination with the 100 mg dose of tm38837, placebo tm38837, 
or placebo rimonabant (23/32 or 71.9%, 25/34 or 73.5%, and 13/14 or 
92.9% respectively). Euphoria was less common when thc followed 
administration of tm38837 500 mg or rimonabant (16/31 or 51.6%, and 
5/10 or 50% respectively). In the nervous system disorder class, the most 
frequent adverse event was somnolence, which occurred in a similar 
frequency for tm38837 100 mg (20/32 or 62.5%), 500 mg (20/31 or 64.5%), 
rimonabant (5/10 or 50.0%), and placebo tm38837 + thc (19/34 or 55.9%) 
treatment groups, to a larger extent in the placebo rimonabant + thc 
treatment group (12/14 or 85.7%) and to a lesser extent in the placebo 
group (10/30 or 33.3%).
Other frequently occurring adverse events in all treatment groups, 
including placebo, were: fatigue (14.3% to 41.2%), dizziness (3.3% to 
35.7%), headache (6.7% to 18.8%), and hypersomnia (6.7% to 28.6%). These 
adverse events were less frequent in the placebo group, and of similar 
frequency in the active treatment groups.
No clinically relevant changes were found for blood pressure, 
haematology, biochemistry, urinalysis or any of the ecg intervals. Heart 
rate changes were analysed as pharmacodynamic parameters.
Pharmacokinetics and population 
pharmacokinetic models
The pharmacokinetics of thc, tm38837 and rimonabant was 
described by a two compartmental pharmacokinetic model with first-
order elimination. The oral absorption of rimonabant and tm38837 
followed a first-order process, and the pulmonary absorption of 
thc was considered as a bolus administration. The increase of the 
concentration after administration of rimonabant was insufficiently 
detailed to estimate the first-order absorption rate constant with 
sufficient precision. Therefore this parameter was fixed to the value for 
the absorption rate constant reported by Martinez et al. (2007) at Ka = 
1.17 h-1. For all models, the residual error model was proportional and 
individual empirical Bayes’ estimates were employed to describe the 
concentration profile used in the population pharmacokinetic and pk-
pd analyses. 
An overview of the pharmacokinetic parameters can be found in 
Table 3 (non-compartmental analysis) and in Table 4 (compartmental 
analysis). tm38837 and rimonabant show different concentration-
time profiles (Figure 1). tm38837 had a relatively flat pharmacokinetic 
profile compared with rimonabant, which was related to the low 
absorption rate constant and the low clearance. This caused similar 
exposure of tm38837 during all five thc challenge tests within a study 
occasion, whereas for rimonabant during the first 3 thc challenges the 
exposure levels to the cb¡ antagonist were distinctly higher than for the 
2 thc challenges that were given on the second day of a study occasion. 
tmax of tm38837 (12.55 h to 13.01 h) was larger compared with 
rimonabant (4.11 h). tm38837 had a long half-life of 771 h, whereas the 
half-life of rimonabant was 12.7 h as estimated using compartmental 
analysis. 
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Pharmacodynamics
thc showed significant increases on body sway, heart rate, feeling high 
and external perception. For internal perception, almost half of the sub-
jects showed no response (12 non-responders vs. 16 responders) and the 
average effect was limited. No thc effect was found on vas mood, and 
only limited effects were found on vas alertness and calmness (estimate 
of difference: -5.5% and 4.1% respectively). Therefore vas internal percep-
tion, alertness, mood, and calmness were not considered relevant efficacy 
parameters for evaluating inhibition of thc induced effects, and were 
therefore not further described. 
thc period effects were found for vas feeling high (0.101 log mm, p = 
0.0004) and heart rate (1.4 beats per minute, p = 0.0338). As these changes 
were very small compared to the treatment effects, the period effects of 
vas feeling high and heart rate parameters were not considered to have 
had a significant impact on the study results.
A graphical representation of tm38837 and rimonabant effect pro-
files on thc-induced feeling high can be found in Figure 2. tm38837 an-
tagonizing effects started on day 1 and reached their maximum on day 2, 
whereas for rimonabant the effects were maximal on the first measure-
ment of day 1 (4 hours post dosing) and diminished during the second 
day. Overall this seemed to be consistent with the plasma concentration 
time profiles and the shorter tmax (≈4 h) and t~ (13 h) of rimonabant 
as compared to tm38837 using non-compartmental pharmacokinetic 
analysis. 
Because of the different time frames of tm38837 and rimonabant 
time-effect profiles, no proper comparison of peak effects could be made. 
Instead, the complete effect profiles were compared from the data of the 
5-way subanalysis. The results of these comparisons are given in Table 5. 
The results of the 4-way cross-over analysis including all subjects were 
very similar to the results from the 5-way cross-over subanalysis and 
are therefore not shown. tm38837 100 mg did not significantly inhibit 
thc effects, except for a small reduction of vas external perception, 
which failed to reach significance with the higher dose of tm38837. Both 
rimonabant 60 mg and tm38837 500 mg inhibited all other thc effects.
Another graphical analysis of effects was performed to avoid the 
differences in time frames between tm38837 and rimonabant. Figure 3 
represents a visualisation of heart rate effects plotted against body sway 
and P (feeling high›12) expressed as inhibition ratios that were estimated 
using the pk-pd models. Each point estimate represents the effects 
that were measured after one of the five thc dosages. The estimated 
values and 90% confidence intervals (90%ci) are given in Table 6. When 
comparing the effects on heart rate to those on P (feeling high›12) 
(expressed in inhibition of the thc effect), rimonabant has similar 
effect magnitudes for both heart rate and P (feeling high›12) (around 
80% inhibition of the thc-effect). tm38837 500 mg maximally inhibits 
thc-induced heart rate increase by 87.8% (90% confidence interval 80.4, 
92.5%) and feeling high by 30.4% (90%ci 24.0, 38.6%). tm38837 100 mg 
shows a 59.3% (90%ci 45.6, 71.3%) heart rate inhibition against a 7.47% 
(90%ci 5.5, 10.0%) inhibition of feeling high. The relationship between 
heart rate and body sway is comparable with the association between 
heart rate and P (feeling high›12) although slightly less pronounced 
(see Figure 3 for the relationship between the effects, and Table 6 for the 
estimated values and 90%ci).
pk-pd modelling
In Figure 4, schematic overviews of the population pk-pd models of 
tm38837 and rimonabant are given. All pk-pd models included a base-
line level, effect compartments that equilibrated with the plasma con-
centration, and a model to relate the effect compartment concentration 
to the pharmacodynamic response. The period effects of vas feeling high 
and heart rate were included in the thc pk-pd model. Heart rate and 
body sway were best described by a maximum effect model. For feeling 
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high a probability model was used to quantify the probability for a vas 
score › 12 at the study population level. The vas value of 12 was the central 
value in the distribution of positive vas scores in the study, which served 
as a reference point. All models included the thc challenge effect and the 
antagonizing effect of rimonabant and tm38837, either by shifting the 
ec∞º (maximum effect model), or decreasing the P (feeling high›12). An 
overview of the pk-pd parameters can be found in Table 7. The results of 
the vpcs can be found in the article’s supplement.
The population pk-pd models confirmed the expected thc-induced 
increase of heart rate, body sway, and P (feeling high›12). The equili-
bration time of thc with the effect compartment was relatively small 
(0.217 hr for heart rate, 1.94 hr for body sway, and 1.31 hr for P (feel-
ing high›12), indicating a fast onset of the effects. The equilibration 
half-life of tm38837 was long compared with rimonabant (Heart rate: 
85.5 versus 1.27 hr, body sway: 89.4 versus 1.21 hr, feeling high: 4.63 versus 
1.27 hr). This caused a larger delay in the onset of tm38837 effects, 
compared with rimonabant. For heart rate the half maximal inhibi-
tory concentrations (ic∞º) were similar for tm38837 (65.2 ng/ml) and 
rimonabant (95.3 ng/ml), whereas for body sway and feeling high, the 
ic∞º of rimonabant was 4 times and 56 times larger respectively than for 
tm38837 (Body sway; tm38837: 49.9 ng/ml, rimonabant: 206 ng/ml. 
Feeling high; tm38837: 347 ng/ml, rimonabant: 19,500 ng/ml). 
Similarly to the graphical differences in time-effect profiles in the 
previous sections, the inhibition ratios of heart rate, body sway and P 
(feeling high›12) that were estimated using the pk-pd models suggested 
a maximal inhibition of tm38837 on day 2, whereas rimonabant’s 
inhibition was maximal at the first measurement on day 1, as can be seen 
in Table 6. These effect profiles are comparable with the pharmacokinetic 
profiles of the compounds in Figure 1.
discussion
This study aimed to investigate the central and peripheral effectivity 
of tm38837 and rimonabant in healthy subjects. We hypothesised that 
tm38837 would show no effects or small effects on central nervous sys-
tem parameters, whereas rimonabant would show large effects on all 
pharmacodynamic tests. This study suggested that tm38837 is 56 times 
less potent than rimonabant in antagonizing the thc effect on feeling 
high when comparing the ic∞º values, and 4 times less potent on body 
sway in healthy male volunteers. However, the antagonizing effect on 
heart rate increase had a similar potency for tm38837 and rimonabant. 
tm38837 100 mg, which is an anticipated effective human therapeutic 
dose, did not clearly antagonize thc effects when complete time-effect 
curves were compared, but between 24 to 27 hours after administration 
this dose caused close to 60% inhibition of thc-induced tachycardia. 
In contrast, a therapeutic concentration of rimonabant showed pro-
nounced maximal inhibition ratios that were about 80% for heart rate, 
body sway as well as feeling high. With heart rate increase being suggest-
ed to represent a primarily peripheral effect of thc (Strougo et al., 2008), 
this altogether implies that tm38837 is able to induce clear peripheral 
effects with much less central activity, whereas rimonabant shows rela-
tively large central effects. These acute outcomes suggest that tm38837 
could be effective for peripherally associated clinical indications such as 
metabolic disorders, with a lower propensity for centrally mediated side 
effects than rimonabant (Van Gaal et al., 2005; Van Gaal et al., 2008), al-
though this clearly still needs to be demonstrated in prolonged studies 
with more relevant metabolic endpoints.
chapter v – peripheral cb1 antagonist tm38837
– 167 –
novel approaches in clinical development of cannabinoid drugs
– 166 –
Population pk and pk-pd analysis
The current population pk and pk-pd models could be used for 
simulations of new study designs. However, the possibilities of tm38837 
multiple dose designs could not be explored accurately. Due to the low 
clearance and the long terminal half-life, an unknown accumulation 
of the tm38837 plasma concentration and effects could occur after 
multiple dosing. The low clearance and long terminal half-life could 
be caused by factors like a slow inter-compartmental clearance, but 
this could not be examined any further with the current study design. 
A future multiple dose study, or a study using labelled tm38837 could 
investigate the influence of the pharmacokinetic parameters on the 
accumulation of tm38837 in a multiple dose design.
The population pharmacokinetic model of tm38837 calculated a 
terminal half-life of 771 h, whereas the non-compartmental analysis 
found a terminal half-life of approximately 12 to 13 hours. The reason 
for this apparent discrepancy is that the population pharmacokinetic 
model included the pre-dose ‘baseline’ samples, which often contained 
measurable tm38837 concentrations of previous occasions despite 
long washout periods. This provided an improved accuracy of terminal 
half-life estimation. The non-compartmental analysis was not able 
to include the pre-dose ‘baseline’ because of the sparse and relatively 
short sampling scheme during the terminal elimination. The terminal 
half-life that was estimated using the non-compartmental analysis is 
therefore not a reliable estimation of the terminal half-life, but rather an 
estimation of a pre-terminal half-life.
The current study design did not include measurements between 11 
and 24 hours after drug administration, which would have been difficult 
to perform and interpret during the night. This could have influenced 
the estimation of some of the pharmacodynamic and pharmacokinetic 
parameters, such as the (time of) maximal concentration and effect, 
which for tm38837 may well have fallen within this period. In a future 
study, the pk-pd model should be optimised by the integration of data 
from another sampling scheme that would compensate for the time 
points between 11 and 24 hours after tm38837 administration. This 
could result in more accurate estimations of the pharmacokinetic and 
pharmacodynamic effects. However, the current study found a large 
variability on the bioavailability of tm38837 that could not be explained 
completely by the time gap in the sampling scheme. This large inter-
individual variability in tm38837 pharmacokinetics could be caused by 
several factors, such as inter-individual differences in absorption, which 
could not be explored in the current study.
In conclusion, tm38837 induces relatively strong effects on heart 
rate compared to the central nervous system effects. At the anticipated 
therapeutic dose, no clear central nervous system effects were found, 
in contrast to pronounced heart rate effects. Compared to rimonabant, 
tm38837 exhibits relatively strong heart rate effects compared to central 
nervous system effects, which might be an indication of peripheral 
selectivity. tm38837 doses up to 100 mg can possibly induce beneficial 
effects in patients suffering from metabolic disorders, without centrally 
mediated side effects.
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table 1  Overview of study day procedures
Time (hours) Procedures study day
-1h30m – 0h00m Arrival, breakfast, vital signs, drug screen, alcohol breath test, pd-block* (twice),  




2h48m – 4h00m pd-block* (twice), vital signs, lunch
4h00m 1st thc administration 
04h05m – 06:30h Blood sampling tm38837 or rimonabant (04h06m) and thc (04h05m, 4h19m, 5h50m),  
pd-block* (thrice), snack
6h30m 2nd thc administration
6h35m-9h00m Blood sampling tm38837 or rimonabant (6h36m) and thc (6h35m, 6h49m, 8h20m),  
pd-block* (thrice), dinner
9h00m 3rd thc administration
9h05m – 1d00h00m Blood sampling tm38837 or rimonabant (9h06m) and thc (9h05m, 09h19m, 10h50m),  
pd-block* (four times), vital signs (twice), breakfast
1d00h00m 4th thc administration
1d00h05m – 1d02h30m Blood sampling tm38837 or rimonabant (1d00h06m) and thc (1d00h05m, 1d00h19m, 
1d00h50m), pd-block* (thrice), vital signs, lunch
1d02h30m 5th thc administration
1d02h30m – 1d06h00m Blood sampling tm38837 or rimonabant (1d04h21m) and thc (1d02h35m, 1d02h49m, 
1d04h20m), pd-block* (thrice), vital signs, snack
* Pharmacodynamic block consists of body sway measurement, vas B&L and Bowdle, heart rate measurement.  
 aes and concomitant medication were recorded continuously.
table 2  The study consisted of a 4-way cross-over part and a parallel part. Rimonabant or placebo rimonabant were 
always randomly administered at the fifth occasion. All subjects received all treatments from occasion 1 to 4 and the 
subjects were split up in two groups for occasion 5 with half of the subjects receiving rimonabant 60 mg and the other 
half received placebo rimonabant 60 mg.
Occasion Study design Study sample tm38837* Rimonabant thc**
Occasion 1-4 Cross-over 100% 100 mg Placebo Placebo
500 mg Placebo Placebo
Placebo Placebo 5•4mg
Placebo Placebo Placebo
Occasion 5 Parallel 50% Placebo Placebo 5•4mg
50% Placebo 60 mg Placebo
* Penn Pharma, Gwent, United Kingdom
** Farmalyse b.v., Zaandam
table 3  Pharmacokinetic parameters from non-compartmental analysis with means (standard deviation).  
Median t¡/™term was 12.08 h for tm38837 100 mg and 12.98 h for tm38837 500 mg.
tm38837 100 mg tm38837 500 mg Rimonabant
Cmax (ng/ml) 2,860 (2,377) 12,449 (1,620) 620 (113)
Tmax (h) 13.01 (8.28) 12.55 (8.53) 4.11 (0.03)
auc0-∞ (ng.h/ml) 86,088 (49,862) 327,907 (190,569) 6,952 (1534)
table 4  Population pk parameter estimates for tm38837, rimonabant and thc with relative standard error 
(rse, %) inter-individual variability as %cv. F=Bioavailability; iiv=inter-individual variability (%) iov=inter-
occasion variability (%)
thc tm38837 Rimonabant
Parameter estimate Estimate (rse) iiv iov Estimate (rse) iiv Estimate (rse) iiv
Clearance/F (L/h) 200 (5.9) 31.2 - 2.20 (9.29) 66.2 9.30 (6.87) 25.6
Central volume/F (L) 28.5 (8.91) 40.8 25.1 18.7 (16.3) 132.0 39.3 (15.5) 20.6
Peripheral volume of 
distribution/F (L)
107 (14.3) - - 10.8 (42.4) - 93.0 (12.8) -
Intercompartmental 
clearance/F (L/h)
106 (6.9) - - 0.00975 (22.0) - 17.9 (17.2) -
Absorption rate  
constant (Ka; h-1)
- - - 0.0789 (9.72) - 1.17** -
Terminal half-life (h)* 1.11 (11.0) 4.98 - 771 (21.8) - 12.7 (11.5) -
 * Parameter derived from the model
** Fixed parameter
table 5  Statistical analysis of pharmacodynamic parameters. Estimated difference (90% confidence interval) and 
p-value. Bold numbers are the significant differences (P‹0.05). Data were analysed for the complete time profile.
vas feeling high * vas external * Body sway Heart rate 
Rimonabant vs 
Placebo












-3.70% ( -7.5%, 
0.2%) p=0.1137


























-3.70% ( -8.2%,  
0.7%) p=0.1650








1.80% ( -2.8%,  
6.5%) p=0.5089
 * Tests were analysed without placebo results, as these showed no variance.
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table 7  Population pk-pd parameter estimates for vas feeling high, body sway and heart rate with relative standard 
error (rse, %). t50 = equilibration half-life; Emax = maximal effect; ec50 = concentration at 50% of maximal effect; ic50 
= concentration of antagonist at 50% of maximal inhibition; cthc = concentration of thc
Parameter vas feeling high P
 (feeling high ›12) (rse)
Body sway 
 (mm per 2 min) (rse)
Heart rate
 (bpm) (rse)
t50 thc (hr) 1.31 (7.9) 1.94 (92.6) 0.217 (19.2)
t50 Rimonabant (hr) 1.27 (77.5) 1.21 (26.2) 1.27 (32.4)
t50 tm38837 (hr) 4.63 (56.4) 89.4 (24.7) 85.1 (14.3)
Baseline - 230 (5.25) 63.2 (1.8)
Emax - 134 (33.5) 44.0 (39.0)
ec50 thc (ng/ml) - 3.49 (89.2) 33.1 (54.1)
ic50 Rimonabant (ng/ml) - 49.9 (71.2) 95.6 (55.2)
ic50 tm38837 (ng/ml) - 206 (56.3) 65.4 (33.4)
Baseline P (feeling high ›12) 0.00656 (30.0) - -
cthc at P=0.5 (ng/ml) 9.75 (4.4) - -
cthc at P=0.5 during 1st dose (ng/ml) 6.21 (7.3) - -
ic50 Rimonabant (ng/ml) 347 (31.9) - -
ic50 tm38837 (ng/ml) 19500 (27.9) - -
table 6  Simulated inhibition ratios (%) with 90% confidence intervals (90%CI) of thc-induced effects by tm38837 
100 mg and 500 mg, and rimonabant 60 mg calculated per thc administration.
Parameter thc dose 100 mg tm38837 500 mg tm38837 Rimonabant
Estimate 90%CI Estimate 90%CI Estimate 90%CI
Body Sway 1 (1st day) 3.24  (1.34, 7.85) 14.1  (6.33,29.1) 77.4  (58.2, 88.4)
2 (1st day) 4.89  (1.94, 11.8) 20.3  (8.98,39.7) 71.3  (46.2, 87.9)
3 (1st day) 6.42  (2.47, 15.3) 25.4  (11.2,47.0) 61.2  (34.3,82.7)
4 (2nd day) 18.8  (8.84, 35.9) 53.2  (32.2, 73.5) 44.4  (22.7, 69.7)
5 (2nd day) 16.3  (7.19, 33.3) 49.2  (27.9, 71.1) 35.7  (16, 62.2)
Heart Rate 1 (1st day) 16.4  (10.2,25.5) 47.7  (35.2, 60.4) 75.6  (60.6, 85.2)
2 (1st day) 27  (17.6, 39.0) 64  (51.1, 75.5) 74  (54.8, 86.3)
3 (1st day) 35.3  (24.1, 48.5) 72.6  (61, 82.1) 67.2  (46.0, 82.5)
4 (2nd day) 58.4  (44.8, 70.7) 87.4  (79.9, 92.2) 43.8  (25.0, 63.6)
5 (2nd day) 59.3  (45.6, 71.3) 87.8  (80.4, 92.5) 39.9  (22.1, 60.1)
Feeling high 1 (1st day) 3.52  (2.11, 5.77) 16  (9.91, 24.5) 84.6  (75.7, 89.8)
2 (1st day) 5.75  (3.57, 8.73) 24.6  (16.1, 34.4) 83.4  (66.1, 89.8)
3 (1st day) 7.13  (4.76, 10.6) 29.7  (21.0, 40.3) 78.9  (56.9, 86.1)
4 (2nd day) 7.47  (5.5, 10.0) 30.4  (24.0, 38.6) 52.2  (33.4, 63.1)
5 (2nd day) 6.85  (5.09, 9.31) 28.3  (22.3, 36.2) 47.8  (30.5 59.1)
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figure 3  Simulated inhibition ratios (%) of thc-induced effects by tm38837 100 mg (triangles) and 500 mg 
(squares), and rimonabant 60 mg (dots) calculated per thc administration. Figure A gives the relationship between 
heart rate (assumed to primarily represent a peripheral cb¡ effect) and body sway, and figure B between heart rate 
and P (feeling high‹12).
figure 1  Mean concentration-time profile of tm38837 100 mg (black dots) and 500 mg (blank dots) in the left graph, 
and the profile of rimonabant in the right graph. tm38837 treatments were administered at t=0 h, and rimonabant was 
administered at t=2 h. Error bars represent the standard deviation.
figure 2  Effect-time profiles of feeling high after tm38837 100 mg (triangles), 500 mg (open dots), rimonabant 
(squares) or placebo antagonist (black dots) administration.
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figure 4  Schematic representation of the pk-pd models of tm38837 and rimonabant. 1: influence of plasma 
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abstract
aim Although cb¡ antagonists are less widely studied due to market 
withdrawal of rimonabant, this drug class is still very interesting due to 
a the therapeutic potential. The severe psychiatric side effects might be 
overcome due to careful management of drug development, including 
improved studies in healthy volunteers by using cb¡ agonist challenge 
tests and thorough pk/pd analyses. We aimed to build pk/pd models suit-
able for direct comparisons of pharmacological compounds in complex 
clinical setting using a pharmacological challenge test. Secondly, we 
wanted to apply the model to make a direct comparison between four cb¡ 
antagonists.
methods The pharmacokinetic models of multiple thc administra-
tions and the four antagonists drinabant, surinabant, rimonabant and 
tm38837 were built separately. Next, the thc-induced effects in healthy 
volunteers, including changes on heart rate and the visual analogue scale 
of feeling high were modelled by a pk/pd model linked to the thc pk 
model. Then, the inhibition of the thc-induced effects by the antagonists 
was quantified by incorporating components representing the inhibi-
tory effect. The delay between drug concentration and drug effect was 
described using a biophase compartment. A benchmark simulation was 
then used based on a constructed model to evaluate the reduction rate 
of each antagonist on the reversal of the thc-induced effect in a unified 
simulation scenario. 
results  The final pk model of thc and antagonists was a two-com-
partment model with first order absorption and first order elimination. 
An Emax model and logistic regression model were used as effect mea-
sures and the antagonist effect was added in these models in a competi-
tive binding manner. T¡/™ke0 ranged from 0.00462 to 63.7 hours for 
heart rate and from 0.964 to 150 hours for vas. ic∞º ranged from 6.42 to 
202 ng/ml for heart rate and from 12.1 to 376 ng/ml for vas. rses were 
‹100% for heart rate, and ‹65% for feeling high, except for a 193% rse on 
t∞º after rimonabant administration. After the benchmark simulation, 
drinabant and tm38837 showed relatively larger effects on heart rate 
than feeling high compared to surinabant and rimonabant.
conclusions Our pk/pd modelling and simulation approach was 
suitable for modelling and simulation of heart rate and feeling high for 
four cb¡ antagonists in a thc challenge test. We were able to directly 
compare four antagonists and we found differences in efficacy profiles 
that might be translated to differences in therapeutic efficacy in future 
studies.
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introduction
Obesity is one of the world wide, emerging, serious, life threatening 
diseases (World Health Organization, 2011). The lack of efficient and 
well-tolerated drugs to treat obesity has led to an increased interest in 
new targets for the development of new drugs (Patel and Pathak, 2007; 
Barth, 2005). A specifically interesting target is the cb¡ receptor, which is 
located in the central nervous system (cns) and at peripheral sites such 
as the heart, liver, pancreas and adipose tissue (Bermudez-Silva et al., 
2008; Bermudez-Silva et al., 2010). At these sites, the cb¡ receptor has a 
modulatory role in the regulation of a variety of complex physiological 
systems, such as the nervous system, and the digestive and endocrine 
system in metabolism (for a review, see Melamede (2005)). Activation of 
the cb¡ receptor leads to effects including feeling high and altered time 
perception, increased body sway and getting hungry (‘the munchies’) (for 
a review, see (Zuurman et al., 2009)).
This widespread involvement of the cb¡ receptor and its ligands 
provides numerous opportunities for the development of new 
medicines for neuronal and metabolic disorders including movement 
disorders, diabetes mellitus, and dyslipidemia. In the late 1990’s 
the pharmaceutical industry became particularly interested in the 
metabolism effects of cb¡ receptors and focused on new chemical entities 
that could decrease appetite by cb¡ receptor antagonism. It was found 
that cb¡ antagonists were indeed able to block feeding behaviour and 
they also showed other characteristics (including decreased gastric 
emptying and increased insulin sensitivity (Patel and Pathak, 2007; Xie 
et al., 2007)) that underlined the potential of cb¡ antagonist in obesity 
treatment.
In 2006, the first cb¡ antagonist rimonabant (formerly known as 
sr141716) was registered for the treatment of obesity and overweight 
with obesity-associated disorders (Wathion, 2009). Besides rimonabant, 
Sanofi developed more cb¡ antagonists, such as drinabant (formerly 
known as ave1625 with possible inverse agonism properties) and 
surinabant (sr147778). However, in 2008, rimonabant was withdrawn 
from the market due to unacceptable psychiatric adverse effects. Almost 
all pharmaceutical companies, including Sanofi, terminated all studies 
involving cb¡ receptor antagonists (such as rimonabant, otenabant and 
taranabant).
Nevertheless, there are studies suggesting that the beneficial 
metabolic effects of rimonabant might be regulated predominantly by 
peripheral cb¡ receptors, whereas the psychiatric side effects could be 
regulated by centrally located cb¡ receptors (Cluny et al., 2010; Nogueiras 
et al., 2008). There is considerable evidence to suggest that the beneficial 
metabolic effects of cb¡ antagonists are mediated by cb¡ receptors that 
are present at locations which are specifically associated with metabolic 
regulation, such as the liver, the pancreas, and fat cells (Bermudez-
Silva et al., 2008; Bermudez-Silva et al., 2010; Gomez et al., 2002). If the 
therapeutic effects of cb¡ antagonists have their target site in peripheral 
tissues and the (serious) side effects originate in certain regions of the 
cns, it is crucial to understand how the specific antagonist could affect 
the several central and the peripheral target sites.
One of the problems with the investigation of the different sites and 
effects of cb¡ antagonism is that there are now validated measurements 
of these effects after acute administration of cb¡ antagonists or in 
healthy subjects. To partly overcome this problem, challenge tests 
with the cb¡/™ partial antagonist ∆9-tetrahydrocannabinol (thc) 
were developed (Klumpers et al., 2013; Strougo et al., 2008; Zuurman 
et al., 2008). With this challenge test, the endocannabinoid system is 
stimulated using thc, which induces a range of dose- and concentration-
related responses. Several of these measures, such as the characteristic 
euphoric ‘high’ feeling, are clearly indicative of central nervous system 
effects. Other parameters like heart rate are more likely to be peripherally 
mediated (Strougo et al., 2008; Zuurman et al., 2008; Zuurman et al., 
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2008). The thc-challenge has been found to be an effective tool to 
demonstrate the pharmacological effects of a cb¡ antagonist, since co-
administration of a selective cb¡ antagonist causes a near-complete block 
of the acute thc-induced effects. The use of the variety of measures such 
as feeling high, body sway and heart rate allow us to create individual 
effect profiles for the different cb¡ antagonists.
Previously, our clinical research centre separately investigated the 
concentration-effect relationships of four different cb¡ antagonists: 
rimonabant, surinabant, ave1625 (drinabant) and tm38837 (Zuurman 
et al., 2010; Klumpers et al., 2013). This was performed in three separate 
studies by using thc-challenge tests, all with different thc dosages 
and dosing time intervals. This approach allowed us to analyse the 
pharmacological characterisation of the individual antagonists. 
However, a thorough comparison among the antagonists was hampered 
by the different dose regimes of the thc challenge tests. In the current 
study, we built an integrated pk/pd model for all antagonists that 
would compensate for these differences between the thc challenge 
tests, allowing a direct comparison of the different cb¡ antagonists with 
regards to pk and pd characteristics.
pk/pd modelling is an approach to characterize the concentration–
time profile and the relationship between concentrations and effects 
using a mathematical model. Model estimation can be based on both 
individuals and populations. The assumption that all individual 
concentration–effect relationships can be described with the same 
structural model is based on the notion that the drug activates the 
same pharmacological system in all subjects (or systems for different 
responses). pk/pd modelling is performed by using a non-linear mixed 
effect modelling approach which provides estimates of the population 
average parameters (assuming that each individual can be described 
using the same structural model) and their associated inter-individual 
variability, which allows individuals to differ from each other. Residual 
error describing the variability of the difference between predicted 
values and the observations is also estimated (Beal, 2013; Holford and 
Sheiner, 1981). Simulation is a subsequent step, following the modelling. 
It can be used to predict model outcomes using an existing model 
structure given different scenarios (model input), for instance with 
different dosages, sampling times and other covariates. 
Our first aim was to build an integrated pk/pd model that would 
be suitable for direct comparisons of pharmacological compounds in 
complex clinical setting using a pharmacological challenge test. We 
would do this for four different cb¡ antagonists (drinabant, surinabant, 
rimonabant and tm38837) and a thc-challenge test for efficacy 
parameters feeling high and heart rate. Our second aim was to apply the 
model for direct comparisons of the different pharmacokinetic profiles 
and efficacy of the four different cb¡ antagonists to better understand 
the behaviour of cb¡ antagonists in healthy humans.
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From 2003 until 2009, three thc challenge studies were performed at 
chdr in healthy male volunteers, in which four cb¡ antagonists were 
administered: a study with drinabant (ave1625), one with surinabant 
(sr147778), and another study that investigated both rimonabant 
(sr141716) and tm38837 (referred to as ‘the rimonabant-tm38837 
study’) (Tonstad and Aubin, 2012; Zuurman et al., 2008). The three 
studies were all performed in a double-blind, randomized, placebo-
controlled, (partial) cross-over manner. The complete design and clinical 
results of these studies were published separately (Zuurman et al., 
2010b; Klumpers et al., 2013c; Klumpers et al., 2013). The treatments per 
study and subject demographics are summarized in Table 1 and Table 
2, respectively. In short, each cb¡ antagonist or placebo administration 
was followed by a series of inhaled doses of a vaporized solution of thc 
in ethanol or thc vehicle, which consisted only of vaporized ethanol. 
thc was vaporized using a Volcano vaporizer® (Storz & Bickel GmbH 
& co. kg, Tuttlingen, Germany). In each study, the first thc dose was 
administered around the expected tmax of the cb¡ antagonist. Blood 
sampling for pk and selected pd responses were taken accordingly after 
multiple thc challenge and/or antagonist administration and the last 
sampling time points were shortly after the last challenge dose of thc.
Pharmacokinetic and pharmacodynamic 
measurements
Blood samples of thc and four antagonists were analyzed as published 
before (Zuurman et al., 2010b; Klumpers et al., 2013c; Klumpers et al., 
2013). In short, thc samples were measured using tandem mass spec-
trometry with a lower limit of quantification of 0.1 ng/ml. Concentra-
tion of ave1625 was measured using Flow Chromatography – Mass 
Spectrometry/Mass Spectrometry (tfc-ms/ms) and the limit of quan-
tification was 0.2 ng/ml. Concentration of surinabant was measured us-
ing liquid chromatography coupled with tandem mass spectrometry 
(lc-ms/ms) method with a lower limit of quantification (lloq) of 1.0 ng/
ml. Concentrations of tm38837 and rimonabant were measured by liq-
uid chromatography with tandem mass spectrometry method with a 
lower limit of quantification of 0.1 ng/ml for tm38837, and 1.0 ng/ml for 
rimonabant. 
In all studies, Visual analogue scales (vas) according to Bowdle 
(psychedelic effects) and heart rate were assessed frequently (Bowdle et 
al., 1998; Zuurman et al., 2008). Heart rate was measured using Nihon-
Koden bsm-1101K monitor (Lifescope ec, Tokyo, Japan) blood pressure 
apparatus. The adapted version of the Bowdle scales consists of 100 mm 
visual analogue lines, to indicate subjective feeling high, and on a range 
of other subjective effects that cluster as factors internal perception and 
external perception, both composite scores that are affected differently 
by thc as previously described (Zuurman et al., 2008). 
Modelling and simulation
pk and pk/pd modelling was performed using population approach 
nonlinear mixed effect modelling program nonmem 7.1.0 (Beal, 2013). 
Nonlinear mixed effect modelling considers the repeated observations as 
a function of time in a population of individuals. The model to describe 
these observations adopts a common structural model and distribution 
of residuals, while allowing the parameters in the model to vary between 
individuals. The location (typical value or fixed effect) and spread be-
tween individuals (variability or random effect) of the model parameters 
are estimated by fitting the parameters to the data by minimizing an 
objective function based on the log likelihood (-2 x ll). Using the popu-
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lation values (both location and spread), individual specific empirical 
Bayes’ estimates (post hoc estimates of individual deviates (etas) from 
the random effects distributions) are determined that allow description 
of individual time profiles. 
Different models are compared with increasing complexity in the 
structural model and the number of random effects. The objective is to 
find the simplest model that describes the data adequately. Competing 
models are compared using the likelihood ratio test, which compares 
the difference between log-likelihoods for the models (difference in 
objective function value, ∆ ofv) to a Chi-square distribution with degrees 
of freedom corresponding to the difference in number of parameters 
between the two models (p-value used was less than 0.01: ∆ ofv = -6.63). 
Models were qualified by visual inspection for goodness of fit and check 
of weighted residuals.
A general overview of the two-step modelling approach is displayed 
in Figure 1. First, pk models for thc and four antagonists were built 
separately for every compound to obtain estimated pk parameters 
based on ofv and goodness of fit. The pk model was only built to 
optimally describe the pk profile. Therefore, a separate thc model (if 
possible with a similar structure) was built for each of the three studies. 
Secondly, the pk/pd model was built. The integrated models only 
regard the pd models to enable direct comparison of the different cb¡ 
antagonists. Individual empirical Bayes’ estimates were determined 
to describe the concentration profile and used in the subsequent pk/pd 
analyses. Parameter estimation for population pk modelling of thc and 
antagonists was performed under advan 5 and the pk/pd modelling of 
all pd parameters was performed under advan6 tol 5. The rse (relative 
standard error) was calculated for all parameters. Inter-individual 
variability (iiv) and inter-occasion variability expressed as coefficient of 
Variation (%cv) using:
        
  (1)
First order conditional estimation (foce) with interaction was the stan-
dard method of estimation, with the exception of vas feeling high pd 
model, for which laplace was used. Within each model, additive and/or 
proportional residual error models were compared.
Pharmacokinetic and pharmacodynamic 
analyses
The population pk model of thc was based on the results of previous 
chdr studies with multiple thc inhalations, using a two-compartment 
model with bolus administration (Strougo et al., 2008) and first order 
elimination. pk analyses of four antagonists were performed in a similar 
way with compartmental model, including first order absorption and 
first order elimination. 
A biophase compartment is used when drug action is delayed by 
distribution from plasma to the site of action. The rate of equilibration 
of drug in the plasma with the site of action is denoted ke0, the rate 
constant for exit of drug from the biophase compartment (Groenendaal 
et al., 2008; Hull et al., 1978; Sheiner et al., 1979). 
A biophase compartment was first used to account for the delayed 
response of vas. To minimize the effect of over- and under-dispersion 
due to the subjectivity of the vas scale, and to include non-response in 
the model, the vas feeling high scale was translated into a binary scale, to 
accommodate the possibility to construct a probability model for feeling 
high (Klumpers et al., 2013). The anchor point for this translation was the 
median of all scores higher than 0 (on a 100 point scale) for the treatment 
arms where only thc was dosed. Inverse logit transformation is used for 
binary data:
 (2)
With        
  (3)
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In which cut was the anchor point that changed depending on the 
study; b¡ is the coefficient of thc effect; b is the coefficient of the shift 
of the thc effect caused by the antagonist. The effect of antagonists in 
the above equation reverses the thc induced increase in probability 
of scoring a vas›cut. Every subject receives multiple thc inhalations, 
causing a tolerability that affected the scores of the vas. To cope with 
this, kd, the elimination rate of tolerance, was included to decrease the 
possibility of feeling high caused by time factor tad, the time after the 
first dosing time point. 
A biophase compartment was used to account for the delayed 
response of heart rate as well. Because the all antagonists bind with 
the cb¡ receptor in competition with thc, the biophase compartment 
concentration of thc and respective antagonist was used for the pd 
analyses by using a maximum effect equation (Eq. 4). In this equation, 
the antagonist could cause a shift to the right of the apparent ec∞º 
depending on the impact of the thc challenge effect and the effect is 
described as:       
  (4)
Where E0 is the baseline of the effect; Emax is the maximal achievable 
effect; cthc is thc concentration in biophase compartment; ec∞º is 
the concentration that causes 50% of the Emax. b is the coefficient that 
describes the antagonist shift by the thc effect; cantagonist is the cb¡ 
antagonist concentration in the biophase compartment. 
Based on pd model parameters, ic∞º and t¡/™ke0 can be then be 
derived from parameter estimation by using equations 3 and 4. These 
two parameters describe the inhibition potential of cb¡ antagonists. ic∞º 
is a measure of the effectiveness of a compound in inhibiting biological 
function. It indicates how much of a particular antagonist is needed to 
inhibit a given effect of thc by half. t¡/™e0 is the apparent half life of a 
drug effect. It is derived from ke0, which indicates the rate constant of 
the elimination of a drug effect:
        
  (5)     (6)
Visual predictive checks
Visual predictive checks (vpc) were performed for all pk and pd models 
using R version 2.12.0 (R: A Language and Environment for Statistical 
Computing, R Development Core Team, R Foundation for Statistical 
Computing, Vienna, Austria, 2010) with the lsoda (deSolve Package 1.8.1) 
and mvrnorm functions (mass Package v7.3-8). The visual predictive 
check encompassed a projection of the simulated dependent variable 
as a function of time using the final model on the observations. The 
simulations were performed considering the estimated population 
parameters (q vector) as well as the covariance matrix describing 
iiv (W matrix). The residual variability (S matrix) was not included 
in the simulations. The simulations and the data were grouped by 
antagonists’ dose. Summary statistics of the simulations (median and 
the 95% prediction interval of the simulated iiv) enabled a comparison 
of the predicted and the observed variability. For each dose group 1000 
individuals were simulated. 
Simulation
We selected a benchmark scenario to try to maximally cover the major 
part of the original study designs. Due to differences in tmax, the 
time points of the first thc administration relative to the antagonist 
administration were different among the different study designs. 
As original study designs, the time between administration of cb¡ 
antagonists and first thc was the same as the tmax of antagonist. In 
this way, the first thc inhalation would be administered at the expected 
tmax of cb¡ antagonists. We kept this the same in the benchmark 
scenario and we compensated for these differences by simulating the 
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thc challenge profile rather than using the actual challenges. During 
this simulated challenge, individuals received 4 doses (2, 4, 6 and 6 
mg) of thc inhalation at an hourly interval. Drinabant, surinabant, 
rimonabant and tm38837 were simulated as single dose administered 
at 3, 1.5, 2 and 4 hours before thc challenge, respectively, similar to the 
dose regimens in the actual studies. A wide dose range of the antagonists 
was simulated with dosages from 2mg to 1000mg to optimise the dose 
response curve. The reduction rate was used as drug response in the dose 
response curve and was calculated as the difference between the auc (area 
under the curve) of the pd response of the thc challenge only and the 
thc challenge + antagonist. For auc calculation observations were used 
from the first administration of thc until one hour after the 4th thc 
administration. The reduction rate was calculated as:
        
  (7)
Where rr is the reduction ratio, aucthc is the area under the curve 
of thc alone; aucantagonist+thc is the area under the curve of co-
administration of thc and the antagonist.
Simulations were performed in a similar way as for vpc by 
implementing the identified models and the estimated parameters in R 
using the function lsoda from the deSolve library (version 1.8.1) and the 
function mvrnorm from the mass library (version 7.3-8). The results of 
the simulations were used to plot the population-typical dose-response 
curves.
results
thc pharmacokinetic modelling 
In all three studies, a two-compartmental structure model with first-or-
der elimination was the best model to describe thc concentration-time 
curve. The pulmonary administration was implemented as a bolus input 
in the central compartment. 
The pk parameters of thc of the three separate studies are presented 
in Table 3. No significant differences were found among the studies for 
the model parameter estimations and they were also similar to the param-
eters from the models by Strougo et al. (2008). All rses of the estimations 
were smaller than 30% (from 5.19% to 14.3%). Inter-individual variability 
(iiv) was identified on the apparent central distribution volume, ranging 
from 10.3% to 40.8%. iiv on apparent clearance was 18.8% and 31.2% for the 
drinabant study and the rimonabant-tm38837 study, separately. For the 
surinabant study the iiv on the apparent clearance could not be identi-
fied. Additionally, inter-occasion variability on the apparent central dis-
tribution volume was included to account for differences in bioavailabil-
ity between individual dosing occasions in the surinabant study and the 
rimonabant-tm38837 study and was 78.0% and 25.1% respectively. The 
residual error model was only proportional to concentration.
Antagonist pharmacokinetic modelling 
The pk models of the four antagonists were built separately. All of them 
could be described using a two-compartmental model with first-order 
elimination and first-order absorption. Surinabant was found to have 
a lag time of 0.550 hours (rse = 5.7%) and its ka was dose-proportional 
with a dose effect of 0.00486 (rse = 14.4%) as defined by the following 
equation:
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 (8) ka (dose) = 0.448x (1 - αxdose)    
    
In wich α is the dose effect to ka. For each compound, the rses of the 
parameter estimations varied between 3.91% and 42.4% (Table 4). iiv and 
iov were incorporated in the model if it improved goodness of fit. iiv 
for the clearance of surinabant, rimonabant and tm38837 ranged from 
25.6% to 66.2%. For apparent central distribution volume, the iiv varied 
from 20.6% to 132%. The goodness of fit plot was improved by adding an 
iov of 24% for the central distribution volume of drinabant. Inspection 
of the data showed that the upswing of the concentration after 
administration of rimonabant was insufficiently detailed to estimate the 
first-order absorption rate constant. Therefore, this parameter was fixed 
to the value for the absorption rate constant as reported by Martinez 
(Martinez et al., 2007). The pk parameter estimations of the antagonists 
were presented separately in Table 4, including the rse, inter-individual 
variability and inter-occasion variability. vpcs and diagnostic plots were 
also performed for all four antagonists pk model for model validation.
The thc-induced effects were modelled using data from treatment 
arms with thc dosages only. To enable a direct comparison of the 
antagonists, an integrated thc pd model was applied on the three trials 
for the same set of pd parameters: heart rate and feeling high. An Emax 
model gave the best fit for heart rate. The baseline was estimated at 64.2 
bpm with a rse of 1.14%. Within the study, the highest heart rate observed 
was around 120 bpm. Although physiologically, higher heart rates are 
possible for higher thc dosages, we chose to fix the Emax of heart rate to 
two times the baseline, resulting in proper diagnostic plots and vpcs. iiv 
and iov were both incorporated at the baseline at 7.98% and 5.91%. rses 
of all heart rate model parameters were below 30%. 
A logistic regression model was used for modelling the vas feeling 
high, the parameters of which had a relatively low rse (smaller than 
20%). The estimated parameters of vas feeling high are shown in Table 5.
Antagonist pharmacodynamic modelling 
An effect compartment was built for thc and the antagonists to 
describe the time delay between the concentration effect profiles. 
An equilibration half-life (t¡/™ke0) was defined, which ranged from 
0.00462 (0.502%) to 63.7 (35.4%) hours for heart rate with all rses smaller 
than 100%; and 0.964 (193%) to 150 (16.8%) hours for vas. These wide cv 
ranges suggested a large variability in drug distribution rates to the 
target locations for the different antagonists. Rimonabant presented a 
relatively high rse, which was the only one that was bigger than 100%. 
This suggested a low uncertainty of the parameter estimation.
The range of ic∞º also ranged widely, from 6.42 (36.9%) to 202 (38.6%) 
ng /ml for heart rate, and from 12.1 (25.9%) to 376 (15.3%) ng /ml for vas 
feeling high with all rse smaller than 100%. 
All pd parameter estimates of the four different antagonists are 
presented in Table 6. Both diagnostic plot and vpc were performed, 
which confirmed that the proposed model fit the data properly with 
acceptable predictive ability. 
Dose-response curve simulations
The simulations of two dose-response curves (in this case dose-reduction 
rate curves) of the antagonists are graphically displayed in Figure 2. The 
dose range for the simulation ranged from 2 to 1000 mg. All antagonists 
caused a maximal reduction of thc-induced effects of 70% to 85%. 
The order and shape of the curves that depict the relations between 
dosages and reduction rates varied considerably among the different 
cb¡ antagonists and effects. For example, the reduction rates for heart 
rate were larger than for vas high in the case of drinabant and tm38837, 
whereas for surinabant and rimonabant, vas feeling high had a higher 
reduction rate than heart rate. This suggests that different antagonists 
can show different selectivity for various target sites. 
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discussion
Our aims were to build integrated pk/pd models for thc and four cb¡ 
antagonists and to apply them for direct comparison of the different 
antagonists to improve our understanding on the behaviour of cb¡ 
antagonists in healthy volunteers.
We found that our pk/pd modelling and simulation approach was 
suitable for direct comparisons of pharmacological compounds in 
complex clinical settings using a thc challenge test, even when the 
data came from different studies with different thc dosing regimens. 
Our integrated pk/pd models have a few advantages and disadvantages 
compared to the individual pk/pd models that we built in previous 
studies (Strougo et al., 2008; Klumpers et al., 2013a; Klumpers et al., 
2013b). Integration on the pd level enabled us to compare the different 
antagonists directly; however this approach resulted in enlarged 
inaccuracy of parameter estimation. The method of calculating the 
inhibition ratios of the antagonists as performed in the surinabant study 
and the rimonabant-tm38837 study was highly dependent on sampling 
time points and did not consider the whole effect-time profile (Strougo et 
al., 2008; Klumpers et al., 2013a; Klumpers et al., 2013b), while our study 
presented an improved method to calculate inhibition ratios based on 
the auc of pd responses. In this way, we were able to make estimations 
along the whole time-effect curve.
We have found that surinabant and rimonabant induced larger effects 
on inhibition of thc-induced vas feeling high than on inhibition of 
thc-induced heart rate rising effect, whereas drinabant and tm38837 
showed an opposing behaviour. This was consistent when (graphically) 
comparing the findings from previous studies (Zuurman et al., 2010; 
Klumpers et al., 2013a; Klumpers et al., 2013b). The different effect 
profiles in healthy humans of drinabant and tm38837 compared to 
surinabant and rimonabant suggest differences in clinical efficacy in 
patient groups. Considering the previously suggested associations 
of heart rate effects and peripheral effectivity, it would be tempting 
to imply that drinabant and tm38837 have a larger preference for 
peripheral target sites, resulting in larger peripheral effects compared 
to centrally induced effects. This would be a more desired effect profile, 
considering the severe unwanted psychiatric side effects as previously 
observed in clinical rimonabant dosages. However, patient studies 
are needed to investigate the efficacy of compounds with increased 
peripheral selectivity and their translation to efficacy parameters in 
healthy volunteers.
Despite the market withdrawal of rimonabant, it would still be very 
interesting to investigate the efficacy and tolerability of rimonabant as 
well as surinabant in more detail. From our previous research (Klumpers 
et al., 2013a) we analysed that the clinically used cb¡ antagonist dosages 
and steady state plasma concentrations were well above the dosage and 
concentration that maximally blocked thc-induced effects. The analyses 
were performed over specific time periods during which the antagonist 
concentrations where at maximum reaching maximum inhibition of 
thc-induced effects. This implies that the clinically applied rimonabant 
dosage might have been higher than needed to induce favourable 
therapeutic effects and high enough to induce severe unwanted 
side effects. We hypothesise that a lower dose and concentration of 
rimonabant (and the right dose for surinabant) might result in an 
acceptable balance between efficacy and side effects, which could be 
different for different patient groups. To confirm this, future research 
should perform additional patient studies and carefully translate our 
model (i.e. the results from studies in healthy subjects) to patient groups.
In conclusion, we were able to build suitable pk/pd models in which 
cb¡ antagonists drinabant, surinabant, rimonabant and tm38837, 
and the agonist thc were integrated. We found that the effects of the 
antagonists showed different profiles, with drinabant and tm38837 
showing relatively larger heart rate effects than effects on vas feeling 
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high compared with surinabant and rimonabant. We suggest that 
drinabant and tm38837 might have a larger therapeutic potential than 
rimonabant and surinabant, due to the potential higher risk of severe 
psychiatric side effects for the latter two compounds, which is based on 
their relatively large central effects (i.e. feeling high). 
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table 1  Subject demographics. Mean with standard deviation (sd). bmi: Body Mass Index.
Name of study Subject number Age Weight (kg) Height (cm) bmi (kg/m2)
Drinabant 36 22 (3) 76 (11) 183 (6) 23 (3)
Surinabant 30 23.2 (5.3) 78.94 (8.23) 187.7 (6.7) 22.39 (1.94)
Rimonabant-tm38837 36 21.2 (3.8) 77.25 (10.18) 183.42 (6.99) 22.9 (2.1)
table 2  Treatments per study. 
Name of study Treatment Time of thc administra-





Drinabant Placebo drinabant+ thc vehicle
3, 4, 5, 6 2, 4, 6, 6
Placebo drinabant + thc challenge
20 mg drinabant + thc challenge
60 mg drinabant + thc challenge
120 mg drinabant + thc challenge
120 mg drinabant + thc vehicle
Surinabant Placebo surinabant + thc vehicle
1.5, 2.5, 3.5, 4.5 2, 4, 6, 6
Placebo surinabant + thc challenge
5 mg surinabant + thc challenge
20 mg surinabant + thc challenge
60 mg surinabant + thc challenge
60 mg surinabant + thc vehicle
Rimonabant-
tm38837
Placebo tm38837 + Placebo 
rimonabant+ thc vehicle
2, 4.5, 7, 22, 24.5* 4, 4, 4, 4, 4
Placebo tm38837 + Placebo 
rimonabant+ thc challenge
100 mg tm38837 + Placebo 
rimonabant+ thc challenge
500 mg tm38837 + Placebo 
rimonabant+ thc challenge
4, 6.5, 9, 24, 26.5** 4, 4, 4, 4, 4
Placebo tm38837 + 60 mg 
rimonabant+ thc challenge
Placebo tm38837 + Placebo 
rimonabant+ thc challenge
*  Time of thc administration after rimonabant administration
**  Time of thc administration after tm38837 administration
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table 5  pk/pd parameter estimates of thc alone for heart rate and vas feeling high with percentage coefficient 
of variation (cv). t50 = equilibration half-life of the elimination from the biophase compartment; Emax = maximal 
effect; ec50 = concentration at 50% of maximal effect; iiv = inter individual variability; iov = inter occasion variability; 
Betathc = coefficient of the antagonist-induced shift of the thc effect; Kd = elimination rate of tolerance
Parameter Units Estimate (%rse) iiv iov
Heart rate t¡ /™ hr 0.33 (28.2) - -
Eº bpm 64.2 (1.14) 7.98 5.91
Emax bpm 64.2 (-) - -
ec50 ng/ml 73.7 (18.4) - -
Feeling high t¡ /™ hr 2.26 (16.3) - -
cut1 2.78 (2.98) - -
Betathc -0.519 (16.7) - -
Kd  0.131 (18.6) - -
table 6  pk-pd parameter estimates of antagonists for vas feeling high, body sway and heart rate with percentage 
coefficient of variation (cv). T¡/™e0 = equilibration half-life; ic50 = concentration of antagonist at 50% of maximal  
inhibition
Parameter Units Estimate 
(%rse)




Drinabant Surinabant tm38837 Rimonabant 
Heart rate t¡ /™eo hr 6.25 (34.6) 0.00462 (0.502) 63.7 (35.4) 1.12 (26.3)
ic50 ng/ml 6.42 (36.9) 107 (34.4) 175 (36.6) 202 (38.6)
Feeling high t¡ /™eo hr 1.75 (34.7) 6.7 (62.9) 150 (16.8) 0.964 (193)
ic50 ng/ml 12.1 (25.9) 61.6 (44.9) 376 (15.3) 92.8 (65)
table 3  pk parameters of thc in the different studies, with the relative standard error (rse, %) and the inter-individ-
ual variability (iiv) as %cv. F=Bioavailability; iov=inter-occasion variability (%)
Drinabant Surinabant Rimonabant-tm38837
Parameter Estimate (%rse) iiv iov Estimate (%rse) iiv iov Estimate (%rse) iiv iov
Clearance/F (L/h) 228 (5.19) 18.8 - 228 (7.39) - - 200 (5.9) 31.2 -
Central volume/F (L) 35.5 (6.95) 10.3 - 35.2 (8.88) 38.9 78 28.5 (8.91) 40.8 25.1
Peripheral volume  
of distribution/F (L)
145 (6.45) - - 103 (6.79) - - 107 (14.3) - -
Intercompartmental 
clearance/F (L/h)
134 (6.08) - - 128 (7.16) - - 106 (6.9) - -
table 4  pk parameters of drinabant, surinabant, rimonabant and tm38837 with the relative standard error (rse, %) 
and the inter-individual variability (iiv) as %cv. F=Bioavailability; iov=inter-occasion variability (%)
Drinabant Surinabant Rimonabant tm38837
Parameter Estimate 
(%rse)
iiv iov Estimate 
(%rse)
iiv iov Estimate 
(%rse)
iiv iov Estimate 
(%rse)
iiv iov
Clearance/F (L/h) 32.5 
(14.8)
- - 4.4 (12.7) 62.5 - 9.30 
(6.87)







36.3 24 4.99 
(16.3)
66.4 - 39.3 
(15.5)





2170 (30) - - 515 
(12.5)
102. - 93.0 
(12.8)







- - 15.9 (6.5) 91.2 - 17.9 
(17.2)







39.8 - c0.448 
(3.91)
7.83 - 1.17 
(fixed)
- - 0.0789 
(9.72)
-
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figure 1  Schematic representation of the pk-pd models. 
figure 2  Simulated dose-effect relationship and the estimated reduction rate (i.e. antagonism of thc-induced effects) 
of heart rate (solid line) and vas feeling high (dashed line) of: (A) drinabant; (B) surinabant; (C) rimonabant; (D) tm38837. 
From the curves we observed that drinabant and tm38837 induce relatively larger heart rate effects than vas feeling 
high effects, whereas this is opposite for surinabant and rimonabant.
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For already thousands of years, cannabis has been the most widely used 
illicit drug for recreational and medicinal purposes. The receptors 
on which cannabinoids act are part of one of the most phylogenically 
ancient and widely preserved pharmacological systems in biology. 
Nonetheless, this endocannabinoid system has only been discovered 
during the last few decades, and scientific progress in understanding 
the relevance of this system in health and disease has been limited and 
slow. As a result, only a few drugs that act on the endocannabinoid system 
have been registered, most of which are components of Cannabis sativa. 
At the end of 2006, just when cannabis research was flourishing, the 
industry suddenly lost its interest due to concerns of the fda about the 
safety of cb¡ antagonist rimonabant, an anti-obesity drug with inverse 
agonistic properties. The registration of rimonabant, which was hailed 
as a breakthrough in drug research and in treatment of the metabolic 
syndrome, was quickly followed by a market withdrawal in 2008. This 
resulted in an almost complete and unanimous ban on cb¡ antagonist 
research, which is still felt today.
The demise of rimonabant reflects many of the difficulties of 
cannabinoid drug development. Some of these are related to public 
perceptions. Research on cannabinoid agents is often regarded sus-
piciously because of concerns of abuse. Many of the most promising 
potential indications for cannabinoid drugs are disputed: obesity is not 
considered a disease by the American Medical Association (ama Council, 
2013), addiction is often viewed as an individual failure of character 
(Gartner et al., 2012), and many pharmaceutical industries regard 
psychosis as too risky for commercial drug development (van Gerven and 
Cohen, 2011).
The unfortunate fate of rimonabant is also related to some funda-
mental scientific complexities of endocannabinoid research. Some of 
these are mentioned in the introduction: widespread distribution, lim-
ited subtype specificity, local production of highly lipophilic and rapidly 
degraded transmitters, complex physiological integration, lack of good 
effect measures, all leading to unclear pathophysiological involvement. 
But the focus of endocannabinoid research on cannabis can also be mis-
leading. Many of the putative indications for cannabinoid agonists or an-
tagonists are inspired by the well-known effects of recreational cannabis 
consumption. Although feeling pleasant and ‘high’, getting the ‘munch-
ies’, or suffering from panic attacks after using cannabis, are undoubted-
ly founded in the functional pharmacology of endocannabinoid systems, 
these effects reflect limited aspects of gross overstimulation. They hardly 
represent the local functions of endocannabinoids in the subtle regulato-
ry modulation of normal physiological processes, or their involvement in 
intercellular or systemic derangements of complex multicascadic func-
tional networks. 
The failure of rimonabant also reflects some weaknesses of current 
drug development. Rimonabant was considered a ‘miracle drug’ for 
the treatment of obesity and smoking (Boekholdt and Peters, 2010), 
with ‘blockbuster’ potential. Its development was based on the ‘logical’ 
notion that blocking hunger or reward (and associated physiological 
processes) will reduce weight and craving (i.e. induce the opposite of 
cannabis-associated munchies and abuse). But it was disregarded that 
along the same reasoning, inhibition of pleasant feelings (i.e. inverse of 
cannabis-induced euphoria) would be expected to have a negative impact 
on mood. Nonetheless, to the best of our knowledge, emotional or 
cognitive effects have never been studied systematically in clinical trials. 
There seems to have been no systematic evaluation of the balance of the 
inferred beneficial and detrimental effects of rimonabant, which would 
be essential for the determination of a therapeutic window. 
In this thesis, we explore some improvements in the early develop-
ment of cannabinoids, by systematically investigating new cannabinoid 
compounds and formulations to enhance their pharmacological activi-
ties, experimenting with new methodology to optimise effect measure-
ment, and applying new concentration-effect models to improve the 
simulation and prediction of future studies.
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improving pharmacology
In Chapter 2 we investigated the pharmacology of different administra-
tion methods of Namisol® thc tablets, which are based on an improved 
emulsifying technology to enhance absorption. Somewhat unexpect-
edly, we have found that oral administration resulted in a quicker thc 
absorption into the blood compartment compared to sublingual ad-
ministration of a crushed tablet and we suggested that the absorption 
via oromucosal tissue is relatively slow compared to gastrointestinal ab-
sorption. If we compare our results to the findings from thc inhalation 
studies (e.g. from Chapter 3, 4 and 5), the proportion of active metabolite 
(11-oh-thc) to thc is larger for the oral administration, meaning that 
relatively more active metabolite is formed than after inhalation. Com-
pared with the literature on other oral thc formulations, Namisol® 
seems to have a shorter absorption time (or tmax) with reduced vari-
ability, probably contributing to a faster and more predictable onset of 
effects. We concluded that Namisol® seems to have benefits over com-
mon oral cannabis and thc treatments and we suggested that Namisol® 
offers potential improvements over currently registered cannabinoid-
treatments including registered oral thc formulations. However, this 
would require a direct comparison of the pk and pd of the oral thc tablet 
Namisol® with the current registered oral, oromucosal and sublingual 
formulations. Also, the absolute bioavailability of the various formula-
tions should be studied, although this would be limited by the lack of a 
standardised intravenous dosage.
Because the endocannabinoid system is relative inactive under 
physio logical circumstance, cannabinoid antagonists show no acute ef-
fects under normal resting conditions. We therefore used a thc-chal-
lenge test in Chapter 4 and 5 to examine the pharmacology of new cb¡ 
antagonists in healthy subjects. The effects of a thc challenge test are 
clearly measurable in healthy subjects and we have previously demon-
strated that these effects can be inhibited by cb¡ antagonists (Zuurman 
et al., 2010).
In Chapter 4 we investigated the pharmacokinetics of surinabant and its 
pharmacodynamic effects on those of thc. As a consequence of the recent 
rimonabant incident, we aimed to characterize the dose-effect relation-
ships for surinabant, to support the prediction of optimal effects and 
minimal risk for unwanted (central) side effects in patient studies. Al-
though surinabant exhibited no effects of its own on a wide range of dif-
ferent cns-function tests, we concluded that the dose-related inhibition 
of thc, demonstrates unequivocal cb¡ receptor antagonism in humans. 
A single surinabant dose between 5 to 20 mg was able to completely an-
tagonize thc-induced effects in humans. Higher doses were well tolerat-
ed, but did no show additional pharmacological activity. During the time 
of study performance we hoped that our results would allow the deter-
mination of clinically effective doses with minimised central side effects. 
However, shortly after our study surinabant development was ceased 
due to adverse psychiatric effects in phase 2. The relevant doses were de-
termined prior to the start of our study, based on different grounds than 
those of our study. The plasma concentration range at which the adverse 
events prominently occurred were relatively high compared to our study 
(Sanofi, personal communication). 
To improve the therapeutic window between metabolic improve-
ments and mental disturbance, tm38837 was developed as a peripher-
ally selective cb¡ antagonist. In rodents, this antagonist only hardly pen-
etrates through the blood-brain barrier in dosages that show beneficial 
effects on metabolism. Chapter 5 describes the first study of this com-
pound in humans. It was also the first direct comparison of two cannabi-
noid antagonists (tm38837 and the formerly registered rimonabant) in a 
clinical study, which is an efficient way to characterize new compounds. 
This study gave us insight into the pk and effect profiles of a peripherally 
acting antagonist and the differences compared to rimonabant by statis-
tical analyses and pk and pk-pd modelling. When directly compared to 
rimonabant, tm38837 had a relatively large inhibiting effect on thc-
induced heart rate (which had previously been argued to be a mainly pe-
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ripheral effect (Zuurman et al., 2009; Strougo et al., 2008)) with relatively 
small effects on subjective scores associated with cns activity (e.g. feel-
ing high) and body sway. The lowest tm38837 dose of 100 mg was pre-
dicted to be at least equipotent to rimonabant with regard to metabolic 
disorders in rodent models and had no significant impact on cns-effects 
in our study. These results provide support for further development of 
tm38837 as a peripherally selective cb¡ antagonist for indications such 
as metabolic disorders, with a reduced propensity for psychiatric side ef-
fects. The pk-pd analyses were put in a larger perspective in Chapter 6, 
in which the results from Chapter 4 and 5 and the results from a previ-
ous study with drinabant (ave1625) (Zuurman et al., 2010) were all used 
for building a general antagonist model. These analyses confirmed our 
graphical interpretation that tm38837 has a relatively larger peripheral 
effect than central effects when compared to rimonabant, surinabant and 
drinabant. We concluded that the relatively low central activity and the 
large effects on heart rate suggest a potential for therapeutic treatment 
development of tm38837, with minimal risks of the central side effects at-
tributed to rimonabant. 
optimising measurements
Besides the limited knowledge on the endocannabinoid system, and 
the pharmacology that limits the possibilities of pharmacotherapy, 
optimisation of drug development is limited by the lack of validated 
effect measurements. New techniques can be important tools to better 
understand the physiology of the cannabinoid system, to optimize dose 
selection and effect profiling, and to improve our understanding of the 
involvement of cannabinoid systems in general. 
Since all central nervous system (cns) functions ultimately depend 
on the activity of neuronal networks, connectivity analyses of neuro-
physiological (electroencephalography (eeg), magnetoencephalogra-
phy (meg)) or neuroimaging technologies (positron emission tomogra-
phy (pet), functional magnetic resonance imaging (fmri)) may provide 
useful tools for a more direct assessment of drug- or disease-induced 
functional cns-changes. In Chapter 3 we measured brain connectivity 
changes after thc administration by using resting-state functional mri 
(rs-fmri.) We found that thc induced increases and decreases of brain 
connectivity for various networks of interest. These clear effects (which 
are also found with other medications by other members of our research 
group) suggested that rs-fmri is a suitable method to apply in early clin-
ical stages of drug development. The brain regions in which the connec-
tivity changes were found were comparable with the functional regions 
that are associated with the behavioural effects after thc or cannabis use 
such as postural stability and altered time perception. rs-fmri has some 
unique features, compared with other cns measures that we used in this 
thesis. As opposed to more commonly applied neurophysiological, func-
tional and subjective methods, rs-fmri is able to detect a wide range of 
direct and indirect (acute) effects and to ‘objectively’ measure effect pro-
files, with less concealed interference from compensatory mechanisms 
and motivational aspects or other factors that can affect responses and 
performance. Moreover, this might enable early phase clinical research 
on compounds at low concentrations with a functional impact that can 
be easily compensated, or which is too limited to noticeably affect perfor-
mance. rs-fmri may also show effects of antagonists that do not induce 
acute measurable effects in the commonly used neurophysiologic tests, 
although this remains to be established. 
Overall, we concluded that thc induces connectivity changes in 
brain regions that are comparable with the functional regions that are 
associated with the behavioural effects after thc or cannabis use, and 
that rs-fmri is a suitable technique for clinical drug development, 
including development of cannabinoid pharmacotherapies. Future 
research could maturate the applicability of the rs-fmri methodology 
by investigating dose-effect relationships, for example by developing 
a pk-pd model for rs-fmri. Also, it would be interesting to understand 
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the implications of the methodology in a wider perspective, for example 
by exploring the relationships between the connectivity changes and 
functions. This will allow us to optimise the usability of the technique, 
but also to improve our understanding of the biological systems of the 
brain in general. 
improving analyses 
For the analysis of Chapter 5 which describes a study with the 
peripherally specific cb¡ antagonist tm38837 and rimonabant in a thc-
challenge test, pk-pd models were developed for heart rate, postural 
stability and feeling high. All pk-pd models included a baseline level, 
effect compartments that equilibrated with the plasma concentration, 
and a model to relate the effect compartment concentration to the 
pharmacodynamic response. Heart rate and body sway were best 
described by a maximum effect model. For feeling high a probability 
model was used to quantify the probability for a vas score › 12 at the study 
population level. All models included the thc challenge effect and the 
antagonizing effect of rimonabant and tm38837. The equilibration 
half-life of tm38837 was long compared with rimonabant, causing 
a larger delay in the onset of tm38837 effects. For heart rate the half 
maximal inhibitory concentrations (ic∞º) were similar for tm38837 
and rimonabant, whereas for body sway and feeling high the ic∞º 
of rimonabant was 4 times and 56 times larger respectively than for 
tm38837. This suggests that tm38837 induces relatively smaller central 
effects than peripheral effects when compared with rimonabant. The 
time profiles of the effects were comparable with the pharmacokinetic 
profiles of the compounds. Unfortunately, no therapeutic trials have 
been performed with tm38837 so far, to verify these predictions. 
In Chapter 6 we built pk-pd models for four different cb¡ antagonists: 
drinabant (ave1625), surinabant (sr147778), rimonabant (sr141716) 
and tm38837. This approach gave us insight in the differences of the 
pk and pd between the four antagonists and increased our knowledge 
on the behaviour of cb¡ antagonists in general. Compared to tm38837, 
surinabant and rimonabant effect profiles induced relatively larger 
centrally regulated pd effects than heart rate effects. The models can 
be applied for optimization as well as development of future clinical 
studies by simulation and prediction of the pk and pd of cannabinoid 
antagonists. As of today, research continues developing the mechanism-
based pk-pd modelling with for example more emphasis on disease 
system analysis. Mechanism-based pk-pd modelling is an important 
field that should continue in the future. Besides the desire to develop a 
translational tool from healthy subjects to patients, also in other phases 
of drug development tools for translation, simulation and prediction of 
pharmacokinetics and effects could be applied (e.g. from preclinical to 
clinical studies). 
general conclusion
The aim of this thesis was to explore some ways to advance cannabinoid 
drug design, by improvements of study designs, measurements and 
analyses in early phase clinical studies. Such improvement seem to 
be needed to increase our understanding of the pharmacology of 
cannabinoids in healthy people, and enable a more effective control of 
the cannabinoid system in pathology. 
In this thesis, we have introduced a new oral thc formulation and a 
new cb¡ antagonist, which we tested in healthy subjects. We concluded 
that the new formulations showed more beneficial pharmacological ef-
fects compared to current treatments. We have also optimized and ap-
plied new methodologies. We have provided indications that resting 
state fmri is a suitable technology for early phase clinical drug devel-
opment. We have also demonstrated that the thc-challenge test can be 
applied for pharmacological characterisation and dose optimisation 
of antagonists. For this, we developed pk-pd models for thc and the 
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cb¡ antagonists drinabant, surinabant, tm38837 and inverse agonist 
rimonabant. These models can be applied for simulation and prediction 
of pk and pd, for example to optimise future study designs. These meth-
ods provide more information than the ‘traditional’ approaches in early 
development, where dose selection is essentially based on extrapolation 
of preclinical results, pharmacokinetic optimisation of dosing regimens, 
and estimation of maximum tolerated doses – at best supplemented 
with some indications of pharmacodynamic effects. This approach can 
easily fail if the investigative compound has a novel mechanism of ac-
tion, and particularly when it has no effects under physiologically stable 
conditions. This seems to have been the case for rimonabant, which had 
to be withdrawn shortly after registration, because of adverse psychi-
atric events that perhaps in hindsight were not unexpected. We used 
the pk-pd-approach that is described in this thesis to determine a phar-
macologically optimised dose for rimonabant as well as for other novel 
cb¡-antagonists. This analysis suggested that rimonabant may have been 
overdosed, possibly because the compound is so well tolerated in healthy 
subjects where it has no ‘spontaneous’ effects. Clearly, this remains spec-
ulative as long as confirmatory studies have not been performed. 
At present, there are still questions about the predictive value of 
the pharmacological biomarkers, for clinically relevant therapeutic 
or inadvertent effects of cb¡-antagonists. It remains to be established, 
therefore, whether functional challenge studies and pharmacological 
pk-pd-analyses would actually allow the determination of a therapeutic 
window that is large enough for a safe and effective use of cb¡-
antagonists. Nonetheless, a pharmacological approach gives hope 
that drug development in the field of endocannabinoids is feasible 
and potentially useful, despite the many problems that are inherent 
to this complex system. The hope for cannabinoid research and drug 
development may also be fuelled by the break-down of taboos on 
cannabis use. The recreational use of cannabis gradually gained more 
acceptance since the 1970’s, and an increasing number of countries 
and states in the usa have decriminalised cannabis [ (Robison, 2013) for 
visualisation, see Reeve (2013)]. The spread of cannabis use, particularly 
for medical purposes also increases general social acceptance and 
stimulation of further research of cannabis-related compounds.
overall conclusions
Our results lead to the conclusion that there is room for improvement in 
cannabinoid research – enough to give confidence that the cannabinoid 
system still has potential as a target for pharmacological therapies, 
despite the setback after the market withdrawal of the first registered 
cannabinoid antagonist shortly after launch. Although the current 
amount of cannabinoid research is relatively low, and clinical research is 
particularly limited, the social acceptance of cannabis, also as a medicine, 
could facilitate a revival of research on the cannabinoid system. Our 
research shows that this requires novel approaches to the administration 
of cannabinoids, to the measurements and the study designs, and to 
the analyses of the effects. This reflects the complexity of the highly 
integrated endocannabinoid system, but also sets the stage for other 
innovative drug development programs. 
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Al duizenden jaren is cannabis wereldwijd een van de meest populaire 
drugs. Cannabis wordt vooral gebruikt voor recreatieve en medische 
doeleinden. De cb¡- en cb™-receptoren waaraan cannabinoïden (canna-
bisachtige stoffen) zich binden, zijn onderdeel van het endocannabino-
idesysteem, een van de oudste farmacologische systemen in de biologie 
die wijd verspreid in verschillende organismen voorkomen. 
Ondanks haar ouderdom is het cannabinoïdesysteem pas enkele de-
cennia geleden ontdekt en is de algemene kennis over de relevantie van 
het systeem in ziekte en gezondheid nog steeds erg beperkt. Bovendien 
levert nieuw wetenschappelijk onderzoek slechts langzaam nieuwe in-
formatie op. Dit heeft tot gevolg dat er maar enkele geneesmiddelen ge-
registreerd zijn die op het endocannabinoïdesysteem werken. De meeste 
stoffen die hierbij gebruikt worden zijn direct afkomstig uit de plant 
Cannabis sativa. Eind 2006, toen het cannabinoïdenonderzoek op een 
bloeiend hoogtepunt was, verloor de industrie plotseling haar interes-
se. Dit werd veroorzaakt doordat de fda zorgen uitte over de veiligheid 
van cb¡-antagonist rimonabant, een medicijn tegen obesitas met een 
werking die tegengesteld is aan de werking van cannabinoïden. De re-
gistratie van rimonabant, die werd gezien als een grote doorbraak in het 
geneesmiddelenonderzoek voor onder meer de behandeling van het me-
taboolsyndroom, werd bijna direct, in 2008, weer van de markt gehaald. 
Dit leidde ertoe dat de farmaceutische industrie indertijd vrijwel volle-
dig stopte met het onderzoek naar cb¡-antagonisten. De consequenties 
daarvan zijn nog steeds voelbaar.
Buiten de grote nalatenschap van rimonabant zijn er verschillende 
andere moeilijkheden waarmee het cannabinoïdenonderzoek te maken 
heeft. Zo is er bijvoorbeeld de maatschappelijke kwestie waarbij onder-
zoek naar cannabinoïde stoffen vaak in verband wordt gebracht met 
cannabismisbruik. Bovendien zijn veel van de potentiële indicaties voor 
cannabinoïde middelen mikpunt van discussie: vetzucht wordt niet als 
een ziekte gezien door bijvoorbeeld de American Medical Association (ama 
Council, 2013) en verslaving wordt vaak gezien als een gedragsstoornis 
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in plaats van een ziekte (Gartner, Carter, & Partridge, 2012). Bovendien is 
binnen de farmaceutische industrie de mening ontstaan dat de ontwik-
keling van middelen voor psychiatrische aandoeningen in het algemeen 
te risicovol is (van Gerven & Cohen, 2011).
Het lot van rimonabant is ook gerelateerd aan de wetenschappelijk 
fundamentele complexiteiten van het endocannabinoïdenonderzoek, 
zoals: wijdverspreide (receptor)distributie, beperkte receptorsubty-
pespecificiteit, locale productie van zeer lipofiele en snel degraderende 
transmitters, complexe fysiologische integratie en gebrek aan goede ef-
fectmaten. Dit alles tezamen leidt tot onduidelijke betrokkenheid bin-
nen de pathofysiologie. Aan de andere kant kan de focus van het endo-
cannabinoïdenonderzoek misleidend zijn. Veel van de vermeende indi-
caties voor cannabinoïde agonisten en antagonisten worden gekoppeld 
aan de bekende effecten van recreationeel cannabisgebruik. Alhoewel 
een prettig en ‘high’ gevoel, de ‘munchies’ (hongeraanvallen) en de pa-
niekaanvallen na cannabisgebruik ongetwijfeld diep geworteld zijn in 
de functionele farmacologie van het endocannabinoïdesysteem, zijn dit 
slechts enkele gevolgen van een excessieve overstimulatie. Door juist op 
deze grote effecten te focussen raken de lokale functies van cannabinoï-
den, die vooral een rol spelen bij subtiele regulatoire modulatie van nor-
male fysiologische processen, en hun betrokkenheid bij intercellulaire of 
systemische balansverstoringen van complexe multicascadische functio-
nele netwerken, ondergesneeuwd.
Het falen van rimonabant legt ook een teken van zwakte bloot van het 
huidige geneesmiddelenonderzoek. Rimonabant werd indertijd gezien 
als een wondermiddel voor de behandeling van obesitas en roken (Boek-
holdt & Peters, 2010) met zogenaamd ‘blockbuster’-potentieel. Rimona-
bants ontwikkeling was gebaseerd op het gegeven dat het blokkeren van 
gevoelens van honger of beloning (en de daarmee geassocieerde fysiolo-
gische processen) leidt tot afname van gewicht en verslaafbaarheid; of 
met andere woorden: het stopt de cannabisgeassocieerde ‘munchies’ en 
het misbruik. Opvallend genoeg werd de mogelijkheid genegeerd, dat 
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hiermee plezierige gevoelens kunnen worden geremd (als potentieel ge-
volg van het tegengaan van cannabisgeïnduceerde euforie). Voor zover 
ons bekend, zijn de emotionele of cognitieve effecten van rimonabant in-
dertijd niet specifiek bestudeerd in klinisch onderzoek. Het lijkt erop als-
of er nooit een systematische evaluatie van de balans tussen de gunstige 
en de nadelige effecten van rimonabant heeft plaatsgevonden, wat juist 
essentieel is voor het bepalen van een therapeutisch venster.
In dit proefschrift onderzochten we verbeteringen in vroege klini-
sche ontwikkeling van cannabinoïden, waarbij we systematisch te werk 
probeerden te gaan. We onderzochten nieuwe cannabinoïdeliganden 
en formuleringen om de farmacologische activiteit te vergroten, we ex-
perimenteerden met een nieuwe methodologie om effectmetingen te 
optimaliseren en we pasten nieuwe concentratie-effectmodellen toe om 
simulaties en voorspellingen van toekomstige studies te verbeteren.
farmacologische verbeteringen 
In hoofdstuk 2 onderzochten we de farmacologie van verschillende 
toedieningsmethoden van de thc-tablet Namisol®. Deze tablet is ge-
produceerd met een verbeterde emulsietechnologie om de absorptie 
te verhogen. Tegen onze verwachting in vonden we dat de orale toedie-
ningsvorm een snellere thc-absorptie naar de bloedbaan gaf dan sublin-
guale toediening van een verkruimelde tablet. Hieruit leidden we af dat 
de absorptie via oromucosaal weefsel relatief langzaam is vergeleken 
met gastrointestinale absorptie. Toen we onze resultaten vergeleken 
met de bevindingen uit inhalatiestudies met thc (zoals bijvoorbeeld in 
hoofdstuk 3, 4 en 5), zagen we dat de verhouding van actieve metaboliet 
(11-oh-thc) tot thc groter is voor de orale toedieningen, wat betekent 
dat er relatief meer actieve metaboliet wordt gevormd dan bij inhalatie. 
Toen we Namisol® vergeleken met andere thc-formuleringen in de li-
teratuur, bleek dat Namisol® een kortere absorptietijd (ofwel tmax) en 
een geringere variabiliteit heeft, wat waarschijnlijk bijdraagt aan snel-
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lere en beter voorspelbare effecten. We concludeerden dat Namisol® 
waarschijnlijk farmacologische voordelen heeft boven de bekende orale 
cannabis- en thc-middelen, die zich mogelijk vertalen in therapeutische 
voordelen voor patiënten. Om deze hypothese te kunnen bevestigen, is 
een vervolgstudie nodig waarbij de farmacokinetiek (pk) [en eventueel 
de farmacodynamiek (pd)] van Namisol® direct wordt vergeleken met 
de huidige geregistreerde orale, oromucosale en sublinguale formule-
ringen. Er zou hierbij ook naar de absolute biologische beschikbaarheid 
van de verschillende middelen gekeken kunnen worden, alhoewel dit 
beperkt wordt door het ontbreken van een gestandaardiseerde intrave-
neuze toedieningsvorm.
Het endocannabinoïdesysteem is onder normale omstandigheden 
weinig actief, waardoor cannabinoïde-antagonisten bij gezonde mensen 
geen directe effecten laten zien. Om in hoofdstuk 4 en 5 toch de farma-
cologie van nieuwe cb¡-antagonisten te kunnen testen, hebben we een 
thc-challengetest toegepast bij gezonde vrijwilligers. De effecten van 
een thc-challenge zijn ook bij gezonden duidelijk meetbaar. Al eerder 
hadden we aangetoond dat deze effecten door de cb¡-antagonisten sterk 
kunnen worden onderdrukt (Zuurman et al., 2010).
In hoofdstuk 4 onderzochten we de farmacokinetiek van surinabant 
en haar farmacodynamische effecten op thc-geïnduceerde effecten. Door 
het recente gebeuren rond rimonabant wilden we de dosis-respons-rela-
tie voor surinabant onderzoeken waarmee we een dosisvoorspelling kon-
den doen met enerzijds optimale effecten en anderzijds een minimaal ri-
sico op ongewenste (centrale) bijwerkingen tijdens patiëntenstudies. Al-
hoewel surinabant zelf geen effecten liet zien in de verschillende centraal 
zenuwstelsel (czs)-testen, concludeerden we dat de dosisgerelateerde 
remming van thc-effecten wijst op cb¡-receptorantagonisme in mensen. 
Een enkele dosis surinabant tussen 5 en 20 mg kon de effecten van thc 
compleet antagoneren. Hogere enkelvoudige doseringen werden goed 
verdragen, maar lieten geen extra farmacologische remming zien. Ten tij-
de van de studie-uitvoer hoopten we dat onze resultaten zouden leiden tot 
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het bepalen van een klinisch effectieve dosering met minimale centrale 
bijwerkingen. Echter, kort na de uitvoer van onze studie werd de verdere 
ontwikkeling van surinabant gestaakt door psychiatrische bijwerkingen 
in een fase ii-studie. Deze studie was al eerder in gang gezet met doses die 
op andere gronden waren gekozen. De plasmaconcentratie waarbij deze 
bijwerkingen duidelijk optraden was relatief hoog vergeleken met de 
concentraties in onze studie (Sanofi, persoonlijke communicatie).
Om het therapeutische venster te vergroten tussen metabole verbeter-
ingen en psychiatrische bijwerkingen, is de perifeer selectieve cb¡-antag-
onist tm38837 ontwikkeld. Dit middel dringt bij proefdieren nauwelijks 
door de bloedhersenbarrière heen, in doseringen die wel gunstige me-
tabole effecten hebben. Hoofdstuk 5 beschrijft de eerste studie met dit 
middel in mensen. Dit was ook de eerste keer dat twee cannabinoïde-an-
tagonisten (namelijk tm38837 en rimonabant) direct werden vergeleken 
binnen dezelfde klinische studie, wat een efficiënte manier is om nieuwe 
middelen te karakteriseren. Deze studie verschafte inzicht in de pk en de 
effectprofielen van een perifeer werkende antagonist en de verschillen 
met rimonabant, zoals bepaald door statistische analyses en pk- en pk-
pd-modellering. Vergeleken met rimonabant veroorzaakt tm38837 een 
relatief grote remming op thc-geïnduceerde hartslagversnelling, een ef-
fect waarvan voorheen beredeneerd is dat het vooral samenhangt met per-
ifere cannabinoïde werking (Zuurman, Ippel, Moin, & van Gerven, 2009; 
Strougo et al., 2008). Er waren relatief geringe effecten op subjectieve 
effecten in het czs, zoals high gevoel en op de ‘body sway’, een maat van 
houdingsstabiliteit. De metabole effecten van de laagste dosis tm38837 
van 100 mg zouden (op grond van voorspellingen vanuit knaagdier-
modellen) tenminste equipotent zijn aan die van de onderzochte doser-
ing van rimonabant. tm38837 had in deze lage dosis in onze studie geen 
significante czs-effecten, in tegenstelling tot rimonabant. De resultaten 
bevestigen dat verdere ontwikkeling van tm38837 als een perifeer selec-
tieve cb¡-antagonist interessant is voor indicaties zoals metabole ziekten, 
met daarbij een lagere kans op psychiatrische bijwerkingen.
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In hoofdstuk 6 worden de pk-pd-analyses in een groter perspectief ge-
plaatst. In dit hoofdstuk worden de resultaten van hoofdstukken 4 
en 5 en de resultaten van een eerdere studie met drinabant (ave1625) 
(Zuurman et al., 2010) gebruikt voor het bouwen van een algemeen an-
tagonistenmodel. Deze analyses laten zien dat tm38837 relatief gro-
tere perifere effecten dan centrale effecten veroorzaakt vergeleken met 
rimonabant, surinabant en drinabant. Hieruit concludeerden we dat 
tm38837 potentie heeft om doorontwikkeld te worden voor perifere 
indicaties, zoals het metaboolsyndroom, met beperkte risico’s op de 




Naast de beperkte kennis over het cannabinoïdesysteem en de beperkte 
mogelijkheden die de farmacologische eigenschappen van dit systeem 
bieden, wordt geneesmiddelenontwikkeling verder beperkt door het ge-
brek aan gevalideerde effectmetingen. Nieuwe meetmethoden kunnen 
belangrijk zijn om de fysiologie van het cannabinoïdesysteem beter te 
begrijpen, om de juiste dosering te selecteren, om de effecten van stoffen 
beter te vergelijken, en om ons algehele begrip van het cannabinoïdesys-
teem te verbeteren.
Effecten in het czs manifesteren zich als activiteit van neurale netwer-
ken. Deze activiteiten kunnen direct worden gemeten, door middel van 
connectiviteitsanalyses. Er zijn verschillende technieken die hier gebruik 
van maken, met name neurofysiologische methoden ([electroencefalo-
grafie (eeg), magnetoencefalografie (meg)] en neurovisualisatietechno-
logieën [positron emissie tomografie (pet), functionele magnetische resonan-
tiebeeldvorming (fmri)]. Met behulp van deze netwerkanalyses kunnen 
verandering in het czs die door ziekten of medicijnen worden veroorzaak, 
directer worden gemeten dan met testen van czs-functies zoals gedrags-
maten of subjectieve veranderingen.
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In hoofdstuk 3 hebben we veranderingen in hersenconnectiviteit geme-
ten na thc-toediening, met behulp van de zogenaamde resting-state 
functionele mri (rs-fmri). We vonden dat thc in sommige ‘networks 
of interest’ een significante toename in hersenconnectiviteit veroorzaakt 
en in andere netwerken juist een significante afname. Deze duidelijke ef-
fecten, welke ook werden gevonden in studies van onze groep bij andere 
middelen, wekken de suggestie dat rs-fmri een geschikte methode is 
voor vroege fase klinisch geneesmiddelenonderzoek. De hersengebie-
den waarin de connectiviteitsveranderingen werden gevonden waren 
vergelijkbaar met de functionele hersengebieden die worden geassoci-
eerd met de bekende gedragseffecten na thc- of cannabisgebruik, zo-
als houdingsinstabiliteit en een veranderde tijdsperceptie (beide in het 
cerebellum). rs-fmri heeft als methodologie unieke eigenschappen 
vergeleken met andere (gangbaardere) czs-metingen die we in dit proef-
schrift hebben toegepast. In contrast met de algemeen toegepaste neu-
rofysiologische, functionele en vooral subjectieve methoden is rs-fmri 
in staat om een zeer wijd spectrum van zowel directe als indirecte (acute) 
effectprofielen te meten. Daarbij is deze manier van meten ‘objectief’; 
dat wil zeggen: er is minder verborgen interferentie van compensatoire 
mechanismen of motivatie-aspecten of andere factoren die de respons en 
de uitvoering van testen kunnen beïnvloeden. Bovendien biedt deze me-
thodologie de ruimte om in vroege fase klinisch onderzoek met zeer lage 
geneesmiddelenconcentraties te werken, waarvan de effecten eenvoudig 
gecompenseerd worden door compensatoire mechanismen, of in ander-
soortige testen gewoonweg niet kunnen worden waargenomen. Ook kan 
rs-fmri geschikt zijn om functioneel ‘stille’ geneesmiddel effecten waar 
te nemen, zoals van cb¡-antagonisten die bij gezonde vrijwilligers geen 
acuut meetbare veranderingen laten zien van de gangbare neurofysiolo-
gische testen. Dit moet echter nog wel worden onderzocht.
Samengevat concluderen we dat thc connectiviteitsveranderingen te-
weeg brengt in hersengebieden die geassocieerd zijn met gedragseffec-
ten na thc- of cannabisgebruik. rs-fmri lijkt een geschikte techniek 
nederlandse samenvatting
– 223 –
voor klinisch geneesmiddelenonderzoek, waaronder de ontwikkeling 
van cannabinoïde farmacotherapieën. Met behulp van verder onderzoek 
naar dosis-effect-relaties, bijvoorbeeld door pk-pd-modellen voor rs-
fmri te ontwikkelen, kan de toepasbaarheid van rs-fmri verder worden 
uitgebouwd. Ook is het interessant om de implicaties van de methodol-
ogie in een breder perspectief te begrijpen, bijvoorbeeld door de relatie 
tussen connectiviteitsveranderingen en hersenfuncties verder te onder-
zoeken. Op deze manier kunnen we de toepassing van de techniek opti-
maal benutten en tegelijkertijd onze nog beperkte kennis over endocan-
nabinoïde systemen in de hersenen vergroten.
 
analyses verbeteren
In hoofdstuk 5, waarin een studie wordt beschreven met de perifeer se-
lectieve cb¡-antagonist tm38837 en met rimonabant, ontwikkelden 
we pk-pd-modellen voor hartslagfrequentie, houdingsstabiliteit (body 
sway) en het high gevoel. Alle pk-pd-modellen bevatten een basisniveau 
(baseline), effectcompartimenten die equilibreren met de plasmaconcen-
tratie en een model om de effectcompartimentconcentratie te relateren 
aan de farmacodynamische respons. De modellen voor hartslag en body 
sway werden het best omschreven door een maximaal-effect-model. Voor 
het high gevoel werd een waarschijnlijkheidsmodel (‘probability model’) 
gebruikt, waarbij de kans werd bepaald dat de vas-score boven of onder 
de mediaan van de studiepopulatie zou liggen. Alle modellen bevatten 
zowel de effecten van de thc-challenge-effecten als de remmende wer-
king van rimonabant en tm38837. De equilibratie-halfwaardetijd van 
tm38837 was lang vergeleken met rimonabant. Dit veroorzaakte een 
grotere vertraging in de aanvang van de effecten van tm38837. Hart-
slag liet half-maximale inhibitoire concentraties (ic∞º) zien die voor 
tm38837 en rimonabant overeenkomstig waren, terwijl rimonabant bij 
body sway en high gevoel zelfs een ic∞º had van respectievelijk 4 en 56 
keer groter dan voor tm38837. Dit doet vermoeden dat tm38837 relatief 
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kleinere centrale dan perifere effecten heeft dan rimonabant. De tijdpro-
fielen van de effecten zijn vergelijkbaar met de pk-profielen van beide 
stoffen. Helaas zijn er op dit moment nog geen studies uitgevoerd die 
de therapeutische mogelijkheden van tm38837 nader onderzoeken en 
onze hypotheses over het grotere therapeutische venster van tm38837 
kunnen verifiëren.
Voor vier verschillende cb¡-antagonisten, namelijk drinabant 
(ave1625), surinabant (sr147778), rimonabant (sr141716) en tm38837, 
hebben we in hoofdstuk 6 pk-pd-modellen gebouwd, waarbij de verschil-
lende antagonisten per pd-parameter werden geïntegreerd in één model. 
Deze aanpak verschafte ons inzicht in de pk- en pd-verschillen tussen de 
vier antagonisten en verbeterde onze kennis over het gedrag van cb¡-an-
tagonisten in het algemeen. Vergeleken met tm38837 lieten surinabant 
en rimonabant effectprofielen zien met relatief grotere centraal geregu-
leerde pd-effecten dan effecten op de hartslag. Drinabant leek meer op 
tm38837 dan op de andere cb¡-antagonisten. Deze modellen kunnen 
onder meer worden toegepast voor de ontwikkeling en optimalisatie van 
toekomstige klinische studies door simulatie en voorspellingen van de 
pk en pd van cannabinoïde-antagonisten te genereren. Onderzoek op het 
gebied van ‘mechanism-based’ pk-pd-modelleren blijft zich ook vandaag 
de dag nog ontwikkelen met bijvoorbeeld meer nadruk op systeemana-
lyse van ziekten. Het is een onderzoeksveld van grote betekenis en verdere 
ontwikkeling in de toekomst is belangrijk; niet alleen voor de ontwikke-
ling van translationele modellen van gezonde personen naar patiënten, 
maar ook in andere fases van geneesmiddelenontwikkeling zijn modellen 
voor translatie, simulatie en voorspelling van pk en pd van groot belang 
(bijvoorbeeld in de overgang van preklinisch naar klinisch onderzoek). 
algemene conclusies
Het doel van dit proefschrift was om verschillende manieren te onder-
zoeken die kunnen bijdragen aan de verbetering van cannabinoïdege-
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neesmiddelen, door te kijken naar verbeteringen in het ontwerp van 
vroege fase klinische studies, en door toepassing van nieuwe meetme-
thoden en analyses. Deze verbeteringen zijn hard nodig voor ons nog be-
perkte begrip van de farmacologie van cannabinoïden in gezonde perso-
nen en om cannabinoïden effectief te kunnen gebruiken voor de behan-
deling van ziekten.
In dit proefschrift hebben we een nieuwe orale thc-formulering en 
een nieuwe cb¡-antagonist geïntroduceerd in studies met gezonde per-
sonen. Hieruit concludeerden we dat de nieuwe formuleringen betere 
farmacologische effecten lieten zien vergeleken met de huidige behan-
delingen. Ook hebben we in dit proefschrift nieuwe methodologieën 
geoptimaliseerd en toegepast. Zo lieten we onder meer zien dat resting 
state-fmri een geschikte technologie is voor vroege fase klinisch genees-
middelenonderzoek en dat de thc-challengetest toegepast kan worden 
voor farmacologische karakterisering en dosisoptimalisatie van anta-
gonisten. Om dit verder uit te breiden hebben we pk-pd-modellen ont-
wikkeld voor thc en voor de cb¡-antagonisten drinabant, surinabant, 
tm38837 en de inverse agonist rimonabant. De toepassing van deze mo-
dellen is van belang voor simulatie en voorspelling van pk en pd, bijvoor-
beeld om toekomstige studie-ontwerpen te kunnen optimaliseren. In 
vroege fasen van geneesmiddelenontwikkeling levert deze methodolo-
gie meer informatie op dan de meer traditionele aanpak waarbij de selec-
tie van doseringen in feite voornamelijk gebaseerd wordt op extrapolatie 
en allometrische schalen van preklinische resultaten, pk-optimalisatie 
van doseringsschema’s en de schatting van de maximaal getolereerde do-
sering – welke in het beste geval wordt aangevuld met enkele indicaties 
van farmacodynamische effecten. De traditionele aanpak geeft vooral 
gemakkelijk verkeerde informatie wanneer bijvoorbeeld het te onder-
zoeken geneesmiddel een nieuw werkingsmechanisme heeft, en ook 
wanneer er geen meetbare effecten zijn onder fysiologisch stabiele con-
dities. Het lijkt er sterk op dat dit van toepassing was op rimonabant, dat 
kort na registratie van de markt af werd gehaald vanwege psychiatrische 
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bijwerkingen die achteraf gezien misschien verwacht hadden kunnen 
worden. In dit proefschrift onderzochten we op gestructureerde manier 
de pk-pd-relaties om zowel voor rimonabant als voor de andere nieuwe 
cb¡-antagonisten de farmacologisch optimale dosering te bepalen. Onze 
analyse geven aanwijzingen dat rimonabant in de praktijk mogelijk 
werd overgedoseerd, wat vermoedelijk werd veroorzaakt door de goede 
verdraagbaarheid van het middel in gezonde personen, die immers geen 
‘spontane’ effecten lieten zien. Dit blijft speculatief zolang er geen ver-
volgstudie is uitgevoerd die onze hypothese bevestigt. 
Het is nog steeds een grote vraag wat de voorspellende waarde van de 
toegepaste farmacologische biomarkers is voor klinische relevante the-
rapeutische of juist ongewenste effecten van cb¡-antagonisten. Verder 
onderzoek is dan ook nodig naar de vraag in welke mate functionele chal-
lengestudies en pk-pd-analyses in staat zijn om een therapeutisch ven-
ster te bepalen dat groot genoeg is voor een veilig en effectief gebruik van 
cb¡-antagonisten. Toch vergroot een farmacologische aanpak de hoop 
dat geneesmiddelenonderzoek naar (endo)cannabinoïden realiseerbaar 
is en potentie heeft, ondanks de serieuze problemen die inherent zijn 
aan onderzoek naar een dergelijk complex systeem. Deze hoop voor can-
nabinoïdenonderzoek en geneesmiddelenontwikkeling wordt mede 
gevoed door de afname van taboes op cannabisgebruik. Het recreatio-
nele gebruik wordt sinds de jaren 1970 steeds meer geaccepteerd en een 
toenemend aantal landen en staten in de vs decriminaliseren cannabis [ 
(Robison, 2013), voor een illustratie, zie Reeve (2013)]. Deze verspreiding, 
met name bij gebruik voor medische toepassingen, vergroot de algemeen 
maatschappelijke acceptatie van cannabis, wat een stimulans kan bieden 
aan verder onderzoek naar cannabisgerelateerde middelen.
algehele conclusie
Onze resultaten leidden tot de conclusie dat er veel ruimte is voor verbe-
teringen in het cannabinoïdenonderzoek – voldoende om het vertrou-
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wen te geven dat het cannabinoïdesysteem nog steeds potentie heeft in 
het kader van farmacologische therapieën, ondanks dat de eerste geregis-
treerde cannabinoïde-antagonist kort na registratie weer van de markt 
gehaald werd. Alhoewel er momenteel weinig cannabinoïdenonderzoek 
met vooral erg weinig klinisch werk plaatsvindt, kan de toenemende 
maatschappelijke acceptatie van cannabis, ook als een geneesmiddel, bij-
dragen aan een herleving van onderzoek aan het endocannabinoïdensys-
teem. Ons onderzoek laat zien dat hiervoor nieuwe manieren nodig zijn 
om cannabinoïden toe te dienen, de studies te ontwerpen en om hun ef-
fecten te meten en te analyseren. Dit reflecteert de complexiteit van het 
diep geïntegreerde endocannabinoïdesysteem en effent ook de weg voor 
andere innovatieve geneesmiddelenontwikkelingsprogramma’s. 
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